• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

FY 2008 Inspectional Observation Summaries

 

Number of 483s issued from the System* 

Inspections ending between 10/1/2007 12:00:00 AM and 9/30/2008 12:00:00 AM

Center Name 483s issued
Foods 1854
Devices 776
Drugs 498
Bioresearch monitoring 347
Incidental text 330
Biologics 239
Parts 1240 and 1250 183
Veterinary medicine 173
Human tissue for transplantation 101
Special requirements 5
Radiological health 3
Sum Product Area 483s from System* 4509
Actual Total in system 483s** 3979

* This table does not represent the complete set of 483's issued during the fiscal year as some 483's were manually prepared and not available in this format. The sum of 483's for all Product Areas will be greater than the actual Total 483's issued during the fiscal year since a 483 may include citations related to multiple product areas, and counted more than once, under each relevant product center.

** This is the Actual Total number of 483's issued from this system, and that are represented in this spreadsheet.

Back to Inspectional Observation Summaries


Foods

Center Name Cite Id Ref No Frequency Short Description Long Description
Foods 1524 21 CFR 123.11(b) 262 Sanitation monitoring You are not monitoring the sanitation conditions and practices with sufficient frequency to assure conformance with Current Good Manufacturing Practices including [safety of water that comes into contact with food or food contact surfaces, including water used to manufacture ice] [condition and cleanliness of food contact surfaces] [prevention of cross-contamination from insanitary objects] [maintenance of hand washing, hand sanitizing, and toilet facilities] [protection of food, food packaging material, and food contact surfaces from adulteration] [proper labeling, storage and use of toxic chemicals] [control of employee health conditions] [exclusion of pests].  Specifically, ***
905 21 CFR 123.6(b) 259 HACCP plan implementation You did not implement the [monitoring] [recordkeeping] [verification] procedures listed in your HACCP plan.  Specifically, ***
1560 21 CFR 110.35(c) 207 Lack of effective pest exclusion Effective measures are not being taken to [exclude pests from the processing areas] [protect against the contamination of food on the premises by pests].  Specifically, ***
904 21 CFR 123.6(b) 172 No HACCP plan You do not have a written HACCP plan that outlines controls for a food safety hazard that is reasonably likely to occur.  Specifically, ***
1525 21 CFR 123.11(c) 152 Sanitation Records You are not maintaining sanitation control records that document [monitoring] [corrections of sanitation deficiencies] for [safety of water that comes into contact with food or food contact surfaces, including water used to manufacture ice] [condition and cleanliness of food contact surfaces] [prevention of cross-contamination from insanitary objects] [maintenance of hand washing, hand sanitizing, and toilet facilities] [protection of food, food packaging material, and food contact surfaces from adulteration] [proper labeling, storage and use of toxic chemicals] [control of employee health conditions] [exclusion of pests].  Specifically, ***
945 21 CFR 123.12(a)(2) 150 Importer verification You do not have or have not implemented [written verification procedures] [product specifications] [an affirmative step] for ensuring that [fish] [fishery products] you import are processed in compliance with the Seafood HACCP regulation.  Specifically, ***
1422 21 CFR 110.20(b)(4) 144 Floors, walls and ceilings The plant is not constructed in such a manner as to allow [floors] [walls] [ceilings] to be [adequately cleaned and kept clean] [kept in good repair]. Specifically, ***
908 21 CFR 123.6(d) 134 Signed and dated Your HACCP plan was not signed and dated [upon initial acceptance] [upon modification] [at least annually].  Specifically, ***
961 21 CFR 123.6(c)(3) 133 Critical limits Your HACCP plan [does not list a critical limit that ensures control of one or more hazards] [lists a critical limit that does not ensure control of one or more hazards].  Specifically,
6004 21 CFR 123.6(c)(4) 133 Monitoring - adequacy Your HACCP plan lists monitoring [procedures] [frequencies] that do not ensure compliance with the critical limit.  Specifically***
1552 21 CFR 110.35(a) 124 Buildings/sanitary Failure to maintain buildings, fixtures, or other physical facilities in a sanitary condition.  Specifically, ***
1553 21 CFR 110.35(a) 124 Buildings/good repair Failure to maintain [buildings] [fixtures] [physical facilities] in repair sufficient to prevent food from becoming adulterated.  Specifically, ***
960 21 CFR 123.6(c)(2) 120 Critical control points Your HACCP plan does not list one or more critical control points that are necessary for each of the identified food safety hazards.  Specifically, ***
6008 21 CFR 123.8(a)(3) 116 Verification - record review - frequency You did not review [some of] your [critical control point monitoring][corrective action][calibration][in-process testing][end-product testing] records [within one week][within a reasonable time] after the records were made. Specifically, ***
1695 21 CFR 110.80(b)(2) 106 Manufacturing conditions Failure to [manufacture] [package] [store] foods under conditions and controls necessary to minimize [the potential for growth of microorganisms] [contamination].  Specifically, ***
1306 21 CFR 110.20(b)(7) 105 Screening Failure to provide adequate screening or other protection against pests.  Specifically, ***
963 21 CFR 123.6(c)(5) 104 Corrective action plan Your HACCP plan includes a corrective action plan that is not in accordance with 21 CFR 123.7(b) to ensure [affected product is not entered into commerce] [the cause of the deviation was corrected].  Specifically***
6020 21 CFR 123.9(a) 100 Records - content Your records do not include the [name and location of the processor or importer] [date and time of the activity the record reflects] [signature or initials of the person performing the operation] [identity of the product and the production code, if any].  Specifically, ***
959 21 CFR 123.6(c)(1) 88 Food safety hazards Your HACCP plan does not list the food safety hazards that are reasonably likely to occur.  Specifically, ***
1287 21 CFR 110.20(a)(1) 87 Harborage areas Failure to [properly store equipment] [remove litter and waste] [cut weeds or grass] that may constitute an attractant, breeding place, or harborage area for pests, within the immediate vicinity of the plant buildings or structures.  Specifically, ***
1427 21 CFR 110.20(b)(5) 85 Safety lighting and glass Failure to provide safety-type [light bulbs] [lighting fixtures] [skylights] [glass] suspended over exposed food.  Specifically, ***
1405 21 CFR 110.10(b)(6) 84 Failure to wear Failure to wear [hair nets] [head bands] [caps] [beard covers] [hair restraints] where appropriate.  Specifically, ***
933 21 CFR 123.8(a)(2)(ii) 80 Calibration - adequacy Your process monitoring equipment is not calibrated to ensure that it reads accurately.  Specifically, ***
1007 21 CFR 110.10(b)(9) 73 Precautions against contamination--micro, foreign substances Failure to take necessary precautions to protect against contamination of [food] [food contact surfaces] [food packaging systems] with [microorganisms] [foreign substances].  Specifically, ***
1689 21 CFR 110.80 72 Reasonable precautions All reasonable precautions are not taken to ensure that production procedures do not contribute contamination from any source. Specifically, ***
6001 21 CFR 123.11(b) 72 Sanitation monitoring documentation Your sanitation control records do not accurately document the conditions or practices observed at your firm.  Specifically***
1554 21 CFR 110.35(a) 71 Cleaning and sanitizing operations Failure to conduct cleaning and sanitizing operations for utensils and equipment in a manner that protects against contamination of [food] [food-contact surfaces] [food-packaging materials].  Specifically, ***
1581 21 CFR 110.37(e) 70 Running water at suitable temperature Hand-washing facilities lack running water of a suitable temperature.  Specifically, ***
990 21 CFR 110.10(b)(3) 68 Not washed/sanitized when appropriate Employees did not [wash] [sanitize] hands thoroughly in an adequate hand-washing facility [before starting work] [after each absence from the work station] [at any time their hands may have become soiled or contaminated].  Specifically, ***
2386 21 CFR 110.80(a)(1) 66 Storage Failure to store raw materials in a manner that [protects against contamination] [minimizes deterioration].  Specifically, ***
6021 21 CFR 123.10 66 HACCP training or qualification No one associated with your firm has completed the required HACCP training or is HACCP qualified through job experience.  Specifically, ***
1173 21 CFR 110.40(f) 65 Q.C. instrument accuracy, maintenance Instruments used for [measuring] [regulating] [recording] conditions that control or prevent the growth of undesirable microorganisms are not [accurate] [adequately maintained].  Specifically,***
3659 21 CFR 110.37(e)(3) 63 Hand drying Lack of a sanitary towel service or suitable hand drying devices.  Specifically, ***
1701 21 CFR 110.80(b)(7) 61 Equipment, containers, utensils Failure to [construct] [handle] [maintain] equipment, containers and utensils used to [convey] [hold] [store] food in a manner that protects against contamination.  Specifically, ***
1597 21 CFR 110.37(b)(3) 60 As source of contamination Plumbing constitutes a source of contamination to [food] [water supplies] [equipment] [utensils].  Specifically, ***
9931 21 CFR 120.6(b) 60 Sanitation monitoring You are not monitoring the sanitation conditions and practices with sufficient frequency to assure conformance with current good manufacturing practice including [safety of water that comes into contact with food or food contact surfaces, including water used to manufacture ice] [condition and cleanliness of food contact surfaces] [prevention of cross-contamination from insanitary objects] [maintenance of hand washing, hand sanitizing, and toilet facilities] [protection of food, food packaging material, and food contact surfaces from adulteration] [proper labeling, storage and use of toxic chemicals] [control of employee health conditions] [exclusion of pests]. Specifically, *** 
1556 21 CFR 110.35(b)(2) 59 Storage requirements Failure to properly [identify] [hold] [store] toxic [cleaning compounds] [sanitizing agents] [pesticide chemicals] in a manner that protects against contamination of [food] [food-contact surfaces] [food-packaging materials].  Specifically, ***
1424 21 CFR 110.20(b)(4) 55 Drip and condensate The plant is not constructed in such a manner as to prevent [drip] [condensate] from contaminating [food] [food-contact surfaces] [food-packaging materials]. Specifically, ***
1066 21 CFR 110.40(b) 50 Seams on food contact surfaces Failure to have smoothly bonded or well maintained seams on food contact surfaces, to minimize accumulation of [food particles] [dirt] [organic matter] and the opportunity for growth of microorganisms.  Specifically, ***
3658 21 CFR 110.37(e)(2) 50 Hand cleaning and sanitizing preparations Lack of effective hand [cleaning] [sanitizing] preparations.  Specifically, ***
6005 21 CFR 123.6(c)(6) 49 Verification procedures - adequacy Your HACCP plan lists verification [procedures] [frequencies] that have not been developed in accordance with 21 CFR 123.8(a) to ensure that your HACCP plan is adequate to control food safety hazards, and is being effectively implemented.  Specifically, ***
12720 21 CFR 1.225 49 Not registered Your food facility is not registered as required.  Specifically, ***
1615 21 CFR 110.93 47 Storage/transportation of finished goods (contamination) Failure to [store] [transport] finished food under conditions that would protect against [physical] [chemical] [microbial] contamination.  Specifically, ***
1006 21 CFR 110.10(b)(8) 45 Personal food/drink/tobacco Employees were observed to be [eating food] [chewing gum] [drinking beverages] [using tobacco] in areas where [food is exposed] [equipment or utensils are washed].  Specifically, ***
901 21 CFR 123.6(a) 44 Hazard analysis You did not conduct, or have conducted for you, a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur for each kind of fish and fishery product you process. Specifically, ***
2392 21 CFR 110.80(b)(1) 43 Maintenance of equip., utensils, and finished food packaging Failure to maintain [equipment] [utensils] [finished food containers] in an acceptable condition through appropriate cleaning and sanitizing.  Specifically, ***
3652 21 CFR 110.37(e)(1) 43 Suitable locations Failure to provide [hand washing] [hand sanitizing] facilities at each location in the plant where needed.  Specifically, ***
1292 21 CFR 110.20(b)(1) 41 Sufficient space Failure to provide sufficient space for [placement of equipment] [storage of materials] as necessary for the maintenance of sanitary operations and the production of safe food.  Specifically, ***
913 21 CFR 123.8(a)(1) 40 Reassessment of HACCP plan Your verification procedures do not include, at a minimum, reassessment of the HACCP plan [at least annually] [whenever modifications to the process are made].  Specifically, ***
1125 21 CFR 110.40(a) 40 Materials and workmanship The [design] [materials] [workmanship] of [equipment] [utensils] does not allow proper [cleaning] [maintenance].  Specifically, ***
931 21 CFR 123.8(d) 39 Verification - recordkeeping You do not maintain records of [calibration of process-monitoring instruments] [periodic end-product or in-process testing].  Specifically, ***
985 21 CFR 110.10(b)(1) 39 Suitable outer garments Suitable outer garments are not worn  that protect against contamination of [food] [food contact surfaces] [food packaging materials]. Specifically, ***
1562 21 CFR 110.35(d) 39 Failure to clean - general Failure to clean [food-contact surfaces] [utensils] as frequently as necessary to protect against contamination of food.  Specifically, ***
4470 21 CFR 108.25(c)(2) 39 Process filing Failure to provide the FDA, before packing any new product, information on the scheduled processes for each acidified food in each container size. Specifically, ***
1005 21 CFR 110.10(b)(7) 38 Storage of personal items Personal [clothing] [belongings] were stored  in an area where [food is exposed] [equipment or utensils are washed].  Specifically, ***
1172 21 CFR 110.40(e) 38 Lack of thermometer Lack of an accurate indicating thermometer, temperature measuring device, or temperature recording device in each freezer and cold storage compartment used to store food capable of supporting the growth of microorganisms.  Specifically, ***
3661 21 CFR 110.37(e)(5) 38 Signs Lack of posted, readily understandable signs directing employees to wash and sanitize hands as appropriate.  Specifically, ***
1402 21 CFR 110.10(b)(4) 37 Unsecured jewelry Employees failed to remove unsecured jewelry or other objects which might fall into [food] [equipment] [containers].  Specifically, ***
1696 21 CFR 110.80(b)(3) 37 Holding foods - refrigerate/freeze/heat Failure to hold foods which can support the rapid growth of undesirable microorganisms at a temperature that prevents the food from becoming adulterated.  Specifically, ***
6015 21 CFR 123.6(c)(6) 35 Verification procedures - none/frequency  Your HACCP plan does not list verification [procedures] [frequencies] that have been developed to ensure that the HACCP plan is adequate to control food safety hazards, and is being effectively implemented.  Specifically, ***
1126 21 CFR 110.40(a) 34 Precluding contaminants The [design] [construction] [use] of equipment and utensils fails to preclude the adulteration of food with [lubricants] [fuel] [metal fragments] [contaminated water] [contaminants].  Specifically, ***
6018 21 CFR 123.7(a) 33 Corrective action per predetermined plan You did not take corrective action that ensured [affected product was not entered into commerce] [the cause of the deviation was corrected].  Specifically,***
1406 21 CFR 110.10(b)(6) 32 Effective use of hair restraint Failure to wear [hair nets] [head bands] [caps] [beard covers] [appropriate hair restraints] in an effective manner.  Specifically, ***
906 21 CFR 123.6(b) 31 HACCP plan location Your HACCP plan is not specific to [the location where the fish are processed] [the kind of fish or fishery product processed].  Specifically, ***
1571 21 CFR 110.35(d)(5) 31 Shown to be effective The [facility] [procedure] [machine] used for [cleaning] [sanitizing] of [equipment] [utensils] has not been shown to provide adequate [cleaning] [sanitizing treatment].  Specifically, ***
6010 21 CFR 123.8(a)(3)(i) 31 Monitoring record review adequacy Your review of critical control point monitoring records does not [ensure that the records are complete] [verify that they document values that are within critical limits].  Specifically, ***
9930 21 CFR 120.6(c) 31 SSOP records You do not [always] maintain sanitation standard operating procedure records that document [the monitoring of conditions and practices during processing] [corrections to conditions and practices that were not met].  Specifically, ***
1426 21 CFR 110.20(b)(5) 30 Adequate lighting Failure to provide adequate lighting in [hand-washing areas] [dressing and locker rooms] [toilet rooms] [areas where food is examined, stored, or processed] [areas where equipment and utensils are cleaned].  Specifically, ***
1599 21 CFR 110.37(b)(5) 30 Backflow prevention Lack of backflow protection from piping systems that discharge [waste water] [sewage].  Specifically, ***
3086 21 CFR 114.100(b) 30 Maintenance of processing and production records Failure to maintain [processing] [production] records showing adherence to the scheduled processes, including records of [pH measurement] [critical factors] intended to ensure a safe product.  Specifically, ***
918 21 CFR 123.8(a) 29 Verification - reviewers qualifications The [reassessment of your HACCP plan] [monitoring, corrective action, or verification record review] was not done by an individual who had successfully completed training in the application of HACCP principles to fish and fishery product processing, or was otherwise qualified through job experience to perform these functions.  Specifically, ***
1698 21 CFR 110.80(b)(5) 29 Work-in-progress Failure to handle work-in-progress in a manner that protects against contamination.  Specifically, ***
6007 21 CFR 123.9(a) 29 Records entries - timing Processing or other information was not [always] entered on your records at the time it was observed.  Specifically, ***
3656 21 CFR 110.37(d)(3) 28 Self-closing doors Toilet facilities lack self-closing doors.  Specifically, ***
6019 21 CFR 123.8(a)(2) 27 Ongoing verification - complaints, calibration records Your verification procedures do not include, at a minimum, ongoing verification activities including [review of consumer complaints] [calibration of process monitoring instruments] [review of monitoring, corrective action, and calibration records].  Specifically, ***
3654 21 CFR 110.37(d)(1) 26 Maintained Failure to maintain toilet facilities in a sanitary condition.  Specifically, ***
1293 21 CFR 110.20(b)(2) 25 Contamination with microorganisms, chemicals, filth, etc. Proper precautions to protect [food] [food-contact surfaces] [food-packaging materials] from contamination with [microorganisms] [chemicals] [filth] [extraneous material] cannot be taken because of deficiencies in plant [size] [construction] [design].  Specifically, ***
1429 21 CFR 110.20(b)(6) 25 Fans/air blowing equipment Failure to [locate] [operate] fans and other air-blowing equipment in a manner that minimizes the potential for contaminating [food] [food-contact surfaces] [food-packaging materials].  Specifically, ***
9935 21 CFR 120.7(a) 25 No hazard analysis You did not develop, or have developed for you, a written hazard analysis to determine whether there are food hazards that are reasonably likely to occur for [each type of]  juice you produce.  Specifically, ***. Specifically, ***
12742 21 CFR 120.8(a) 25 HACCP plan not implemented You did not [fully] implement the [monitoring] [validation] [verification] [recordkeeping] procedures listed in your HACCP plan.  Specifically, ***
6006 21 CFR 123.6(c)(7) 24 Records values/observations Your monitoring records do not contain the actual values and observations obtained during monitoring.  Specifically, ***
9941 21 CFR 120.8(a) 24 No HACCP plan You do not have a written HACCP plan that outlines controls for one or more food safety hazards that are reasonably likely to occur.  Specifically, ***
1570 21 CFR 110.35(d)(5) 23 Safe and adequate for use Sanitizing agents are [inadequate] [unsafe] under conditions of use.  Specifically, ***
6022 21 CFR 123.12(c) 23 Lack of records You do not have records to document the performance and results of the affirmative steps taken to demonstrate that [fish] [fishery products] imported into the United States were processed in accordance with the seafood HACCP regulation.  Specifically, ***
9958 21 CFR 120.12(c) 23 Records - signed/dated Your [written hazard analysis] [written HACCP plan], required by the juice HACCP regulation, [was] [were] not signed and dated [upon initial acceptance] [upon modification] [upon verification] [upon validation] [by the most responsible individual onsite at the processing facility or by a higher level official].  Specifically, ***
1602 21 CFR 110.37(a) 22 Suitable temp. and pressure Failure to provide running water [at a suitable temperature] [under suitable pressure] for [processing of food] [cleaning of equipment, utensils and food-packaging materials] [employee sanitary facilities].  Specifically, ***
3080 21 CFR 114.83 22 Scheduled process establishment A scheduled process was not established by a qualified person who has expert knowledge acquired through appropriate training and experience in acidification and processing of acidified foods.  Specifically, ***
932 21 CFR 123.7(d) 21 Corrective action documentation You do not have records that document corrective actions that were taken.  Specifically, ***
12745 21 CFR 120.8(b)(1) 21 HACCP plan - food hazards not listed Your HACCP plan does not list all food hazards that are reasonably likely to occur.  Specifically, ***
1289 21 CFR 110.20(a)(3) 20 Drainage Lack of adequate drainage of areas which may contribute to contamination of food by [seepage] [foot-borne filth] [providing a breeding place for pests]. Specifically, ***
1578 21 CFR 110.37(f) 20 Odor, attractant for pests, harborage The [conveyance] [storage] [disposal] of [rubbish] [offal] does not minimize the [development of odor] [potential for waste becoming an attractant and harborage or breeding place for pests].  Specifically, ***
9954 21 CFR 120.11(a)(1)(iv) 20 Verification - CCP, CA record review You did not review [all of] your [critical control point monitoring] [corrective action] records within one week (7 days) of the day the records are made.  Specifically, ***
9955 21 CFR 120.11(a)(1) 20 Verification activities - minimum Your verification activities do not include, at a minimum, [review of consumer complaints to determine whether they relate to the performance of the HACCP plan] [calibration of process monitoring instruments] [end-product or in-product testing] [review of critical control point monitoring, corrective action, and calibration records] to ensure that your HACCP system is being properly implemented.  Specifically, ***
12734 21 CFR 120.12(a) 20 Records required - not maintained You do not maintain [complete] records documenting [the implementation of your sanitation standard operating procedure] [your written HACCP plan] [your written hazard analysis] [monitoring of critical control points and their critical limits] [corrective actions taken in response to a deviation] [the verification of your HACCP system] [the validation of your HACCP plan] [the validation of your hazard analysis].  Specifically, ***
1067 21 CFR 110.40(c) 19 Non food-contact equipment in processing area Non food-contact equipment in [manufacturing] [food handling] areas is not constructed so that it can be kept in a clean condition.  Specifically, ***
1128 21 CFR 110.40(a) 18 Installation and maintenance of equipment (S) Failure to [install] [maintain] equipment so as to facilitate cleaning of [the equipment] [all adjacent spaces].  Specifically, ***
1596 21 CFR 110.37(b)(2) 18 Convey sewage Plumbing is not [of adequate size and design] [adequately installed and maintained] to properly convey sewage and liquid disposable waste from the plant.  Specifically, ***
1702 21 CFR 110.80(b)(8) 18 Metal / extraneous materials Failure to take effective measures to protect against the inclusion of [metal] [extraneous material] in food.  Specifically, ***
6016 21 CFR 123.6(c)(7) 18 Records system Your HACCP plan does not provide for a recordkeeping system that documents the monitoring of the critical control points.  Specifically, ***
9947 21 CFR 120.11(b) 18 HACCP plan - not validated You did not validate that your HACCP plan is adequate to control food hazards [at least once within 12 months after implementation] [at least annually] [when a change in the process occurred that could have affected the hazard analysis or altered the HACCP plan in any way].  Specifically, ***
2361 21 CFR 110.80 17 Testing Failure to perform [chemical] [microbial] [extraneous material] testing where necessary to identify [sanitation failures] [possible food contamination]. Specifically, ***
3655 21 CFR 110.37(d)(2) 17 Good repair Failure to keep toilet facilities in good repair.  Specifically, ***
4464 21 CFR 108.25(c)(1) 17 Registration Failure to register with the FDA information including the name, principal place of business and the location of the processing establishment within 10 days after engaging in the manufacture, processing and packaging of acidified foods. Specifically, ***
6014 21 CFR 123.6(c)(2) 17 Monitoring - none Your HACCP plan does not list the [procedures for monitoring] [frequency of monitoring] at each critical control point to ensure compliance with the critical limit.  Specifically,
9932 21 CFR 120.6(a) 17 Sanitation SSOP - none or not implemented You do not [always] have or have not implemented a sanitation standard operating procedure that addresses sanitation conditions and practices before, during and after processing.  Specifically, ***
1565 21 CFR 110.35(d)(3) 16 Non-food-contact surfaces (S) Failure to clean non-food-contact surfaces of equipment as frequently as necessary to protect against contamination.  Specifically, ***
1598 21 CFR 110.37(b)(4) 16 Drainage Plumbing is not [of adequate size and design] [adequately installed and maintained] to provide adequate floor drainage.  Specifically, ***
3647 21 CFR 110.10(c) 16 Training of handlers and supervisors Appropriate training in food handling techniques and food protection principles has not been provided to [food handlers] [supervisors].  Specifically, ***
9928 21 CFR 120.12(b) 16 Records - general - include name, date, time Your required records do not [always] include [the name of the processor] [the name of the importer] [the location of the processor] [the location of the importer] [the date and time of the activity] [the signature or initials of the person performing the operation or creating the record] [the identity of the product] [the production code].  Specifically, ***
12747 21 CFR 120.8(b)(3) 16 HACCP plan - critical limits not listed or not adequate Your HACCP plan [does not list one or more of the critical limits that must be met at each critical control point] [lists a critical limit that does not prevent, eliminate, or reduce to an acceptable level the occurrence of an identified food hazard].  Specifically, ***
3073 21 CFR 114.80(a)(2) 15 pH testing Failure to exercise sufficient control including [frequent testing] [recording of results] so that the finished equilibrium pH values are not higher than 4.6.  Specifically, ***
3078 21 CFR 114.80(b) 15 Code - required elements Each container is not marked with an identifying code specifying the [establishment where the product was packed] [product contained therein] [year] [date] [packing period]. Specifically, ***
12746 21 CFR 120.8(b)(2) 15 HACCP plan - critical control points not listed Your HACCP plan does not list the critical control points for each of the identified food hazards.  Specifically, ***
12755 21 CFR 120.11(a)(1)(iv)  15 Records - not signed and dated by qualified individual Your review of [critical control point monitoring records] [corrective action records] [calibration records] [periodic end-product or in-process testing records] are not [performed] [signed] [dated] by an individual who is trained in the application of HACCP principles to juice processing or otherwise qualified through job experience. Specifically, ***
1697 21 CFR 110.80(b)(4) 14 Preventive control measures Failure to use adequate [sterilization] [irradiation] [pasteurization] [freezing] [refrigeration] [pH control] [water activity control] to destroy or prevent the growth of undesirable microorganisms in food.  Specifically, ***
3062 21 CFR 114.10 14 Personnel Operators of processing and packaging systems are not under the operating supervision of a person who has attended and satisfactorily completed a school approved by the Commissioner.  Specifically, ***
3662 21 CFR 110.37(e)(6) 14 Refuse receptacles Refuse receptacles for hand washing facilities are not [constructed] [maintained] to protect against contamination of food.  Specifically, ***
9939 21 CFR 120.7(c) 14 All hazards not considered In evaluating what food hazards are reasonably likely to occur, [you] [the person who performed the evaluation for you] did not consider [microbiological contamination] [parasites] [chemical contamination] [unlawful pesticide residues] [decomposition] [natural toxins] [use of unapproved color or food additives] [presence of undeclared ingredients that may be allergens] [physical hazards].  Specifically, ***
12749 21 CFR 120.8(b)(6) 14 HACCP plan - verify procedures / frequency - none listed Your HACCP plan does not list the verification [procedures] [frequencies] that have been developed to ensure that the HACCP plan is being implemented.  Specifically, ***
1403 21 CFR 110.10(b)(4) 13 Hand jewelry - remove/cover Failure to [remove] [adequately cover] hand jewelry which cannot be adequately sanitized during periods where food is being manipulated by hand.  Specifically, ***
3071 21 CFR 114.80(a)(1) 13 Scheduled process Acidified food is not manufactured in accordance with the scheduled process.  Specifically, ***
3075 21 CFR 114.80(a)(4) 13 Container testing Failure to [test] [examine] containers often enough to ensure that containers suitably protect the food from leakage and contamination.  Specifically, ***
6009 21 CFR 123.8(a)(3)(iii) 13 Verification - record review - calibration You did not review [some of] your calibration records within a reasonable time after the records were made.  Specifically, ***
9936 21 CFR 120.7(a) 13 Hazard analysis - written - elements Your written hazard analysis does not consist of [an identification of food hazards] [an evaluation of each food hazard identified to determine if it must be addressed in the HACCP plan] [an identification of the control measures that can be applied] [a review of your current process to determine whether modifications are necessary] [an identification of critical control points].  Specifically, ***
950 21 CFR 123.12(d) 12 Determination of compliance You have not provided evidence that the [fish] [fishery products] you import have been processed under conditions that comply with the Seafood HACCP regulation.  Specifically, ***
975 21 CFR 123.9(b)(1) 12 Record retention Your [monitoring] [corrective action] [verification] records are not maintained at your facility for at least the required time period.  Specifically, ***
1090 21 CFR 110.40(d) 12 Holding, conveying, mfg systems - design & construction Lack of appropriate [design] [construction] to enable [holding] [conveying] [manufacturing] systems to be maintained in an appropriate sanitary condition.  Specifically, ***
1129 21 CFR 110.40(a) 12 Food-contact - corrosion resistant Lack of corrosion-resistant food contact surfaces.  Specifically, ***
1566 21 CFR 110.35(d)(4) 12 Single-service articles Failure to [store] [handle] [dispense] [use] [dispose of] single-service articles in a manner that protects against the contamination of food and food-contact surfaces.  Specifically, ***
1766 21 CFR 110.35(b)(1) 12 Unacceptable toxic compounds Storage or use of toxic materials which are not required to maintain clean and sanitary conditions, are unnecessary for use in laboratory testing procedures, are unnecessary for plant and equipment maintenance, and are unnecessary for use in plant operations.  Specifically, ***
3085 21 CFR 114.100(a) 12 Raw materials, packaging, finished product Records are not maintained of the examination of [raw materials] [packaging materials] [finished products] [supplier's guarantees or certificates] to verify compliance with FDA regulations and guidelines or action levels.  Specifically, ***
3712 21 CFR 110.93 12 Storage/transportation of finished goods (deterioration) Failure to [store] [transport] finished food under conditions that would protect against deterioration of the food and its container.  Specifically, ***
929 21 CFR 123.8(b) 11 Verification - corrective action You did not take immediate corrective action to ensure that [no affected product entered into commerce] [the cause of the deviation was corrected] [the HACCP plan was reassessed] when your verification procedure revealed the need to take a corrective action.  Specifically, ***
986 21 CFR 110.10(b)(2) 11 Personal cleanliness Employees in contact with [food] [food-contact surfaces] [food-packaging materials] were not maintaining adequate personal cleanliness.  Specifically, ***
1601 21 CFR 110.37(a) 11 Safe and adequate sanitary quality Failure to use water which is [safe] [of adequate sanitary quality] in food and on food-contact surfaces.  Specifically, ***
1763 21 CFR 110.35(b)(1) 11 Safe and adequate for use Use of cleaning compounds and sanitizing agents which are not [free from undesirable microorganisms] [safe and adequate under the conditions of use].  Specifically, ***
2393 21 CFR 110.80(b)(1) 11 Teardown equipment/thorough cleaning Failure to take apart equipment as necessary to ensure thorough cleaning.  Specifically, ***
3067 21 CFR 114.80(a) 11 Quality control procedures Appropriate quality control procedures are not employed to ensure that finished foods do not present a health hazard.  Specifically, "***
3643 21 CFR 110.10(b)(5) 11 Glove condition Gloves used in food handling are not maintained in an intact, clean, and sanitary condition.  Specifically, ***
3657 21 CFR 110.37(d)(4) 11 Doors opening into processing areas Toilet doors open into areas where food is exposed to airborne contamination, and there are no alternative means taken to prevent such contamination.  Specifically, ***
4295 21 CFR 110.40(a) 11 Food contact - non-toxic materials Food-contact surfaces are not made of non-toxic materials.  Specifically, ***
9919 21 CFR 120.10(a) 11 Corrective action - predetermined plan inadequate You did not take corrective action that ensured [affected product was not entered into commerce] [the cause of the deviation was corrected]. Specifically, ***
1060 21 CFR 123.11(a) 10 SSOP(S) You [do not have] [have not implemented] a written sanitation standard operating procedure (SSOP).  Specifically, ***
1130 21 CFR 110.40(a) 10 Food-contact - withstand food & cleaning cmpds. Food contact surfaces are not designed to [withstand the environment of their intended use] [withstand the action of food] [withstand cleaning compounds and sanitizing agents].  Specifically, ***
1425 21 CFR 110.20(b)(4) 10 Spacing of equipment Aisles or working spaces between equipment and walls are [obstructed] [of inadequate width].  Specifically, ***
1561 21 CFR 110.35(c) 10 Insecticides/rodenticides Use of [insecticides] [rodenticides] without observing necessary precautions and restrictions to protect against contamination of [food] [food-contact surfaces] [food-packaging materials].  Specifically, ***
1709 21 CFR 110.80(b)(13) 10 Filling, assembling, packing controls Failure to perform [filling] [assembling] [packaging] in a manner that protects food from becoming contaminated.  Specifically, ***
2385 21 CFR 110.80(a)(1) 10 Inspection, segregation, handling of raw materials Failure to [inspect] [segregate] [handle] raw materials to ascertain that they are clean and suitable for processing into food.  Specifically, ***
1196 21 CFR 110.10(a) 9 Employees with illness,  lesions, contamination source Employees  who appear to have an [illness] [open lesion] [abnormal source of microbial contamination] are not excluded from operations where there is a reasonable possibility of [food] [food contact surfaces] [food packaging materials] becoming contaminated.  Specifically, ***
1641 21 CFR 113.100(b) 9 Review not done/timely A review of processing and production records by a qualified representative of plant management was not done [within one working day after the completion of  the process] [before shipment or release for distribution] to determine [completeness of the records] [whether product was processed as specified by the scheduled process].  Specifically, ***
1711 21 CFR 110.80(b)(15) 9 Proper pH controls Failure to adequately [monitor pH] [maintain a pH of 4.6 or below] for foods that rely principally on the control of pH to prevent the growth of undesirable microorganisms.  Specifically, ***
2427 21 CFR 110.80(b)(9) 9 Proper disposal of adulterated product Failure to dispose of adulterated [food] [raw materials] in a manner which protects against the contamination of other food.  Specifically, ***
4479 21 CFR 108.25(e) 9 Recall procedures Failure to prepare and maintain in files current procedures for [recalling products that may be injurious to health] [identifying, collecting, warehousing and controlling products] [determining the effectiveness of recalls] [notifying FDA] [implementing recall programs]. Specifically, ***
6017 21 CFR 123.7(c) 9 Corrective action per regulation You did not take corrective action that ensured [the affected product was segregated] [a review of the affected product was done to determine its acceptability] [affected product was not entered into commerce] [the cause of the deviation was corrected] [the HACCP plan was reassessed in a timely manner to determine if modifications were needed to reduce the risk of reoccurrence of the deviation and modified as necessary].  Specifically, ***
9943 21 CFR 120.8(a) 9 HACCP plan - location and type of juice Your HACCP plan is not specific to [each location where juice is processed] [each type of juice processed].  Specifically, ***
12751 21 CFR 120.8(b)(7) 9 HACCP plan - recordkeeping system Your HACCP plan does not provide for a recordkeeping system that documents the monitoring of critical control points.  Specifically, ***
15302 21 CFR 120.11(a)(2) 9 Calibration, testing - no records You do not maintain records of [calibration of process-monitoring instruments] [periodic end-product or in-process testing].  Specifically, ***
1184 21 CFR 110.35(e) 8 Storage of cleaned portable equipment (S) Failure to store cleaned and sanitized portable equipment in a [location] [manner] which protects food-contact surfaces from contamination.  Specifically, ***
3090 21 CFR 114.100(d) 8 Product distribution Records identifying initial distribution of finished product are not maintained.  Specifically, ***
3660 21 CFR 110.37(e)(4) 8 Devices and fixtures Devices and fixtures are not designed and constructed to protect against recontamination of clean, sanitized hands.  Specifically, ***
4421 21 CFR 110.20(a) 8 Maintenance of grounds Maintenance of the grounds is inadequate to protect against contamination of food.  Specifically, *** 
4511 21 CFR 108.25(f) 8 Approved school Failure to have personnel involved in [acidification] [pH control] [heat treatment] [critical factors] under the operating supervision of a person who has attended and satisfactorily completed a school approved by the Commissioner. Specifically, ***
4515 21 CFR 108.35(c)(2) 8 Process filing Failure to provide FDA, before packing any new product, information as to the scheduled process for each low-acid canned food in each container.  Specifically, ***
12750 21 CFR 120.8(b)(6) 8 HACCP plan - valid procedures / frequency - none listed Your HACCP plan does not list the validation [procedures] [frequencies] that have been developed to ensure that the HACCP plan is adequate to control food hazards that are reasonably likely to occur.  Specifically, ***
938 21 CFR 123.9(c) 7 Official review You did not make available for official review and copying at reasonable times [all records] [all plans and procedures] required by the regulations.  Specifically, ***
1132 21 CFR 110.40(a) 7 Food-contact - unlawful indirect additives Failure to maintain food contact surfaces to protect food from contamination by any source, including unlawful indirect food additives.  Specifically, ***
1290 21 CFR 110.20(a)(4) 7 Waste disposal Failure to properly maintain operating systems for waste treatment and disposal so that they do not constitute a source of contamination in areas where food is exposed.  Specifically, ***
1595 21 CFR 110.37(b)(1) 7 Sufficient quantities of water Plumbing is not [of adequate size and design] [adequately installed and maintained] to carry sufficient quantities of water to required locations throughout the plant.  Specifically, ***
1642 21 CFR 113.100(b) 7 Review not signed/dated Failure of the reviewer to [sign or initial] [date] the [processing records] [production records] [recording temperature chart(s)] after the completion of the processing of a low-acid food product.  Specifically, ***
2362 21 CFR 110.80 7 Reject and rework Food which has become contaminated to the extent of being adulterated within the meaning of the Act is not rejected or if permissible, treated or processed to eliminate the contamination..  Specifically, ***
3089 21 CFR 114.100(c) 7 Process deviations- identification and records Departures from a scheduled process having a possible bearing on public health or the safety of a food are not [noted] [identified] [recorded] [made the subject of a separate file (or log identifying the appropriate data) delineating them].  Specifically, ***
4181 21 CFR 113.89 7 Process deviation identification Failure to identify, from processor check or otherwise, deviations from the scheduled process or critical factors which are out of control.  Specifically, ***
4419 21 CFR 110.10(c) 7 Level of competency (S) Personnel responsible for identifying [sanitation failures] [food contamination] lack a background of education and experience to provide a needed level of competency.  Specifically, ***
9917 21 CFR 120.10(c) 7 Corrective action documentation You do not have records that [fully] document corrective actions that were taken.  Specifically, ***
972 21 CFR 123.8(a)(1) 6 Modification HACCP plan You did not immediately modify your HACCP plan after a reassessment revealed the plan to no longer be adequate.  Specifically, ***
1428 21 CFR 110.20(b)(6) 6 Adequate ventilation Failure to provide [adequate ventilation] [control equipment] to minimize odors and vapors in areas where they may contaminate food.  Specifically, ***
2384 21 CFR 110.80(a)(7) 6 Receipt/storage - liquid and dry raw materials Failure to receive and store [liquid] [dry] raw materials in bulk form in a manner which protects against contamination.  Specifically, ***
2388 21 CFR 110.80(a)(5) 6 Holding in bulk or suitable containers Failure to hold [raw materials] [rework materials] [ingredients] in bulk or in suitable containers so as to protect against contamination.  Specifically, ***
3645 21 CFR 110.10(d) 6 Supervision Responsibility for assuring compliance with current good manufacturing practices relating to personnel  has not been assigned to competent supervisory personnel.  Specifically, ***
9926 21 CFR 120.14(a) 6 Importer - written procedures You do not have written procedures that describe [product specifications] [affirmative steps] to ensure that juice you receive for import into the United States was processed in accordance with the juice HACCP regulation.  Specifically, ***
12743 21 CFR 120.8(b)(4) 6 HACCP plan - monitoring procedures not adequate Your HACCP plan lists monitoring [procedures] [frequencies of performing procedures] that do not ensure compliance with the critical limits.  Specifically, ***
12744 21 CFR 120.8(b)(4) 6 HACCP plan - monitoring procedures - none listed Your HACCP plan does not list the [procedures for monitoring] [frequency of monitoring] at each critical control point to ensure compliance with the critical limits.  Specifically, ***
12748 21 CFR 120.8(b)(5) 6 HACCP plan - corrective action plan not included Your HACCP plan includes a corrective action plan that is not in accordance with 21 CFR 120.10(a) to ensure [affected product is not entered into commerce] [the cause of the deviation was corrected]. Specifically,***
1176 21 CFR 110.40(f) 5 Insufficient number of Q.C. instruments An inadequate number of instruments used for [measuring] [regulating] [recording] conditions that control or prevent the growth of undesirable microorganisms.  Specifically,***
1330 21 CFR 113.100(a) 5 Processing entry missing information Forms used to record processing or production information lack the [product] [code number] [date] [retort or processing system number] [container size] [approximate number of containers per coding interval] [initial temperature] [actual processing time] [mercury-in-glass thermometer readings] [recording thermometer readings] [appropriate processing data].  Specifically, ***
1472 21 CFR 113.83 5 Critical factors not stated Critical factors that may affect the scheduled process are not specified in the scheduled  process.  Specifically, ***
1486 21 CFR 113.87(b) 5 System not established A system of traffic control to prevent unretorted product from bypassing the retort system has not been established.  Specifically, ***
1534 21 CFR 113.100(b) 5 Entries not done Required entries on [processing records] [production records] were not made by the retort or processing system operator or other designated person for specific retort operations or conditions specified in the scheduled process.  Specifically, ***
1568 21 CFR 110.35(d)(2) 5 Before use and after interruption Failure to clean and sanitize food-contact surfaces in wet-processing [before use] [after any interruption during which they may have been contaminated], to preclude contamination with microorganisms.  Specifically, ***
1688 21 CFR 110.80 5 Supervisory competence The function of supervising overall sanitation of the plant has not been designated to  the supervision of  one or more competent individuals assigned responsibility for this function.  Specifically, ***
2394 21 CFR 110.80(b)(6) 5 Contamination by raw materials, refuse, other ingredients Failure to take effective measures to protect finished food from contamination by [raw materials] [refuse] [other ingredients] .  Specifically, ***
3072 21 CFR 114.80(a)(1) 5 Thermal processing Acidified foods are not thermally processed to an extent that is sufficient to destroy the vegetative cells of microorganisms of public health significance and those of nonhealth significance capable of growing in the food.  Specifically, ***
3077 21 CFR 114.80(b) 5 Visible code Each container is not marked with an identifying code permanently visible to the naked eye.  Specifically, ***
3653 21 CFR 110.37(d) 5 Readily accessible Failure to provide employees with [readily accessible] [adequate] toilet facilities.  Specifically, ***
3877 21 CFR 113.60(c) 5 Coding - required elements The required container identification fails to include the [establishment where packed] [product] [year packed] [day packed]  [period during which packed].  Specifically, ***
6012 21 CFR 123.8(a)(3)(iii) 5 Calibration record review adequacy Your review of [calibration] [in-process testing][end-product testing] records does not ensure [that the records are complete] [that the activities occurred in accordance with your written procedures] [occurred within a reasonable time after the records were made]. Specifically, *** 
9953 21 CFR 120.11(a)(1)(iv)(A) 5 CCP record review adequacy Your review of critical control point monitoring records does not [ensure that the records are complete] [verify that they document values that are within critical limits].  Specifically, ***
9959 21 CFR 120.12(d)(1) 5 Record retention - general You do not retain [all of] the required records at your facility for the required time period.  Specifically, ***
9981 21 CFR 120.12(b)(4) 5 Records - actual values Your records do not [always] contain the actual values and observations obtained during monitoring.  Specifically, ***
9986 21 CFR 120.24(c) 5 Process controls - not exempt, single facility You do not conduct the 5-log reduction process and perform final packaging of your juice within a single production facility operating under current good manufacturing practices. Specifically, ***
12721 21 CFR 1.234 5 Registration not updated You did not submit an update to your facility's registration within 60 calendar days of [a change] [changes] to the registration information previously submitted.  Specifically, ***
12733 21 CFR 120.11(a)(1)(iv)(C) 5 Calibration, testing - record review timeliness You did not review [all of] your [calibration] [periodic end-product testing] [in-process testing] records within a reasonable time after the records were made.  Specifically, ***
12736 21 CFR 120.12(e) 5 Records - review and copying You did not make all required records available for review and copying at reasonable times.  Specifically, ***
976 21 CFR 123.9(b)(2) 4 Process adequacy records The records that relate to the general adequacy of your [processes] [equipment] were not maintained for at least two years after their applicability to the product you produced.  Specifically, ***
1334 21 CFR 113.100(a)(4) 4 Aseptic processing Forms used in recording specific processing and production information for aseptic processing and packaging systems lack [the product temperature in the holding tube outlet] [the product temperature in the final heater outlet] [differential pressure] [product flow rate] [sterilization media flow rate] [sterilization media temperature] [retention time of containers and closures] [sterilization cycle times] [sterilization cycle temperatures].  Specifically, ***
1643 21 CFR 113.100(c) 4 Incomplete information Written records of all container closure examinations did not specify [product code] [date of container closure inspection] [time of container closure inspection] [measurements obtained] [corrective actions taken].  Specifically, ***
1734 21 CFR 113.40(a)(2) 4 Corresponding with MIG Failure to properly adjust the temperature-recording device.  The temperature recorded on the temperature-recording device chart [was higher than] [did not agree with] the mercury-in-glass thermometer during processing.  Specifically, ***
1757 21 CFR 113.40(a)(8) 4 Observable Failure to install bleeders so that the operator can observe that they are functioning properly.  Specifically, ***
3088 21 CFR 114.100(b) 4 Processing and production - required information The [processing] [production] records do not contain sufficient additional information such as [product code] [date] [container size] [product] to permit a public health hazard evaluation of the processes applied to each [lot] [batch] [portion] of production.  Specifically, ***
3644 21 CFR 110.10(b)(5) 4 Impermeable (S) Gloves used for food handling are not impermeable.  Specifically,  ***
3872 21 CFR 113.60(a)(3) 4 Closures other than double seams and glass Failure to [have a qualified person] perform appropriate detailed inspections and tests [at intervals of sufficient frequency] to ensure proper closing machine performance and consistently reliable hermetic seal production.  Specifically, ***
4296 21 CFR 110.80(a)(5) 4 Temperature and humidity Failure to hold [raw materials] [rework materials] [ingredients] at proper temperature and humidity to prevent the food from becoming adulterated.  Specifically, ***
4529 21 CFR 108.35(c)(2)(ii) 4 Process change reporting to CFSAN For an intentional change in a previously filed scheduled process, failure to submit to CFSAN, within 30 days after first use, [a complete description of the modifications made and utilized] [a copy of the file record showing prior substantiation by a qualified scientific authority as to the safety of the changed process].  Specifically, ***
9946 21 CFR 120.11(b) 4 Validation - reviewer's qualifications Your [validation of the HACCP plan] [validation of the hazard analysis] was not done by an individual who had successfully completed training in the application of HACCP principles to juice processing or otherwise qualified through job experience to perform these function.  Specifically, ***
949 21 CFR 123.12(c) 3 Records, English The records that document the performance and results of the affirmative step you chose are not in English.   Specifically, ***
1255 21 CFR 129.20(a) 3 Bottling room separation The bottling room is not [adequately] separated from other plant operations or storage areas, so as to protect against contamination.  Specifically, ***
1288 21 CFR 110.20(a)(2) 3 Roads/yards/parking lots Failure to properly maintain [roads] [yards] [parking lots] so that they do not constitute a source of contamination in areas where food is exposed. Specifically, ***
1529 21 CFR 113.89 3 Process deviation log/file Process deviations were not recorded in a separate file or log that details both the deviations and the actions taken.  Specifically, ***
1640 21 CFR 113.100(b) 3 Entries not signed The retort or processing system operator or other designated person did not initial or sign each record form.   Specifically, ***
1644 21 CFR 113.100(c) 3 Not signed or initialed Written records of container closure examinations were not signed or initialed by the container closure inspector.  Specifically, ***
1651 21 CFR 113.40(a)(1) 3 Thermometer calibration Mercury-in-glass thermometers were not tested against a known accurate standard thermometer [upon installation] [yearly] to ensure accuracy.  Specifically, ***
1653 21 CFR 113.40(a)(1) 3 Unreadable MIG thermometer Mercury-in-glass thermometers were not installed where they can be accurately and easily read.  Specifically, ***
1708 21 CFR 110.80(b)(12) 3 Batters, breading, gravies, sauces, etc. Failure to treat and maintain [batters] [breading] [sauces] [gravies] [dressings and similar preparations] in a manner that protects against [contamination] [growth of microorganisms].  Specifically, ***
1751 21 CFR 113.40(a)(8) 3 Size, fully open Bleeders were [smaller than 1/8-inch] [not wide open during the entire process] [not open during come-up-time].  Specifically, ***
2274 21 CFR 129.80(g)(1) 3 Bacteriological You do not take and analyze samples of bottled drinking water for bacteriological testing at least once a week [for each type of bottled drinking water produced during a day's production run].  Specifically, ***
2329 21 CFR 113.40(c)(5) 3 Size, fully open Bleeders are [smaller than 1/8-inch] [not wide open during the entire process] [not open during come-up-time].  Specifically, ***
2391 21 CFR 110.80(a)(6) 3 Thawed appropriately Failure to thaw frozen raw materials in a manner that prevents them and other ingredients from becoming adulterated.  Specifically, ***
2396 21 CFR 110.80(b)(6) 3 Conveyor transportation Failure to take effective measures to protect food transported by conveyor from contamination.  Specifically, ***
2870 21 CFR 113.40(g)(1)(ii)(e) 3 Readings with sufficient frequency Measurements or observations of the [temperature-indicating device in the holding tube outlet] [temperature recorder in the holding tube outlet] [temperature recorder-controller at the final heater outlet] [differential pressure recorder-controller] [product flow rate] [sterile air pressure] [proper performance of seam seals or similar devices] were not [performed]  [recorded] at intervals of sufficient frequency to ensure the values were as specified in the scheduled process for aseptic packaging operations.  Specifically ***
3082 21 CFR 114.89 3 Process deviation Failure to fully reprocess, thermally process as a low-acid food under 21 CFR 113, or set aside for further evaluation as to any potential public health significance, a portion of food which [deviated from a scheduled process] [had an equilibrium pH of the finished product higher than 4.6].  Specifically, ***
3663 21 CFR 110.40(e) 3 Lack of automatic control / alarm (S) Lack of [an automatic control for regulating  temperature] [an automatic temperature alarm system] for each freezer and cold storage compartment used to store food capable of supporting the growth of microorganisms.  Specifically, ***
3857 21 CFR 113.60(a) 3 Record of visual closure examination Failure to record observations of visual closure examinations performed by a qualified person during production.  Specifically, ***
4062 21 CFR 113.100(a) 3 Critical factors - entry missing information Forms used to record critical factors lack [closing machine vacuum in vacuum-packed products] [maximum fill-in weight] [drained weight] [critical factors specified in the scheduled process].  Specifically, ***
4514 21 CFR 108.35(c)(1) 3 Registration Failure to register with the FDA information including the name, principal place of business and the location of the processing establishment within 10 days after engaging in the manufacture, processing and packaging of low-acid canned foods. Specifically, ***
4523 21 CFR 108.35(f) 3 Recall procedures Failure to prepare and maintain in files current procedures for [recalling products which may be injurious to health] [identifying, collecting, warehousing and controlling products] [determining effectiveness of recalls] [notifying FDA] [implementing recall programs]. Specifically, ***
6002 21 CFR 123.11(b) 3 Sanitation corrections You did not correct sanitation deficiencies in a timely manner.  Specifically,***
9929 21 CFR 120.12(b)(4) 3 Records - information not entered when observed Processing and other information is not [always] entered on your records at the time it is observed.  Specifically, ***
9938 21 CFR 120.7(d) 3 Hazard analysis - evaluation of effect on safety (S) You did not evaluate [product ingredients] [processing procedures] [packaging] [storage] [intended use] [facility and equipment function and design] [plant sanitation, including employee hygiene] to determine the potential effect on the safety of the finished food for the intended consumer.  Specifically, ***
15305 21 CFR 120.14(a)(2) 3 Importer - implementation of affirmative steps You have not implemented affirmative steps to ensure juice you receive for import into the United States was processed in accordance with the juice HACCP regulation. Specifically, *** 
1045 21 CFR 113.10 2 Supervisors Supervisors have not satisfactorily completed training in a school approved by the Commissioner for areas under their responsibility.   Specifically, ***
1082 21 CFR 113.60(a) 2 Jams Failure to conduct visual closure inspections following a jam in a closure machine [after closing machine adjustment] [after startup of a machine] [following a prolonged shutdown].  Specifically ***
1093 21 CFR 110.40(g) 2 Compressed air/gases Failure to ensure that compressed air or other gases [mechanically introduced into food] [used to clean food-contact surfaces or equipment] have been treated in such a way that foods are not contaminated with unlawful indirect food additives.  Specifically, ***
1188 21 CFR 110.37(c) 2 Sewage disposal Failure to dispose of sewage into an adequate sewerage system or by other adequate means.  Specifically, ***
1286 21 CFR 129.35(a) 2 Approved sources The [product] [operations] water [supply is] [supplies are] not from an approved source.  Specifically, ***
1304 21 CFR 129.35(a)(1) 2 Product water quality The product water supply source is not [properly located, protected and operated] [easily accessible] [adequate] [of a safe, sanitary quality] [in conformance at all times with the applicable laws and regulations].  Specifically, ***
1316 21 CFR 113.87(c) 2 Initial temperature The initial temperature of the contents of a container to be processed was [not determined] [not recorded] with sufficient frequency to ensure the temperature was not lower than the minimum initial temperature stated in the scheduled process.  Specifically, ***
1329 21 CFR 113.100(a) 2 Processing entries not done/not timely Required information was not entered on designated forms at the time the observation was made by the retort or processing system operator or designated person.  Specifically, ***
1351 21 CFR 129.35(a)(3)(i) 2 Sampling of product & ops water You do not take and analyze samples of [product] [operations] source water [as often as necessary] [at least once every year for chemical contamination] [at least once every four years for radiological contaminants].  Specifically, ***
1353 21 CFR 129.35(a)(3)(i) 2 Sampling for micro contaminants The [product] [operations] source water that is obtained from other than a public water system is not sampled and analyzed for microbiological contaminants at least once each week.  Specifically, ***
1379 21 CFR 129.35(a)(4)(iv) 2 Compliance with standards Finished bottled water does not comply with bottled water quality standards.  Specifically, ***
1471 21 CFR 113.83 2 Scheduled processes not established Scheduled processes for low-acid foods have not been established by qualified persons having expert knowledge of thermal processing.  Specifically, ***
1499 21 CFR 113.89 2 No corrective action taken No corrective action was taken, e.g. fully reprocessing or setting the lot aside for evaluation, when a deviation from the scheduled process was found.  Specifically, ***
1500 21 CFR 113.89 2 Evaluation by process authority Failure to have a deviation from the scheduled process evaluated for public health significance by a competent processing authority.  Specifically, ***
1533 21 CFR 113.100(b) 2 RTC identification Recording thermometer charts were not identified by [date] [retort number] [data to correlate with written records of lots processed].  Specifically ***
1559 21 CFR 110.35(c) 2 Guard/guide dogs The [guard dog] [guard dogs] [guide dog] [guide dogs] in the plant are likely to result in the contamination of [food] [food-contact surfaces] [food-packaging materials]. Specifically, ***
1569 21 CFR 110.35(d)(2) 2 Continuous operations Failure to clean and sanitize utensils and food-contact surfaces of equipment in continuous wet-processing operations as necessary.  Specifically, ***
1577 21 CFR 110.37(f) 2 Contamination of food, contact surfaces, water supplies, etc The [conveyance] [storage] [disposal] of [rubbish] [offal] does not protect against contamination of [food] [food-contact surfaces] [water supplies] [ground surfaces].  Specifically, ***
1600 21 CFR 110.37(a) 2 General inadequacy Failure to use a water supply that is [sufficient for the operations] [derived from an adequate source].  Specifically, ***
1665 21 CFR 110.80(a)(2) 2 Pasteurization or other adequate treatment [Raw materials] [Ingredients] which contain levels of microorganisms that may produce food poisoning or other disease are not pasteurized or otherwise adequately treated.  Specifically, ***
1669 21 CFR 110.80(a)(3) 2 Aflatoxin and other natural toxins There is no assurance that [raw materials] [ingredients] which are susceptible to contamination with aflatoxin or other natural toxins comply with current FDA standards before being incorporated into food.  Specifically, ***
1670 21 CFR 110.80(a)(4) 2 Safety assurance - pests/extraneous materials There is no assurance that [raw materials] [ingredients] [rework materials] which are susceptible to contamination with [pests] [undesirable microorganisms] [extraneous materials] comply with current FDA standards and defect action levels.  Specifically, ***
1716 21 CFR 113.40(a)(11) 2 Water valves, leakage Failure to supply a suitable water valve used for water cooling to prevent leakage of water into the retort during processing.  Specifically, ***
1735 21 CFR 113.40(a)(2) 2 Unauthorized adjustment There was no means to prevent unauthorized changes in adjustment to the temperature-recording device.  Specifically, ***
1865 21 CFR 113.40(a)(12) 2 Short vent Timing of a process began before the retort [was properly vented] [processing temperature was reached]. Specifically, ***
2065 21 CFR 123.28(c) 2 Shellstock records You do not maintain records that document the [date of harvest] [location of harvest by State and site] [quantity and type of shellfish received] [date of receipt] [name of the harvester OR registration number of the harvester vessel OR the identification number of the harvester issued by the shellfish control authority].  Specifically, ***
2067 21 CFR 123.28(d) 2 Records - shucked shellfish You do not maintain records of shucked molluscan shellfish that document the [date of receipt] [quantity and type of shellfish] [name and certification number of the packer or repacker of the product].  Specifically, ***
2272 21 CFR 129.80(e) 2 Plant records You do not record and maintain information as to the [kind of product] [volume produced] [date produced] [lot code used] [distribution of finished product to wholesale and retail outlets].  Specifically, ***
2275 21 CFR 129.80(g)(2) 2 Chemical, physical, radiological You do not take and analyze samples of bottled drinking water for [chemical] [physical] [radiological] testing at least annually [for each type of bottled drinking water produced during a day's production run].  Specifically, ***
2301 21 CFR 129.80(f) 2 Bacteriological contamination of containers and closures (S) You do not  take a bacteriological swab and/or rinse count at least every three months from at least four containers and closures selected just prior to filling and sealing.  Specifically, ***
2331 21 CFR 113.40(c)(5) 2 Location - from ends Bleeders are not installed [within approximately 1 foot of the outermost location of containers at each end of the retort] [along the top of the retort].  Specifically, ***
2390 21 CFR 110.80(a)(6) 2 Kept frozen prior to use Failure to keep frozen raw materials frozen prior to use.  Specifically, ***
2848 21 CFR 113.40(g)(1)(i)(b) 2 Corresponding with MIG Failure to properly adjust the temperature-recording device.  The temperature recorded on the temperature-recording device chart [was higher than] [did not agree with] a known accurate mercury-in-glass thermometer.  Specifically, ***
2887 21 CFR 113.40(j) 2 Conform to requirements The system, equipment, and procedures used for thermal processing of foods in hermetically sealed containers [did not conform to the applicable requirements of 21 CFR 113.40] [did not conform to methods and controls specified in the scheduled process] [were not operated and administered in a manner that ensures commercial sterility is achieved].  Specifically, ***
3074 21 CFR 114.80(a)(2) 2 Using pH meter Failure to [use a potentiometer to measure pH] [relate in-process measurements by titration or colorimetry to the finished equilibrium pH] when the finished equilibrium pH is above 4.0. Specifically, ***
3083 21 CFR 114.89 2 Process deviation evaluation Process deviations are not evaluated by a competent processing authority in accordance with procedures recognized by competent processing authorities as being adequate to detect any potential hazard to public health.  Specifically, ***
3648 21 CFR 110.20(a)(4) 2 Neighboring grounds Failure to take adequate care to exclude contamination of food from adverse conditions on bordering grounds not under your control.  Specifically, ***
3651 21 CFR 110.37(b)(5) 2 Cross contamination Systems that discharge waste water or sewage are cross-connected to systems that carry water for food or food manufacturing.  Specifically, ***
3708 21 CFR 110.80(a)(1) 2 Water quality -- wash, rinse, convey food Water [used] [re-used] to [wash] [rinse] [convey] food is not [safe] [of adequate sanitary quality].  Specifically, ***
3709 21 CFR 110.80(a)(1) 2 Inspection of containers and carriers upon receipt Failure to inspect [containers] [carriers] of raw materials upon receipt to ensure that their condition does not contribute to the contamination or deterioration of food.  Specifically, ***
3822 21 CFR 113.40(a)(1) 2 Records of calibration (S) Failure to maintain records of accuracy checks of temperature-indicating devices specifying [date] [standard used] [method used] [person performing the test].  Specifically, ***
3874 21 CFR 113.60(b) 2 Cooling water - failure to chlorinate, etc. Failure to chlorinate or otherwise sanitize container cooling water as necessary for cooling canals and recirculated water supplies.  Specifically, ***
3876 21 CFR 113.60(c) 2 Coding - failure to mark Failure to mark each hermetically sealed container of low-acid processed food with an identifying code that is permanently visible to the naked eye.  Specifically, ***
4420 21 CFR 110.110(c) 2 Defects not reduced to lowest level Quality control operations were not used at all times to reduce natural or unavoidable defects to the lowest level currently feasible
4512 21 CFR 108.25(g) 2 Record retention Failure to prepare, review and retain at [the processing plant] [a reasonably accessible location] for three years all records [of processing] [of deviations in processing] [specified in 21 CFR 114]. Specifically, ***
4519 21 CFR 108.35(c)(3)(i) 2 Process adherence Failure to process each low-acid canned food in conformity with at least the scheduled process. Specifically, ***
6011 21 CFR 123.8(a)(3)(ii) 2 Corrective action record review adequacy Your review of corrective action records does not [ensure that the records are complete] [verify that the appropriate corrective actions have been taken].  Specifically, ***
9933 21 CFR 120.6(b) 2 GMP correction - timely  You do not [always] correct deficiencies from good manufacturing practice in a timely manner.  Specifically, ***
9961 21 CFR 120.24(a) 2 Process controls - HACCP plan - 5 log reduction Your HACCP plan does not include control measures that will consistently produce a 5 log reduction in the most resistant microorganism of public health significance that is likely to occur in the juice, for a period at least as long as the shelf life of the product.  Specifically, ***
12753 21 CFR 120.11(a)(1)(iv)(A) 2 CA record review adequacy Your review of corrective action records does not [ensure that the records are complete] [verify that the appropriate corrective actions were taken].  Specifically, ***
12754 21 CFR 120.11(a)(1)(iv)(C) 2 Calibration, testing - record review adequacy Your review of [calibration of process monitoring instruments] [periodic end-product testing] [periodic in-process testing] records does not ensure that [the records are complete] [the activities occurred in accordance with your written procedures].  Specifically, ***
899 21 CFR 123.16 1 Process controls Your HACCP Plan for [smoked] [smoke flavored] fishery product does not include controls for Clostridium botulinum. Specifically, ***
939 21 CFR 123.9(f) 1 Computerized records Your computerized records do not provide that appropriate controls are implemented to ensure the integrity of the electronic data and signatures.  Specifically, ***
977 21 CFR 123.9(b)(3) 1 Records stored at another location You did not immediately return your records for official review upon demand.  Specifically, ***
1245 21 CFR 113.81(a) 1 Raw ingredients There was no means to assure that raw materials and ingredients susceptible to microbiological contamination were suitable for use in processing low-acid food.  Specifically, ***
1276 21 CFR 129.20(c) 1 Adequate ventilation The ventilation in the [processing room] [bottling room] [container washing and sanitizing area] is not adequate to minimize condensation.  Specifically, ***
1303 21 CFR 113.81(f) 1 Critical Factors The critical factors identified in the schedule process for the prevention of the growth of microorganisms not destroyed by the thermal process are not controlled in a manner to ensure the limits established are not exceeded.   Specifically, ***
1317 21 CFR 113.87(d) 1 Timing devices Failure to provide accurate timing devices to ensure that the processing and venting times specified in the scheduled process are achieved.  Specifically, ***
1325 21 CFR 113.100(e) 1 Record retention Copies of processing, production, and other required records for each lot of a low-acid food processed were not retained at the processing plant [for a one year period following manufacture] [or other reasonably accessible location for a total of a three-year record-retention period].  Specifically, ***
1331 21 CFR 113.100(a)(1) 1 Still retorts Forms used in recording specific processing and production information for still retorts lack [the time that steam was turned on] [the time that the retort reached processing temperature] [the time that steam was shut off] [venting time] [venting temperature].  Specifically, ***
1415 21 CFR 129.37(c) 1 Purchase of single service containers, caps, seals Your [single-service containers] [caps] [seals] are not [purchased] [stored] in sanitary closures.  Specifically, ***
1453 21 CFR 129.40(a)(1) 1 Suitability - equipment and utensils Not all plant equipment and utensils are suitable for their intended use.  Specifically, ***
1483 21 CFR 113.87(a) 1 Operating processes not posted Operating processes for each product and container size were not [posted in a conspicuous place near the processing equipment] [readily available to the retort or processing system operator] [readily available to FDA investigators].  Specifically, ***
1639 21 CFR 113.100(b) 1 Entries not timely Entries on [processing records] [production records] were not made at the time the specific retort or processing system condition or operation occurred.  Specifically, ***
1645 21 CFR 113.100(c) 1 Records review infrequent / not done Written records of all container closure examinations are [not reviewed by management] [not reviewed by management with sufficient frequency] to ensure that the containers are hermetically sealed.  Specifically, ***
1660 21 CFR 113.40(a)(1) 1 MIG thermometer not used as reference The mercury-in-glass thermometer was not the reference thermometer for indicating processing temperatures.   Specifically, ***
1707 21 CFR 110.80(b)(11) 1 Heat blanching concerns (S) Failure to minimize thermophilic growth and contamination in blanching operations by the use of [required operating temperatures for the required period of time] [rapid cooling] [the practice of passing the food to the next manufacturing operation without delay] [periodic cleaning].  Specifically, ***
1715 21 CFR 113.40(a)(10) 1 Air valves, leakage Failure to supply a suitable air valve for pressure cooling to prevent air leakage into the retort during processing.  Specifically, ***
1740 21 CFR 113.40(a)(2) 1 Well bleeder Failure to have a 1/16-inch or larger bleeder.  Specifically, ***
1761 21 CFR 129.80(a) 1 Record keeping requirements You do not maintain records at the plant pertaining to physical inspection of equipment used for treatment of product water, including the [type and date] [conditions found] [performance and effectiveness of equipment].  Specifically, ***
1806 21 CFR 129.80(b)(1) 1 Records of mechanical washers You do not keep records of [inspection and conditions found] [physical maintenance] [performance] for mechanical washers.  Specifically, ***
1853 21 CFR 113.40(a)(9) 1 Suitable material Crates, trays, gondolas, etc., for holding containers are not made of strap iron, adequately perforated sheet metal, or other suitable material.   Specifically, ***
1944 21 CFR 129.80(d) 1 Sanitizing operations inadequate Sanitizing operations are not adequate to effect sanitation of the intended product water-contact surfaces and critical areas.  They do not meet the minimum times and intensities required by the regulations.  Specifically, ***
1945 21 CFR 129.80(d) 1 Records of sanitizing times and intensities (S) You do not maintain [adequate] records regarding [the intensity of the sanitizing agent] [the time duration that the sanitizing agent was in contact with the surface being sanitized].  Specifically, ***
2056 21 CFR 123.28(a) 1 HACCP plan Your HACCP plan for raw molluscan shellfish does not include controls to ensure the molluscan shellfish are harvested from an approved source.  Specifically, ***
2058 21 CFR 123.28(c) 1 Tag requirements - shellstock The tags attached to each container of shellstock you receive do not [always] bear [the place and date the shellfish were harvested] [the type and quantity of shellfish] [an identification of the harvester].  Specifically, ***
2059 21 CFR 123.28(d) 1 Labels - shucked shellfish You do not have controls in place to ensure that shucked molluscan shellfish are in containers that bear a label that discloses [the date and place they were harvested] [the type and quantity of shellfish] [by whom they were harvested].  Specifically, ***
2146 21 CFR 113.40(b)(1) 1 Unreadable MIG thermometer Mercury-in-glass thermometers were not installed where they can be accurately and easily read.  Specifically, ***
2169 21 CFR 113.40(b)(9) 1 Operator check and recording The operator failed to [check] [record] the water level at intervals sufficient to ensure adequacy of the water level.  Specifically, ***
2219 21 CFR 113.40(b)(10)(i) 1 Air introduction There was no means to introduce compressed air into the retort at a proper pressure and rate for pressure processing in water.  Specifically, ***
2271 21 CFR 129.80(e) 1 Package identification You do not identify each unit package from a [batch] [segment of a continuous production run] of bottled drinking water with a production code which identifies [the particular batch] [the segment of production run] [the day produced].  Specifically, ***
2298 21 CFR 129.80(f) 1 Inspection of containers and closures You do not [sample] [inspect] all containers and closures to ascertain they are free from contamination.  Specifically, ***
2320 21 CFR 113.40(c)(2) 1 Corresponding with MIG Failure to properly adjust the temperature-recording device.  The temperature recorded on the temperature-recording device chart [was higher than] [did not agree with] the mercury-in-glass thermometer during processing.  Specifically, ***
2332 21 CFR 113.40(c)(5) 1 Location - separation Retort bleeders are installed more than eight (8) feet apart.  Specifically, ***
2334 21 CFR 113.40(c)(5) 1 Observable Failure to install bleeders so that the operator can observe that they are functioning properly.  Specifically, ***
2336 21 CFR 113.40(c)(5) 1 Condensate bleeder The condensate bleeder was not checked with sufficient frequency to ensure removal of condensate or equipped with an automatic alarm system for the continuous monitoring of condensate bleeder functioning.  Specifically, ***
2337 21 CFR 113.40(c)(5) 1 Visual checks of condensate bleeder (S) In the absence of an automatic alarm system, failure to [check] [record] the proper functioning of the condensate bleeder [at intervals of no more than 15 minutes].  Specifically, ***
2342 21 CFR 113.40(c)(6) 1 Heat distribution Heat distribution data or documentary proof from the retort manufacturer or process authority that adequate venting is achieved in the retort was not kept on file.  Specifically, ***
2367 21 CFR 129.80(a) 1 Effective treatment Your treatment of product water is not done in such a manner as to be effective in accomplishing the intended purpose.  Specifically, ***
2389 21 CFR 110.80(a)(5) 1 Identify rework Failure to identify material scheduled for rework as such. Specifically, ***
2428 21 CFR 110.80(b)(9) 1 Proper reconditioning Failure to use a proven effective method of reconditioning adulterated food.  Specifically, ***
2495 21 CFR 113.40(e)(1) 1 Defective thermometer A retort was used without replacing or repairing a mercury-in-glass thermometer [with a divided column] [that could not be adjusted to the standard].  Specifically, ***
2537 21 CFR 113.40(f)(2) 1 Corresponding with MIG Failure to properly adjust the temperature-recording device.  The temperature recorded on the temperature-recording device chart [was higher than] [did not agree with] the mercury-in-glass thermometer during processing.  Specifically, ***
2652 21 CFR 113.40(c)(9) 1 Subsequent handling of removed cans When containers were removed from the retort, following an emergency stop, the subsequent handling methods used for the containers in the retort at the time of the temperature drop were not entered on production records.  Specifically, ***
2826 21 CFR 113.40(g)(1)(ii)(a) 1 Startup Failure to bring the [product sterilizer] [all product contact surfaces downstream from the sterilizer] to a condition of commercial sterility before the start of aseptic processing operations.  Specifically, ***
2842 21 CFR 113.40(g)(1)(i)(a) 1 Not easily readable Thermometers and temperature indicating devices are not installed where they can be accurately and easily read.  Specifically, ***
2843 21 CFR 113.40(g)(1)(i)(a) 1 Not used as reference The temperature-indicating device was not used as the reference instrument for indicating  processing temperatures.  Specifically, ***
2846 21 CFR 113.40(g)(1)(i)(b) 1 Range Graduations on the temperature-recording device exceeded 2 degrees F within a range of 10 degrees F of the processing temperature.  Specifically, ***
2869 21 CFR 113.40(g)(1)(ii)(e) 1 Readings at start of aseptic processing Measurements or observations of the [temperature-indicating device in the holding tube outlet] [temperature recorder in the holding tube outlet] [temperature recorder-controller at the final heater outlet] [differential pressure recorder-controller] [product flow rate] [sterile air pressure] [proper performance of seam seals or similar devices] were not [performed] [recorded] at the start of aseptic processing to ensure the values were as specified in the scheduled process for aseptic packaging operations.  Specifically, ***
2888 21 CFR 113.40(j) 1 Critical factors Critical factors are not [measured] [recorded] at intervals of sufficient frequency to ensure that the factors are within limits specified in the scheduled process.  Specifically, ***
2896 21 CFR 113.40(g)(2)(ii)(b) 1 Process deviations per 113.89 Product packaged below scheduled process specifications was not [segregated] [handled in accordance with 21 CFR 113.89].  Specifically, ***
3068 21 CFR 114.80(a)(1) 1 pH control Acidified foods are not manufactured, processed and packaged to [achieve within the time designated in the scheduled process] [maintain]  a pH value of 4.6 or lower in all finished foods.  Specifically,  ***
3710 21 CFR 110.80(b)(16) 1 Ice manufacturing Ice in contact with food has been made from water which is [unsafe] [of inadequate sanitary quality].  Specifically, ***
3770 21 CFR 113.40(a)(7) 1 Length of steam spreader, horizontal retort Failure of the steam spreader to extend the full length of the horizontal still retort(s).  Specifically, ***
3809 21 CFR 113.40(d)(8) 1 Critical factor recording interval (S) Failure to [measure] [record] critical factors in the scheduled process at intervals of 15 minutes or less.  Specifically, ***
3860 21 CFR 113.60(a) 1 Pertinent observations Failure to record all pertinent visual closure observations.  Specifically, ***
3861 21 CFR 113.60(a) 1 Record of corrective actions Failure to record corrective actions taken to fix irregularities in closures.  Specifically, ***
3862 21 CFR 113.60(a)(1) 1 Failure to perform teardown examinations Failure to [have a qualified individual] perform teardown examinations of double seam cans .  Specifically, ***
3865 21 CFR 113.60(a)(1) 1 Corrective actions following teardown examinations Failure to note corrective actions taken following teardown examination of double seam cans.  Specifically, ***
3866 21 CFR 113.60(a)(1)(i)(a) 1 Required can seam measurements (micrometer) Records of the results of micrometer measurements of double seam cans fail to include [cover hook] [body hook] [width] [tightness] [thickness].  Specifically, ***
3869 21 CFR 113.60(a)(1)(ii) 1 Method of taking seam measurements (micrometer) Failure to measure can double seam characteristics using a  micrometer at three different points approximately 120 degrees apart, excluding the side seam.  Specifically, ***
3870 21 CFR 113.60(a)(2) 1 Glass containers, capper efficiency check Failure to measure the cold water vacuum of the glass container capper before actual filling operations.  Specifically, ***
3871 21 CFR 113.60(a)(2) 1 Record of glass container capper efficiency check Failure to record the results of the glass container capper cold water vacuum test.  Specifically, ***
3878 21 CFR 113.60(c) 1 Coding - Change of pack period Failure to change the packing period in the container identification mark so as to enable ready identification of lots during their sale and distribution.  Specifically, ***
3879 21 CFR 113.60(d) 1 Post process handling - belts and conveyors (S) Cans are handled on belt conveyors which [do not minimize contact between can seams and belt material] [consist of worn, frayed, or dirty materials which may contact can seams].  Specifically, ***
3886 21 CFR 113.87(e) 1 Clock time agreement with time of day (S) Failure of the clock times indicated on recording-temperature charts to reasonably correspond to the time of day on the written processing records.  Specifically, ***
4476 21 CFR 108.25(c)(3)(ii) 1 Process information availability Failure to provide the FDA, after written request, any process and procedure information deemed necessary to determine the adequacy of the process. Specifically, ***
4513 21 CFR 108.25(g) 1 Record inspection and copying Failure to permit [inspection] [copying of records] of [processing] [deviations in processing] [pH] [information specified in 21 CFR 114], upon written demand by FDA, to verify pH and the adequacy of processing. Specifically, ***
4518 21 CFR 108.35(c)(2)(ii) 1 Process change - increase Failure to file with FDA changes in previously filed scheduled processes, where processing parameters were higher or longer, when the processes became regularly scheduled.  Specifically, ***
4521 21 CFR 108.35(d) 1 Notify FDA - spoilage Failure to notify FDA about [spoilage] [process deviations] of potential public health significance when all or part of a lot was distributed. Specifically, ***
4524 21 CFR 108.35(g) 1 Approved school Failure to have personnel involved in [retorts] [thermal processing systems] [aseptic processing and packaging systems] [thermal processing systems] [container closure inspections] under the operating supervision of a person who has attended and satisfactorily completed a school approved by the Commissioner. Specifically, ***
4525 21 CFR 108.35(h) 1 Record retention Failure to prepare, review and retain at the [processing plant] [a reasonably accessible location] for three years, all records [of processing] [of deviations in processing] [of container closure inspections] [specified in Part 113]. Specifically, ***
4528 21 CFR 108.35(c)(2)(ii) 1 Process change recording For an intentional change in a previously filed scheduled process, substantiation was not [promptly recorded] [verified in writing by the authority] [placed in your files for review by FDA].  Specifically, ***
9792 21 CFR 106.30(b)(3) 1 Stability analysis Failure to conduct stability analysis on representative samples of finished product batches.  Specifically, ***
9799 21 CFR 106.100(d) 1 Premix supplier Failure to maintain records of the results of all testing conducted to provide certificates and guarantees concerning nutrient premixes for infant formulas.   Specifically, ***
9962 21 CFR 120.24(b) 1 Process controls - direct treatment  - not exempt Your treatments intended to achieve a 5-log reduction in the most resistant microorganism of public health significance are not applied directly to the juice, and the exemption for surface treatment of fruit does not apply.  Specifically, ***
9963 21 CFR 120.24(c) 1 Process controls - exempt process, single facility You do not process and perform final product packaging in a single facility operating under current good manufacturing practices.  Specifically, ***
12703 21 CFR 129.80(a) 1 Product samples You do not take product water samples after processing and prior to bottling.  Specifically, ***
12709 21 CFR 129.80(c) 1 Records of cleaning/sanitizing solutions You do not maintain records of [sampling] [testing] of cleaning and sanitizing solutions.  Specifically, ***
12717 21 CFR 129.80(h) 1 Certificates You did not retain at the plant current certificates or notifications of approval issued by the government agency or agencies approving the source and supply of product water and operations water.  Specifically, ***
12732 21 CFR 120.10(a) 1 Corrective action - predetermined plan Your HACCP plan includes a corrective action plan.  There was a deviation from a critical limit and you did not take corrective action that ensured [product that was injurious to health or otherwise adulterated did not enter commerce] [the cause of the deviation was corrected].  Specifically, ***
15743 21 CFR 111.210(h)(3)  1 Master manufacturing record - specific actions; quality  The written instructions in your master manufacturing record did not include specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement.  Specifically, ***

Back to top

Devices

Center Name Cite Id Ref No Frequency Short Description Long Description
Devices 3130 21 CFR 820.100(a) 127 Procedures - general Procedures for corrective and preventive action have not been [adequately] established. Specifically, ***
4189 21 CFR 820.198(a) 123 General Complaint handling procedures for [receiving] [reviewing] [evaluating] complaints have not been [established] [defined] [documented] [completed] [implemented].  Specifically, ***
630 21 CFR 803.17 87 Lack of Written MDR Procedures Written MDR procedures have not been [developed] [maintained] [implemented].  Specifically, ***
3696 21 CFR 820.100(b) 85 Lack of documentation of CAPA activities Corrective and preventive action activities and/or results have not been [adequately] documented.  Specifically, ***  
546 21 CFR 820.75(a) 80 General A process whose results cannot be fully verified by subsequent inspection and test has not been [adequately] validated according to established procedures.  Specifically, ***
3415 21 CFR 820.22 74 Quality audits conducted Quality [audits][reaudits] have not been performed.  Specifically, *** 
2327 21 CFR 820.22 68 Quality audit procedures Procedures for quality audits have not been [adequately] established. Specifically, *** 
2371 21 CFR 820.30(a) 68 Design control procedures Procedures for design control have not been established.  Specifically,*** 
4058 21 CFR 820.20 65 Management responsibility Management with executive responsibility has not ensured that an adequate and effective quality system has been fully implemented and maintained at all levels of the organization.  Specifically, ***
447 21 CFR 820.40 64 Document control procedures Document control procedures have not been [established] [maintained].  Specifically,*** 
3103 21 CFR 820.30(i) 61 Design changes - procedures prior to implementation Procedures for design change have not been [adequately] established.  Specifically,***
486 21 CFR 820.50(a) 50 Evaluation of suppliers, contractors and consultants Requirements that must be met by [suppliers] [contractors] [consultants] have not been [adequately] established.   Specifically, ***
3282 21 CFR 820.90(a) 46 Nonconforming product control procedures Procedures have not been [adequately] established to control product that does not conform to specified requirements.  Specifically, *** 
479 21 CFR 820.50 45 Purchasing control procedures Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been [adequately] established.  Specifically, ***
3121 21 CFR 820.80(b) 45 Receiving acceptance procedures Procedures for acceptance of incoming product have not been [adequately] established. Specifically, ***
3666 21 CFR 820.20(c) 45 Management review procedures Procedures for management review have not been [adequately] established.  Specifically,*** 
3837 21 CFR 820.25(b) 44 Training documentation Personnel training is not documented. Specifically, ***
3125 21 CFR 820.80(d) 43 Procedures, finished devices Procedures for finished device acceptance have not been [adequately] established. Specifically, *** 
3172 21 CFR 820.198(c) 42 Investigation of device failures Complaints involving the possible failure of [a device] [labeling] [packaging] to meet any of its specifications were not [reviewed] [evaluated] [investigated] where necessary. Specifically, *** 
3160 21 CFR 820.184 41 Establishing device history record procedures Procedures for device history records have not been [adequately] established.  Specifically,*** 
3291 21 CFR 820.100(b) 41 Procedures The procedures addressing documentation of corrective and preventive action activities were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3371 21 CFR 820.198(a)(3) 41 Processing MDRs {see also 803, 804} Complaint handling procedures have not been [established] [defined] [documented] [completed] [implemented] to ensure that all complaints are evaluated to determine whether the complaint should be filed as a Medical Device Report.  Specifically, ***
3118 21 CFR 820.75(a) 40 Documentation - general Process validation [activities] [results] have not been  [documented] [approved] [adequately documented] [adequately approved].  Specifically, ***
3167 21 CFR 820.198(a) 40 Complete files maintained Complete complaint files are not maintained.  Specifically, ***
3233 21 CFR 820.72(a) 40 Calibration, inspection, equipment control procedures Procedures to ensure equipment is routinely [calibrated] [inspected] [checked] [maintained] have not been [adequately] established.  Specifically, ***
731 21 CFR 803.50(a)(1) 39 Report of Death or Serious Injury An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have caused or contributed to a death or serious injury.  Specifically, ***
2974 21 CFR 812.110(b) 39 Investigator non-compliance with agreement/plan/regulations An investigation was not conducted in accordance with [the signed agreement] [the investigational plan] [applicable FDA regulations] [conditions of approval imposed by an IRB] [conditions of approval imposed by FDA].  Specifically, ***
2302 21 CFR 820.20(e) 36 Quality System Procedures Quality system procedures and instructions have not been established.  Specifically,*** 
3678 21 CFR 820.30(g) 36 Risk analysis Risk analysis [was not performed] [is inadequate] [is incomplete].  Specifically, *** 
3687 21 CFR 820.100(a)(1) 34 Analysis of data sources Appropriate sources of quality data are not adequately analyzed to identify existing and potential causes of nonconforming product and other quality problems.  Specifically, ***
3155 21 CFR 820.181(a) 32 DMR device specifications The device master record does not include or refer to the location of  device software specifications.  Specifically, ***
14505 21 CFR 812.140(a)(3) 32 Investigator's subject records inadequate Records of each subject's [case history] [exposure to the investigational device] are not all [accurate] [complete] [current].  Specifically, ***
3104 21 CFR 820.30(j) 31 Design history file The design history file [was not established] [does not demonstrate that the design was developed following the approved design plan] [does not demonstrate that the design was developed following the requirements of 21 CFR 820].  
3669 21 CFR 820.20(c) 31 Management reviews at defined intervals Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system [at defined intervals] [with sufficient frequency].  Specifically, *** 
2351 21 CFR 820.25(b) 30 Training Employees have not been adequately trained.  Specifically, ***
3369 21 CFR 820.198(a)(1) 30 Uniform and timely processing Complaint handling procedures have not been [established] [defined] [documented] [completed] [implemented] to ensure that all complaints are processed in a uniform and timely manner.  Specifically, ***
3690 21 CFR 820.100(a)(3) 30 Identification of actions needed Not all of the actions needed to correct and prevent the recurrence of nonconforming product and other quality problems have been identified.  Specifically, ***
3159 21 CFR 820.184 29 DHR content - general The device history record does not demonstrate that the device was manufactured in accordance with [the device master record] [21 CFR 820].
541 21 CFR 820.70(c) 28 Environmental control Procedures to control environmental conditions have not been [adequately] established.  Specifically, ***
3101 21 CFR 820.30(g) 26 Design validation procedures Procedures for design validation have not been [adequately] established.  Specifically,*** 
538 21 CFR 820.70(a) 25 Process control procedures Process control procedures that describe any process controls necessary to ensure conformance to specifications were not [established] [defined] [documented] [implemented].  Specifically, ***
3120 21 CFR 820.80(a) 25 General Procedures for acceptance activities have not been [adequately] established.  Specifically,***
2968 21 CFR 812.100 24 Investigator non-compliance with agreement/plan/regulations An investigation was not conducted according to the [signed agreement] [investigational plan] [applicable FDA regulations].  Specifically, ***
3127 21 CFR 820.80(e) 24 Documentation Acceptance activities were not [documented] [maintained as part of the device history record] [adequately documented] [adequately maintained as part of the device history record].  Specifically, ***
2350 21 CFR 820.25(b) 23 Training Procedures Procedures for training and identifying training needs have not been [adequately] established. Specifically, *** 
2981 21 CFR 812.140(a)(2)(i) 23 Investigator device accountability inadequate Records of [receipt] [use] [disposal] of a device that relate to the [type and quantity] [dates of receipt] [batch number or code mark] of the device are not all [accurate] [complete] [current].  Specifically, ***
3164 21 CFR 820.184(d) 23 Acceptance records The device history record does not include [complete] acceptance records that demonstrate the device is manufactured in accordance with the device master record.  Specifically, ***
732 21 CFR 803.50(a)(2) 22 Report of Malfunction An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.  Specifically, ***
2928 21 CFR 812.40 22 Sponsors' general responsibilities For an investigational study, [qualified investigators were not selected] [investigators were not provided with the information they need to conduct an investigation properly] [proper monitoring was not ensured] [IRB review and approval were not ensured] [an IDE application was not submitted to FDA for a significant risk study] [reviewing IRBs were not promptly informed of significant new information about an investigation] [FDA was not promptly informed of significant new information about an investigation].  Specifically, ***
3301 21 CFR 820.100(a)(2) 22 Investigation procedures The corrective and preventive action procedures addressing the investigation of the cause of nonconformities relating to product, processes, and the quality system were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3692 21 CFR 820.100(a)(4) 22 CAPA verification/validation of corrective/preventive action Corrective and preventive actions have not been verified or validated to ensure that the action is effective and does not adversely affect the finished device.  Specifically, ***
3119 21 CFR 820.75(b) 20 Monitoring and control of validated processes Procedures for monitoring and control of process parameters for a validated process have not been [adequately] established. Specifically, ***
3201 21 CFR 820.40(a) 20 Not approved or obsolete document retrieval Documents that were [not approved] [obsolete] were observed at a location where they [could be] [are being] used. Specifically, ***
3299 21 CFR 820.100(a)(1) 20 Procedure for analysis of data sources The corrective and preventive procedures addressing the analysis of sources of quality data to identify existing and potential causes of nonconforming product or other quality problems were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3250 21 CFR 820.72(b)(2) 19 Calibration documentation There is [no] [incomplete] documentation of [the equipment identification] [calibration dates] [the individual performing each calibration] [the next calibration date] for [inspection] [measurement] [test] equipment .  Specifically, ***
3689 21 CFR 820.100(a)(2) 19 Investigation Certain indicators of nonconformities are not investigated to determine the cause of the nonconformity.  Specifically, ***
3102 21 CFR 820.30(h) 18 Design transfer Procedures for design transfer have not been [adequately] established.  Specifically,***
3132 21 CFR 820.120 18 Labeling procedures - general Procedures to control labeling activities have not been [adequately] established. Specifically, *** 
3283 21 CFR 820.90(a) 18 Specific non-conforming product procedures Procedures for addressing the [identification] [documentation] [evaluation] [segregation] [disposition] [investigation] of nonconforming product were not [defined] [documented] [complete].  Specifically, ***
3665 21 CFR 820.20(b)(3) 18 Management representative No management representative had been appointed to ensure that quality system requirements are met, and to report to management on the performance of the quality system.  Specifically, ***
537 21 CFR 820.70(a) 17 Production processes Production processes were not [developed] [conducted] [controlled] [monitored] to ensure that a device conforms to its specifications.  Specifically, *** 
2293 21 CFR 820.20(d) 17 Quality plan A quality plan has not been [adequately] established.  Specifically, ***
2328 21 CFR 820.22 17 Quality audits, auditor independence Individuals who conduct quality audits have direct responsibility for the matters being audited. Specifically, *** 
3128 21 CFR 820.90(a) 17 Nonconforming product control Products that do not conform to specifications are not adequately controlled. Specifically, ***
3680 21 CFR 820.70(a) 17 Process control procedure content Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been [adequately] established.   Specifically, ***
3268 21 CFR 820.80(b) 16 Incoming inspection, testing, verification Incoming product was not adequately inspected or tested to verify conformance to specifications.  Specifically, ***
3284 21 CFR 820.90(a) 16 Nonconforming product evaluation/investigation The [evaluation] [investigation] of nonconforming product has not been documented.  Specifically, ***
3427 21 CFR 820.50(a)(2) 16 Supplier oversight The type and extent of control to be exercised over [the product] [services] [suppliers] [contractors] [consultants] was not clearly defined. Specifically, ***
539 21 CFR 820.70(b) 15 Production and process change procedures Procedures for changes to a [specification] [method] [process] [procedure] have not been [adequately] established.  Specifically, *** 
2650 21 CFR 820.30(f) 15 Design verification Procedures for design verification have not been [adequately] established.  Specifically,*** 
3332 21 CFR 820.184(e) 15 ID label, labeling The device history record does not include the primary identification label and labeling for each device.  Specifically, ***
3380 21 CFR 820.198(e)(6) 15 Results of investigation Records of complaint investigations do not include the [dates] [results] of the investigation.  Specifically, ***
3416 21 CFR 820.70(a)(1) 15 Process control instructions Process controls are not conducted in accordance with documented instructions and standard operating procedures.  Specifically, ***
3688 21 CFR 820.100(a)(1) 15 Analysis of data/reports from data sources Not all [data] [reports] from quality data sources are analyzed to identify existing and potential causes of nonconforming product and other quality problems.  Specifically, ***
4059 21 CFR 820.22 15 Quality audits - effectiveness of quality system Quality audits were not performed [at defined intervals] [at sufficient frequency] to determine whether the quality system activities and results comply with quality system procedures.  Specifically, *** 
2604 21 CFR 820.30(e) 14 Design review procedures - general Procedures for design review have not been [adequately] established.  Specifically,*** 
2648 21 CFR 820.30(f) 14 Design verification procedures Procedures for verifying that design output meets design input were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3117 21 CFR 820.70(i) 14 Software validation for automated processes Software used as part of [production] [the quality system] has not been [adequately] validated for its intended use according to an established protocol.  Specifically, ***
3199 21 CFR 820.40(a) 14 Document review, approval documentation The documentation of approval of documents does not include [the document approval date] [the signature of the approving official].  Specifically, ***
3207 21 CFR 820.50(b) 14 Supplier notification of changes There is no agreement with [suppliers] [contractors] [consultants] to notify you of changes in the product or service.  Specifically, ***
3226 21 CFR 820.70(g)(1) 14 Schedule Schedules for the adjustment, cleaning, and other maintenance of equipment have not been [adequately] established.  Specifically, *** 
3269 21 CFR 820.80(b) 14 Incoming acceptance records, documentation Acceptance or rejection of incoming product was not documented. Specifically, ***
3288 21 CFR 820.90(b)(1) 14 Documentation of disposition, justification, signature There is [no] [incomplete] documentation of the [disposition of nonconforming product] [justification for use of nonconforming product] [the signature of the individual authorizing the use of nonconforming product].  Specifically, ***
3681 21 CFR 820.70(b) 14 Verification or validation of changes Changes to a [specification] [method] [process] [procedure] were not verified or validated.  Specifically, ***
2970 21 CFR 812.100 13 Investigator lack of informed consent Informed consent was not obtained in accordance with the regulations regarding the protection of human subjects. Specifically, ***
3049 21 CFR 812.150(b)(5) 13 Sponsor progress reports for significant risk study Progress reports for a significant risk device study were not submitted [at required intervals] [at least yearly] to [FDA] [all reviewing IRBs].  Specifically, ***
3231 21 CFR 820.70(i) 13 Documentation of software validation Software validation activities and results for computers or automated data processing systems used as part of [production] [the quality system] have not been [adequately] documented.   Specifically, *** 
3302 21 CFR 820.100(a)(3) 13 Identifying corrective & preventive actions The procedures addressing identification of corrective and preventive actions were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3303 21 CFR 820.100(a)(4) 13 Verify, validate change {see also 820.100(a)} The procedures addressing verification or validation of corrective and preventive actions were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
502 21 CFR 820.60 12 Identification Procedures for identifying product during all stages of receipt, production, distribution, and installation have not been [adequately] established.  Specifically, *** 
2429 21 CFR 820.30(b) 12 Establish the design and development plan A design and development plan has not been [established] [defined] [documented] [implemented].  Specifically, ***
3157 21 CFR 820.181(c) 12 DMR QA  procedures and specifications The device master record does not include or refer to the location of [all] quality assurance procedures and specifications.  Specifically, ***
3263 21 CFR 820.250(b) 12 Establishment, appropriateness Sampling plans are not [written][based on valid statistical rationale].  Specifically, *** 
3397 21 CFR 820.80(d)(2) 12 Review of data and documentation Finished devices were released for distribution before the associated data and documentation was reviewed.  Specifically, ***
3426 21 CFR 820.50(a)(1) 12 Documenting evaluation The evaluation of potential [suppliers] [contractors] [consultants] was not documented.  Specifically, *** 
3433 21 CFR 820.75(c) 12 Process changes - review, evaluation and revalidation A validated process was not [reviewed and evaluated] [revalidated] when changes or process deviations occurred. Specifically, ***
2985 21 CFR 812.140(a)(3)(ii) 11 Investigator records of relevant observations inadequate Records for each subject concerning [previous medical history] [condition upon entering the investigation] [condition during the course of the investigation] [all diagnostic test results] are not all [accurate] [complete] [current].  Specifically, ***
3286 21 CFR 820.90(b)(1) 11 Procedures for product review, disposition Procedures that define the responsibility for review and the authority for the disposition of nonconforming product have not been [adequately] established.  Specifically, ***
3417 21 CFR 820.70(a)(2) 11 Production monitoring and control During production, [process parameters] [component and device characteristics] are not [fully] monitored and controlled.  Specifically, ***
3425 21 CFR 820.50(a)(1) 11 Evaluation and selection Potential [suppliers] [contractors] [consultants] were not [evaluated] [selected] based on their ability to meet specified requirements.  Specifically, *** 
3676 21 CFR 820.30(f) 11 Design verification documentation, DHF {see also 820.30(j)} The design verification results, including [identification of the design] [method(s)] [the date] [the individual(s) performing the verification], were not [adequately] documented in the design history file.  Specifically, *** 
3683 21 CFR 820.70(g) 11 Installation, placement qualification The [appropriate design, construction, placement, and installation of manufacturing equipment have not been ensured] [equipment used in the manufacturing process does not meet specified requirements]. Specifically, *** 
4070 21 CFR 820.30(g) 11 Design validation documentation, DHF {see also 820.30(j)} The results of design validation, including [identification of the design] [method(s)] [the date] [the individual(s) performing validation], were not [adequately] documented in the design history file.  Specifically, *** 
7006 21 CFR 812.43(c)(5) 11 No financial disclosure info in investigator agreement A signed agreement was not obtained from each participating investigator that includes [sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement] [a commitment to promptly update financial disclosure information if any relevant changes occur during the investigation and for one year following completion of the study].  Specifically, ***
419 21 CFR 820.20(b) 10 Establish organizational structure The organizational structure has not been [adequately] established and maintained to ensure that devices are [designed] [produced] in accordance with 21 CFR 820.  Specifically, *** 
540 21 CFR 820.70(b) 10 Production and process changes - failure to follow procedure Established procedures were not followed [completely] in making changes to [specifications] [methods] [processes] [procedures].  Specifically, ***
2269 21 CFR 820.20(a) 10 Quality policy established The [quality policy] [quality objectives] [was] [were] not established by management with executive responsibility.  Specifically, *** 
2984 21 CFR 812.140(a)(3)(i) 10 Investigator records of informed consent inadequate Records documenting that informed consent was obtained for each subject prior to participation in the study are not all [accurate] [complete] [current].  Specifically, ***
3123 21 CFR 820.80(c) 10 Procedures Procedures for the [acceptance] [control] of in-process product have not been [adequately] established. Specifically, *** 
3235 21 CFR 820.72(a) 10 Equipment control activity documentation Equipment [calibrations] [inspections] [checks][maintenance activities] have not been documented.  Specifically, ***
3304 21 CFR 820.100(a)(5) 10 Changes to correct/prevent quality problems Changes in methods and procedures needed to correct and prevent identified quality problems are not [implemented] [recorded] [effective].  Specifically, ***
3345 21 CFR 820.200(a) 10 Procedures established Procedures or instructions for [performing servicing activities] [verifying that servicing meets specified requirements] have not been [adequately] established. Specifically, ***
3379 21 CFR 820.198(e)(5) 10 Nature and details of complaint Records of complaint investigations do not include the nature and details of the complaint.  Specifically, ***
3677 21 CFR 820.30(g) 10 Design validation of device software Validation of device software [was not performed] [is inadequate] [is incomplete].  Specifically, *** 
6802 21 CFR 807.21(a) 10 Annual registration Your annual registration [is not current] [was not updated within 30 days of receipt of form FDA 2891a from FDA].   Specifically, ***
14523 21 CFR 812.43(c) 10 No investigator agreement A signed investigator agreement was not obtained from each participating investigator .  Specifically,***
2556 21 CFR 820.30(c) 9 Incomplete, ambiguous, conflicting design requirements Design input requirements that are [incomplete] [ambiguous] [conflicting] were not addressed.  Specifically, ***
2980 21 CFR 812.140(a)(1) 9 Investigator correspondence records inadequate Records relating to correspondence with [another investigator] [an IRB] [the sponsor] [a monitor] [FDA], including required reports, are not all [accurate] [complete] [current].  Specifically, ***
3021 21 CFR 812.150(a)(1) 9 Investigator report of unanticipated adverse effects A complete and accurate report of an unanticipated adverse device effect was not prepared and submitted [within 10 working days after first learning of the effect] to [the sponsor] [the reviewing IRB].  Specifically, ***
3156 21 CFR 820.181(b) 9 DMR production process specifications The device master record does not include or refer to the location of [all] production and process specifications.  Specifically, ***
3170 21 CFR 820.198(b) 9 Review and evaluation for investigation Not all complaints have been [adequately] reviewed and evaluated to determine whether an investigation is necessary. Specifically, ***
3171 21 CFR 820.198(b) 9 Rationale documented for no investigation Records for complaints where no investigation was made do not include required information.  Specifically *** 
3192 21 CFR 820.30(g) 9 Design validation per user needs and intended use Design validation did not ensure the device conforms to defined user needs and intended uses.  Specifically, ***
3203 21 CFR 820.40(b) 9 Change records maintained Records of changes to documents were not [adequately] maintained.  Specifically, ***
3285 21 CFR 820.90(b)(2) 9 Product rework procedures Procedures for rework of nonconforming product have not been [adequately] established.  Specifically, *** 
3300 21 CFR 820.100(a)(1) 9 Statistical methodology Corrective and preventive action procedures addressing the use of appropriate statistical methodology to identify existing and potential causes of nonconforming product or other quality problems were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3667 21 CFR 820.20(c) 9 Management review accomplishment Management reviews do not ensure that the quality system satisfies [the requirements of part 820] [your quality policy and objectives]. Specifically, ***
4191 21 CFR 806.10(a)(1) 9 Report of risk to health A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA.  Specifically, ***
14507 21 CFR 812.140(a)(3)(ii) 9 Investigator adverse effect records inadequate Records for each subject concerning [anticipated] [unanticipated] adverse device effects are not all [accurate] [complete] [current].  Specifically, ***
632 21 CFR 803.17(a)(2) 8 Lack of System for Determining MDR Events The written MDR procedure does not include an internal system which provides for a standardized review process/procedure for determining when an event meets the criteria for reporting.  Specifically, ***
2431 21 CFR 820.30(b) 8 Design plans updated Design plans were not [reviewed] [updated] [approved] as design and development evolves.  Specifically, *** 
2557 21 CFR 820.30(c) 8 Design input documentation Design input requirements were not [adequately] documented.   Specifically, ***
2949 21 CFR 812.46(a) 8 Sponsor securing investigator compliance An investigator was not complying with the [signed agreement] [investigational plan] [requirements of the regulations] [conditions of approval imposed by the IRB or FDA] and [compliance of the investigator was not promptly secured] [shipments of the investigational device to the investigator were not discontinued] [the investigator's participation in the investigation was not terminated].  Specifically, ***
3151 21 CFR 820.180 8 Legibility Required records are not legible. Specifically, ***
3190 21 CFR 820.30(g) 8 Design validation acceptance criteria Acceptance criteria were not established prior to the performance of validation activities.  Specifically, ***
3310 21 CFR 820.120(b) 8 DHR documentation of label release {see also 820.184} The DHR does not include [complete] records of examination and release of device labeling, including date and signature of the examiner.  Specifically, ***
3398 21 CFR 820.80(d)(3) 8 No release signature Finished devices were released for distribution without signature of the individual designated to authorize such release.  Specifically, ***
3664 21 CFR 820.20(b)(2) 8 Training Personnel are not adequately trained to perform [management activities] [work] [assessment activities] [audits]. Specifically, ***
3693 21 CFR 820.100(a)(5) 8 Implementing changes Corrective and preventive action procedures addressing implementation and recording of changes in methods and procedures to correct and prevent identified quality problems were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
4193 21 CFR 806.10(b) 8 Time to report - 10 days A report of the required information regarding device correction and removal actions was not sent to FDA within 10 days of initiating the correction or removal.  Specifically, ***
6803 21 CFR 807.20(a) 8 Devices not listed Devices for which listing is required have not been listed.  Specifically, ***
3108 21 CFR 820.70(e) 7 Contamination control procedures Procedures to prevent contamination of equipment or product by substances that may have an adverse effect on product quality have not been [adequately] established.   Specifically, *** 
3149 21 CFR 820.180 7 Availability Required records [are not maintained at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA] [were not made readily available for review and copying by the FDA] [are not legible] [are not stored to minimize deterioration and prevent loss] [are not backed up when stored in automated data processing systems].  Specifically, *** 
3204 21 CFR 820.40(b) 7 Change records, content Records of changes did not include [a description of the change] [identification of the affected documents] [the signature of the approving official(s)] [the approval date] [when the change became effective].  Specifically, ***
3330 21 CFR 820.181(d) 7 DMR packaging and labeling specifications The device master record does not include or refer to the location of [packaging] [labeling] procedures and specifications.  Specifically, ***
3432 21 CFR 820.75(b)(2) 7 Documentation of validated process performance There is [no] [inadequate] documentation of [monitoring and control methods and data] [the date performed] [the individual performing the process] [the major equipment used] for a validated process. Specifically, ***
3671 21 CFR 820.25(a) 7 Personnel education, background, training & experience Personnel do not have the necessary [education] [background] [training] [experience] to perform their jobs. Specifically, *** 
3702 21 CFR 820.250(a) 7 Appropriateness There is no information to support the appropriateness of the statistical techniques used.  Specifically, ***
6800 21 CFR 807.20 7 Establishment not registered An establishment for which registration is required has not been registered.  Specifically, ***
7012 21 CFR 812.100 7 Investigator lack of control of investigational devices Devices under investigation were not properly controlled.  Specifically, ***
14508 21 CFR 812.140(a)(4) 7 Investigator record of protocol deviations inadequate Records showing [dates] [reasons for] each deviation from the protocol are not all [accurate] [complete] [current].  Specifically,***
631 21 CFR 803.17(a)(1) 6 Lack of System for Event Evaluations The written MDR Procedure does not include an internal system which provides for the timely and effective [identification] [communication] [evaluation] of events that may be subject to medical device reporting requirements.  Specifically, ***
2627 21 CFR 820.30(e) 6 Design reviews performed following schedule Design reviews were not performed at appropriate times, following the review schedule.  Specifically, ***
2628 21 CFR 820.30(e) 6 Design review procedures - personnel Procedures were not [established] [defined] [documented] [complete] [implemented] for ensuring that participants at each design review include [representatives of all functions concerned with the design stage being reviewed] [an individual who does not have direct responsibility for the design stage being reviewed] [any specialists needed].  Specifically, ***
3046 21 CFR 812.150(b)(4) 6 No 6-month sponsor reports of current investigators Current lists of the names and addresses of all investigators participating in an investigation were not [always] submitted to FDA at six month intervals after FDA approval of the investigation.  Specifically, ***
3141 21 CFR 820.150(a) 6 Storage procedures to prevent mix-ups Procedures for controlling the storage of product in storage areas and stock rooms were not [established] [defined] [documented] [complete] [implemented] to prevent mix-ups, damage, other adverse effects.  Specifically, ***
3206 21 CFR 820.50(b) 6 Purchasing records, specification Purchasing data that clearly describe or reference specified requirements for purchased or otherwise received product and services have not been [approved] [established] [adequately approved] [adequately established].  Specifically, *** 
3232 21 CFR 820.72(a) 6 Equipment suitability & capability Certain [inspection] [measuring] [test] equipment is not [suitable for its intended purposes] [capable of producing valid results].  Specifically, ***
3262 21 CFR 820.250(a) 6 Establish procedures for identifying statistical techniques Procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics have not been [adequately] established.  Specifically,*** 
3270 21 CFR 820.80(c) 6 Documentation In-process inspections, tests, or other verification activities and approvals were not documented. Specifically, ***
3313 21 CFR 820.120(d) 6 Records, DHR {see also 820.184(e)} Labels and labeling used for each finished product, lot, or batch, were not sufficiently documented in the DHR.  Specifically, ***
3434 21 CFR 820.75(c) 6 Documentation - review in response to changes or deviations There is no documentation of the [review and evaluation of a process] [revalidation of a process] performed in response to changes or process deviations.  Specifically, ***
3673 21 CFR 820.30(c) 6 Design input approval documentation The approval of design input requirements [(including the date and signature of the individual approving the requirements)] was not documented.  Specifically, ***
3675 21 CFR 820.30(f) 6 Design verification - unresolved discrepancies Unresolved discrepancies were noted at the completion of the design verification.  Specifically, ***
4060 21 CFR 820.20(b)(3)(i) 6 Management representative implementing the quality system The management representative has not ensured that the quality system requirements are effectively established and maintained. Specifically, ***
4168 21 CFR 820.100(a)(7) 6 Management review of CAPA Information on identified quality problems and corrective actions has not been [submitted for review by] [reviewed by] management.  Specifically, ***
4212 21 CFR 806.20(b)(4) 6 Justification for not reporting A  justification for not reporting the correction or removal action to FDA that included [conclusions] [follow-ups] [reviews] by a designated person was not included in the record.  Specifically,***
635 21 CFR 803.17(b)(1) 5 Info evaluated to determine if event was reportable The written MDR procedure does not include documentation and recordkeeping requirements for all information that was evaluated to determine if an event was reportable.  Specifically, ***
2601 21 CFR 820.30(d) 5 Essential design outputs Design outputs that are essential for the proper functioning of the device were not [completely] identified.  Specifically, ***
2630 21 CFR 820.30(e) 5 Design review documentation, DHF {see also 820.30(j)} The design review results, including [identification of the design] [the date] [the individual(s) performing the review], were not documented in the design history file.  Specifically, *** 
2983 21 CFR 812.140(a)(2)(iii) 5 Investigator records of disposition of devices inadequate Records that relate to the [reason why devices] [quantity of devices that] were [returned to the sponsor] [repaired] [disposed of] are not all [accurate] [complete] [current]. Specifically, ***
2991 21 CFR 812.140(b)(1) 5 Sponsor correspondence records inadequate Records relating to correspondence with [another sponsor] [a monitor] [an investigator] [an IRB] [FDA], including required reports are not all [accurate] [complete] [current].  Specifically, ***
2993 21 CFR 812.140(b)(2) 5 Sponsor device disposition records inadequate Records of disposition of a device which describe the batch number or code marks of any devices [returned to the sponsor] [repaired] [disposed of by the investigator or another person] and the reasons for and method of disposition reports are not all [accurate] [complete] [current].  Specifically, ***
3038 21 CFR 812.150(b)(1) 5 Sponsor evaluation rpt not timely, distributed Reports of the results of evaluation of unanticipated adverse device effects were not all submitted [within 10 working days of receiving notice of the effect] to [FDA] [all reviewing IRBs] [all participating investigators].  Specifically, ***
3111 21 CFR 820.70(f) 5 Buildings Buildings [are not of suitable design] [do not contain sufficient space] to [perform necessary operations] [prevent mix-ups] [assure orderly handling of product].  Specifically, *** 
3266 21 CFR 820.86 5 Clearly identified The acceptance status of product was not [identified to indicate conformance or nonconformance with acceptance criteria] [maintained].  Specifically, *** 
3381 21 CFR 820.198(e)(7) 5 Corrective action taken Records of complaint investigations do not include any corrective action taken.  Specifically, ***
3428 21 CFR 820.50(a)(3) 5 Acceptable supplier records Records of acceptable [suppliers] [contractors] [consultants] were not maintained.  Specifically, ***
3686 21 CFR 820.90(b)(2) 5 Product rework documentation, DHR {see also 820.184} Rework and reevaluation activities have not been [fully] documented in the device history record.  Specifically, ***
14516 21 CFR 812.25(e) 5 Sponsor's lack of written monitoring procedures There are no written procedures for monitoring an investigational device study.  Specifically,***
454 21 CFR 820.40(a) 4 Document review, approval by designated individual Documents were  [not reviewed] [not approved] by designated individual(s) prior to issuance .  Specifically, ***
542 21 CFR 820.70(c) 4 Environmental control system periodic inspections Environmental control systems have not been inspected periodically to verify that the system, including necessary equipment, is adequate and functioning properly.  Specifically, ***
633 21 CFR 803.17(a)(3) 4 Lack of  System for Timely Submission of Reports The written MDR procedure does not include an internal system which provides for timely transmission of complete medical device reports to [FDA] [manufacturers].  Specifically, ***
2279 21 CFR 820.20(b)(2) 4 Resources Adequate resources have not been provided for performing [management activities] [work] [assessment activities] [audits].  Specifically, ***
2430 21 CFR 820.30(b) 4 Adequacy of design and development plan Design plans that describe or reference the design and development activities and define responsibility for implementation have not been [adequately] established.  Specifically, ***
2470 21 CFR 820.30(c) 4 Design input procedures - appropriateness Procedures to ensure that a device's design input requirements are appropriate and address its intended use, including user/patient needs, were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
2600 21 CFR 820.30(d) 4 Acceptance criteria not identified Acceptance criteria for design outputs were not identified.  Specifically, ***
2649 21 CFR 820.30(f) 4 Design verification acceptance criteria Acceptance criteria were not [established] [defined] [documented] [complete] [implemented] prior to the performance of verification activities.  Specifically, ***
2930 21 CFR 812.42 4 Sponsor began study before IRB/FDA approval [An investigation] [Part of an investigation] was initiated before [FDA approval] [IRB approval]. Specifically, ***
2973 21 CFR 812.110(a) 4 Subject participation prior to study approval Subjects were allowed to participate in an investigation prior to obtaining [IRB] [FDA] approval to conduct the investigation. Specifically, ***
2992 21 CFR 812.140(b)(2) 4 Sponsor device shipment records inadequate Records of shipment of an investigational device that include the [name and address of the consignee] [type and quantity of device] [date of shipment] [batch number or code mark] reports are not all [accurate] [complete] [current]. Specifically, ***
2994 21 CFR 812.140(b)(3) 4 Sponsor records of investigator agreements inadequate Signed investigator agreements that include the required financial disclosure information are not all [accurate] [complete] [current]. Specifically, ***
3002 21 CFR 812.140(b)(5) 4 Sponsor records of adverse device effects & complaints Records concerning [anticipated adverse device effects] [unanticipated adverse device effects] [complaint] reports are not all [accurate] [complete] [current]. Specifically, ***
3063 21 CFR 812.140(a)(3)(iii) 4 Investigator records of exposure to device inadequate Records of each subject's exposure to the device, including [the date and time of each use] [the use of any other therapy] are not all [accurate] [complete] [current].  Specifically, ***
3139 21 CFR 820.140 4 Handling procedures to prevent mix-ups Procedures for product handling have not been [adequately] established.  Specifically,***
3147 21 CFR 820.170(a) 4 Installation instructions, test procedures [Installation instructions] [inspection instructions] [test procedures] have not been [adequately] established.  Specifically,***
3175 21 CFR 820.186 4 QSR content The quality system record has not been [adequately] maintained   Specifically *** 
3191 21 CFR 820.30(g) 4 Design validation production units The design was not validated [under defined operating conditions] [using initial production units, lots or batches or their equivalents].  Specifically, *** 
3193 21 CFR 820.30(g) 4 Design validation - production units in use conditions The design was not validated under actual or simulated use conditions.  Specifically, *** 
3216 21 CFR 820.70(b) 4 Changes documented Changes were not [documented] [followed].  Specifically, ***
3224 21 CFR 820.70(g)(2) 4 Periodic equipment inspection Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been [adequately] established.  Specifically, *** 
3241 21 CFR 820.72(b)(1) 4 Calibration standard traceability A calibration standard used for [inspection] [measurement] [test] equipment is not traceable to national or international standards nor is it an independent reproducible standard.  Specifically, ***
3305 21 CFR 820.100(a)(6) 4 Dissemination of problem information - procedure The corrective and preventive action procedures addressing dissemination of information on quality problems and nonconforming product to responsible individuals were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3316 21 CFR 820.160(a) 4 Expired or deteriorated devices Procedures have not been [established] [defined] [documented] [complete] [implemented] to ensure that expired or deteriorated devices are not distributed.  Specifically, ***
3377 21 CFR 820.198(e)(3) 4 Device identification and control number Records of complaint investigations do not include device identifications and control numbers used.  Specifically, ***
3396 21 CFR 820.80(d)(1) 4 DMR required activities {see also 820.181} Finished devices were released for distribution prior to completion of activities required in the Device Master Record.  Specifically, ***
3414 21 CFR 820.200(d)(6) 4 Test and inspection data Service reports do not include applicable test and/or inspection data.  Specifically, ***
3670 21 CFR 820.20(c) 4 Management review participants Documentation does not show that management with executive responsibility participated in  management reviews. Specifically, ***
3684 21 CFR 820.75(a) 4 Documentation - specific items Documentation of process validation activities and results does not include [the date and signature of the individuals approving the validation] [the major equipment validated].  Specifically, ***
4057 21 CFR 820.20(a) 4 Management responsibility Management with executive responsibility has not ensured that the quality policy is understood, implemented and maintained at all levels of the organization.  Specifically, *** 
4071 21 CFR 820.30(i) 4 Design changes - validation vs. verification Procedures were not [established] [defined] [documented] [completed] to address when verification of design changes is sufficient in lieu of validation prior to their implementation.  Specifically, ***
4208 21 CFR 806.20(a) 4 Records not kept There is no record maintained of a correction or removal action that was not required to be reported to FDA.   Specifically,***
6847 21 CFR 807.30(b) 4 Listing not updated or update not timely Device listing information was not updated [in a timely manner].  Specifically, ***
733 21 CFR 803.50(b)(1) 3 Reporting Information Reasonably Known An MDR report submitted to FDA did not include all information that was reasonably known to the manufacturer.  Specifically, ***
2276 21 CFR 820.20(b)(1) 3 Responsibility, authority and independence Employees who manage, perform, and assess work affecting quality have not been [assigned the appropriate responsibility and authority] [provided the independence and authority] to accomplish their work. Specifically, ****
2330 21 CFR 820.22 3 Quality audit corrective action, reaudits {see also 820.100} Quality reaudits [are not adequately performed] [do not cover corrective actions for the problem areas].  Specifically, ***
2403 21 CFR 820.25(a) 3 Sufficient personnel Insufficient personnel to assure that all procedures are appropriately carried out as required by the quality system.  Specifically, ***
2598 21 CFR 820.30(d) 3 Design output procedures Procedures for defining and documenting design output in terms that allow an adequate evaluation of conformance to design input requirements were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
2924 21 CFR 812.20(a)(2) 3 Initiation of study prior to FDA IDE approval FDA approval was not obtained prior to initiation of an investigation for which an FDA-approved IDE was required.  Specifically, ***
2940 21 CFR 812.43(c)(4)(i) 3 No investigation agreement statement of commitment A signed agreement that includes a statement of the investigator's commitment to conduct an investigation in accordance with the [agreement] [investigational plan] [applicable FDA regulations] [conditions of approval imposed by the reviewing IRB] [conditions of approval imposed by the FDA] was not obtained from each participating investigator.  Specifically, ***
2982 21 CFR 812.140(a)(2)(ii) 3 Investigator records of persons receiving devices inadequate Records of persons who [received] [used] [disposed] of each device are not all [accurate] [complete] [current]. Specifically, ***
3003 21 CFR 812.140(b)(6) 3 Other sponsor records required by FDA inadequate Records that FDA requires to be maintained for [a category of investigation] [a particular investigation] are not all [accurate] [complete] [current].  Specifically, ***
3034 21 CFR 812.150(a)(6) 3 Investigator final report A final report to the [sponsor] [reviewing IRB] was not submitted [within three months] after [termination] [completion] of the investigation.  Specifically, ***
3113 21 CFR 820.70(g) 3 Design and installation Equipment used in the manufacturing process has not been appropriately [designed] [constructed] [placed] [installed] to facilitate maintenance, adjustment, cleaning, and use. Specifically, *** 
3144 21 CFR 820.160(a) 3 Control/distribution procedures Procedures for the control and distribution of finished devices have not been [established] [defined] [documented] [complete] [implemented] to ensure that only devices approved for release are distributed.  Specifically, ***
3173 21 CFR 820.198(d) 3 Evaluation, timeliness, identification Complaints representing events that are MDR reportable were not [promptly reviewed, evaluated, and investigated by a designated individual] [maintained in a separate portion of the complaint files] [clearly identified]. Specifically, ***
3195 21 CFR 820.30(g) 3 Design validation unresolved discrepancies Unresolved discrepancies were noted at the completion of the design validation.  Specifically, ***
3198 21 CFR 820.40(b) 3 Changes - review and approval Changes to documents were not [reviewed and approved by an individual(s) in the same function or organization that performed the original review and approval] [communicated to appropriate personnel in a timely manner].  Specifically, *** 
3200 21 CFR 820.40(a) 3 Document locations, dissemination Documents were not available at all locations for which they are designated, used, or otherwise necessary.  Specifically, ***
3227 21 CFR 820.70(g)(1) 3 Activity documentation Maintenance activities, including the [date] [individuals performing those activities], have not been documented.  Specifically, ***
3306 21 CFR 820.100(a)(7) 3 Management review The procedures addressing submission of information on identified quality problems and corrective and preventive actions for management review were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
3331 21 CFR 820.181(e) 3 DMR installation/maintenance/servicing procedures A device master record has not been [adequately] maintained.  Specifically, ***
3333 21 CFR 820.184(f) 3 Device identification, control numbers The device history record does not include [certain] [any] device identifications and control numbers used.  Specifically, ***
3343 21 CFR 820.198(e) 3 Maintained Records of complaint investigations are not maintained by the formally designated unit. Specifically, ***
3402 21 CFR 820.80(e)(3) 3 Results Acceptance records did not include the results of certain acceptance activities.  Specifically, ***
3674 21 CFR 820.30(d) 3 Design output documentation Design output was not [adequately] documented before release.  Specifically, ***
3682 21 CFR 820.70(d) 3 Implementing personnel procedures - health, cleanliness, per Requirements addressing the [health] [cleanliness] [personal practices] [clothing] of employees have not been implemented.  Specifically, ***
3700 21 CFR 820.250(a) 3 Invalid technique An invalid statistical technique was used such that there is a likelihood of producing nonconforming and/or defective devices.   Specifically, ***
3701 21 CFR 820.250(a) 3 Techniques not used Statistical techniques are not used for control purposes where statistical techniques are applicable.  Specifically, ***
3838 21 CFR 820.40(a) 3 Document review procedures, designated individual The document control procedures do not designate an individual to review documents for adequacy and approve them prior to issuance.  Specifically, ***
4061 21 CFR 820.20(b)(3)(ii) 3 Management representative's reports The management representative has not [fully] reported on the quality system performance to management with executive responsibility. Specifically, ***
4437 21 CFR 803.40(b) 3 Report of malfunction likely to cause death or injury The importer failed to submit a report to the manufacturer on FDA Form 3500A within 30 days concerning information that one of the devices marketed by the importer has malfunctioned and that such device or a similar device marketed by the importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.  Specifically, ***
7013 21 CFR 812.110(d) 3 Inadequate financial disclosure by investigator The sponsor was not supplied [sufficient financial information to allow submission of complete and accurate certification or disclosure statements] [financial disclosure updates when a relevant change occurred during the course of the study or within one year following study completion].  Specifically, ***
14517 21 CFR 812.35(a)(1) 3 No approval for changes requiring prior approval [FDA] [IRB] approval was not obtained for changes to an investigational plan that require prior approval.  Specifically, ***
636 21 CFR 803.17(b)(2) 2 Reports and information documentation The written MDR procedure does not include documentation and recordkeeping requirements for all Medical Device Reports and information submitted to [FDA] [device manufacturers].  Specifically, ***
642 21 CFR 803.18(b)(1)(i) 2 Adverse events--all info not in file MDR event files do not contain or reference all adverse event information in the possession of the reporting entity, including documentation of the deliberations and decision making process used to determine if an event was or was not reportable.  Specifically, ***
649 21 CFR 803.18(e) 2 Info not obtained or submitted MDR files do not contain explanations of why required information [was not submitted] [could not be obtained].  Specifically, ***
2270 21 CFR 820.20(a) 2 Implement quality policy Not all employees [know there is] [understand] [fully implement] the quality policy. Specifically, ***
2339 21 CFR 820.22 2 Quality audit documentation The dates of quality [audits][reaudits] have not been documented.  Specifically, *** 
2481 21 CFR 820.30(c) 2 Design input procedures - addressing conflicting requirement Procedures for addressing incomplete, ambiguous, or conflicting design input requirements were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
2599 21 CFR 820.30(d) 2 Acceptance criteria and essential outputs Design output procedures do not [contain or reference acceptance criteria] [ensure that essential design outputs are identified] [allow for an adequate evaluation of conformance to design input requirements].  Specifically, ***
2933 21 CFR 812.43(a) 2 Investigator(s) not qualified One or more investigators were selected who were not qualified by [training] [experience] to investigate a device.  Specifically, ***
2935 21 CFR 812.43(b) 2 Sponsor shipped devices to unqualified person(s) Investigational devices were shipped to individuals who were not qualified investigators participating in the investigation.  Specifically, ***
2944 21 CFR 812.43(d) 2 Monitors not qualified Monitors that are qualified by [training] [experience] were not chosen to monitor the investigational study.  Specifically, ***
2972 21 CFR 812.110(a) 2 Informed consent obtained prior to study approval Written informed consent of potential subjects to participate in an investigation was obtained prior to obtaining [IRB] [FDA] approval to conduct the investigation.  Specifically, ***
3007 21 CFR 812.140(d) 2 Record retention inadequate Required records were not all maintained [during the investigation] [for a period of two years after the date on which an investigation was terminated or completed] [for a period of two years after the date that the records were no longer required for purposes of supporting a premarket approval application or a notice of completion of a product development protocol].  Specifically, ***
3025 21 CFR 812.150(a)(3) 2 No investigator progress reports Progress reports on the investigation were not submitted [at the required intervals] [at least yearly] to the [sponsor] [monitor] [reviewing IRB]. Specifically, ***
3027 21 CFR 812.150(a)(4) 2 Investigator non-emergency safety or soundness changes In a non-emergency situation, [changes to] [deviations from] the investigational plan that could have affected [the scientific soundness of the plan] [the rights, safety, or welfare of human subjects] were initiated without prior approval of the changes from [the sponsor] [FDA] [the IRB] .  Specifically, ***
3055 21 CFR 812.150(b)(7) 2 Sponsor final report for significant risk study A final report to [FDA] [all reviewing IRBs] [all participating investigators] was not submitted [within six months] after [completion] [termination] of a significant risk device study.  Specifically, ***
3065 21 CFR 812.140(a)(5) 2 Additional investigator records FDA requires Records that FDA requires by [regulation] [specific requirement] to be maintained for [a category of investigations] [a particular investigation] are not all [accurate] [complete] [current].  Specifically, ***
3109 21 CFR 820.70(d) 2 Personnel procedures-health, cleanliness, personal practices Requirements have not been [adequately] established to address personnel [health] [cleanliness] [personal practices] [clothing].  Specifically, *** 
3162 21 CFR 820.184(b) 2 Quantity manufactured The device history record does not include the quantity of devices manufactured.  Specifically, ***
3163 21 CFR 820.184(c) 2 Quantity released The device history record does not include the quantity of devices released for distribution.  Specifically, ***
3168 21 CFR 820.198(a) 2 Designated unit Complaint files are not [adequately] maintained.  Specifically *** 
3230 21 CFR 820.70(i) 2 Validation of changes to automated process software Changes to software used as part of [production] [the quality system] were not [adequately] validated before approval and issuance.   Specifically, ***
3236 21 CFR 820.72(b) 2 Procedures - content Calibration procedures do not include [specific directions and limits for accuracy and precision] [provisions for remedial action].  Specifically, ***
3276 21 CFR 820.80(e) 2 Maintained as part of the DHR {see also 820.184} Acceptance records were not maintained as part of the device history record.  Specifically, ***
3309 21 CFR 820.120(b) 2 Examination for accuracy Labeling was not sufficiently examined by a designated individual for accuracy including [the correct expiration date] [control numbers] [storage instructions] [handling instructions] [certain additional processing instructions] before release.  Specifically, ***
3312 21 CFR 820.120(d) 2 Mix-ups Labeling and packaging operations were not controlled to prevent labeling mix-ups.  Specifically, ***
3324 21 CFR 820.170(b) 2 Installer's documentation of results The person installing the device did not document complete inspection and test results to demonstrate proper installation.  Specifically, ***
3325 21 CFR 820.180 2 Storage Required records [are not stored so as to minimize deterioration and prevent loss] [that are stored in automated data processing systems are not backed up].  Specifically, ***
3328 21 CFR 820.180(b) 2 Retention period Required records are not retained for [the design and expected life of the device] [at least 2 years from the date of release of the device for commercial distribution].  Specifically, ***
3346 21 CFR 820.200(b) 2 Statistical analysis {see also 820.100(a)(1)} Service reports were not analyzed following appropriate statistical methods. Specifically, ***
3370 21 CFR 820.198(a)(2) 2 Oral complaints Complaint handling procedures have not been [established] [defined] [documented] [completed] [implemented] to ensure that all oral complaints are documented upon receipt.  Specifically, ***
3378 21 CFR 820.198(e)(4) 2 Complainant data Records of complaint investigations do not include the [name] [address] [phone number] of the complainant.  Specifically, ***
3382 21 CFR 820.198(e)(8) 2 Reply to complainant Records of complaint investigations do not include any reply to the complainant.  Specifically, ***
3419 21 CFR 820.70(a)(4) 2 Approval of process Processes have not been approved. Specifically, ***
3668 21 CFR 820.20(c) 2 Management review dates The results and/or dates of management reviews are not documented. Specifically, ***
3699 21 CFR 820.160(b) 2 Records {see also 820.65} Distribution records [were not maintained] [do not include or refer to the location of required information].  Specifically, ***
3840 21 CFR 820.72(b)(1) 2 In-house calibration standards In the absence of a national or international standard, or an independent reproducible standard, no in-house standard has been established for [inspection] [measuring] [test] equipment.  Specifically, ***
3841 21 CFR 820.90(b)(2) 2 Product rework adverse effects {see also 820.184} Documentation of rework and reevaluation activities does not include a determination of whether there has been any adverse effect from rework upon the product.  Specifically, ***
4192 21 CFR 806.10(a)(2) 2 Report of violation of the Act (see 803.52(e)(9)) A violation of the FD&C Act involving a device which might present a risk to health was not reported to FDA.  Specifically, ***
4211 21 CFR 806.20(b)(3) 2 Events A description of the events that led to the correction or removal actions was not contained in the record.  Specifically,***
4436 21 CFR 803.40(a) 2 Report of death, injury by marketed device The importer failed to submit a report to FDA on FDA form 3500A, with a copy to the manufacturer, within 30 days after receiving  information that one of its marketed devices may have caused or contributed to a [death] [serious injury].  Specifically, ***
6808 21 CFR 807.26 2 Changes FDA was not notified within 30 days of changes in [individual ownership] [corporate structure] [partnership structure] [location] of your registered establishment.  Specifically, ***
638 21 CFR 803.17(b)(4) 1 Info which facilitates timely FDA follow-up   The written MDR procedure does not include documentation and recordkeeping requirements for systems that ensure access to information that facilitates timely follow-up and inspection by FDA.  Specifically, ***
734 21 CFR 803.50(b)(2) 1 Providing Incomplete or Missing Information The firm did not obtain and provide FDA with information that is incomplete or missing from reports submitted by user facilities, distributors, and other initial reporters.  Specifically, ***
738 21 CFR 803.52(a)(1) 1 Patient Name or Other Identifier An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block A the patient name or other identifier.  Specifically, ***
739 21 CFR 803.52(a)(2) 1 Patient Age or Date of Birth An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block A the patient's age or date of birth.  Specifically, ***
740 21 CFR 803.52(a)(3) 1 Patient Gender An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block A the patient's gender.  Specifically, ***
741 21 CFR 803.52(a)(4) 1 Patient Weight An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block A the patient's weight.  Specifically, ***
749 21 CFR 803.52(b)(3) 1 Date of Event An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block B the date of the event.  Specifically, ***
751 21 CFR 803.52(b)(5) 1 Description of the Event or Problem An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block B a description of the event or problem to include [a discussion of how the device was involved] [the nature of the problem] [the patient follow-up or required treatment] [any environmental conditions that may have influenced the event].  Specifically, ***
760 21 CFR 803.52(c)(6) 1 Model, Catalog, Serial and Lot Numbers An individual medical device manufacturer report submitted per FDA Form 3500A did not contain in Block D the device [model] [catalog] [serial] [lot] number.  Specifically, ***
778 21 CFR 803.52(f)(1) 1 Type of Reportable Event An individual medical device manufacturer report submitted per FDA Form 3500A did not indicate in Block H the type of reportable event.  Specifically, ***
784 21 CFR 803.52(f)(7) 1 Remedial Action Taken An individual medical device manufacturer report submitted per FDA Form 3500A did not indicate in Block H whether remedial action was taken and type.  Specifically, ***
786 21 CFR 803.52(f)(9) 1 Remedial Action Reported per Section 519 An individual medical device manufacturer report submitted per FDA Form 3500A did not indicate in Block H whether remedial action was reported as a removal or correction under Section 519(f) of the FD&C Act, and listing the correction/removal report number.  Specifically, ***
793 21 CFR 803.53(a) 1 Firm Did Not Submit 5 Day Report A 5 day report was not submitted to FDA on Form 3500A within 5 workdays of becoming aware that a reportable MDR event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health.  Specifically, ***
796 21 CFR 803.55(a) 1 Initial Submission of Baseline Report A baseline report on FDA Form 3417 or approved electronic equivalent was not submitted following the first MDR report on a device model.  Specifically, ***
812 21 CFR 803.56 1 Submission Within One Month A supplemental report was not submitted to FDA within one month following receipt of information that was not provided when the initial report was submitted.  Specifically, ***
2338 21 CFR 820.22 1 Quality audit/reaudit reports Reports of results of quality [audits] [reaudits] are not reviewed by management having responsibility for the matters audited.   Specifically, *** 
2937 21 CFR 812.43(c)(1) 1 No curriculum vitae in investigator agreement The signed investigator agreements obtained from each participating investigator do not all include the investigator's curriculum vitae. Specifically, ***
2939 21 CFR 812.43(c)(3) 1 No research termination info in investigator agreement A signed agreement, that includes an explanation of the circumstances that led to the termination of any investigations in which the investigator was involved, was not obtained from each participating investigator.  Specifically, ***
2952 21 CFR 812.46(b)(1) 1 No evaluation of unanticipated adverse effects An evaluation of reported unanticipated adverse device effects was not conducted. Specifically,***
2969 21 CFR 812.100 1 No investigator protection - subject rights, safety, welfare The rights, safety, and welfare of subjects in an investigational study were not [adequately] protected.  Specifically, ***
2975 21 CFR 812.110(c) 1 Investigator did not supervise use of investigational device An investigational device was used for subjects not under the supervision of an authorized investigator.  Specifically, ***
2976 21 CFR 812.110(c) 1 Supply of investigational device to unauthorized person An investigational device was supplied to a person not authorized to receive it. Specifically, ***
3028 21 CFR 812.150(a)(4) 1 No approval for investigator change in non-emergency Prior approval was not obtained from the sponsor for [changes in] [deviations from] an investigational plan in a non-emergency situation.  Specifically, ***
3029 21 CFR 812.150(a)(4) 1 Investigator report of emergency use The [sponsor] [reviewing IRB] was not notified [within five working days] of a deviation from the investigational plan to protect the life or physical well-being of a subject in an emergency situation.  Specifically, ***
3032 21 CFR 812.150(a)(5) 1 Investigator report for lack of informed consent A report to the [sponsor] [reviewing IRB] regarding the use of an investigational device without obtaining informed consent was not submitted [within five working days after the use occurred].  Specifically, ***
3043 21 CFR 812.150(b)(2) 1 Sponsor notification of IRB approval withdrawal Notification of withdrawal of approval of an investigation by a reviewing IRB was not sent [within five working days of withdrawal] to [FDA] [all reviewing IRBs] [all participating investigators].  Specifically, ***
3052 21 CFR 812.150(b)(6) 1 Sponsor notif. of rqst. to return/repair/dispose not made Notification was not sent to [FDA] [all reviewing IRBs] of a request that an investigator [return] [repair] [dispose of] any units of a device.  Specifically, ***
3115 21 CFR 820.70(h) 1 Procedures for use and removal Procedures for the use and removal of manufacturing material have not been [adequately] established.  Specifically, *** 
3138 21 CFR 820.130 1 Packaging Device packaging and/or shipping containers are not designed and constructed to protect the device from alteration or damage during processing, storage, handling, and distribution.  Specifically, *** 
3142 21 CFR 820.150(a) 1 Storage procedures to avoid release of unsuitable product Procedures for controlling the storage of product in storage areas and stock rooms are not adequate to ensure that no obsolete, rejected, or deteriorated product is distributed.  Specifically, ***
3202 21 CFR 820.40(b) 1 Changes, communication Approved changes were not communicated to appropriate personnel in a timely manner.  Specifically, ***
3208 21 CFR 820.50(b) 1 Approval of purchasing data {see also 820.40(a)} The purchasing data were not approved.  Specifically, ***
3218 21 CFR 820.70(c) 1 Environmental control system-documentation/review inspection Inspections of environmental control system were not [documented] [reviewed]. Specifically, ***
3237 21 CFR 820.72(b) 1 Remedial action When test/measurement equipment was found to not meet accuracy and precision limits, [no] [inadequate] action was taken to [bring the equipment into calibration] [evaluate whether there was any adverse effect on the device's quality].  Specifically, ***
3239 21 CFR 820.72(b) 1 Remedial action - documentation Evaluations of out-of-calibration equipment and remedial actions taken were not documented. Specifically, ***
3264 21 CFR 820.250(b) 1 Procedure for reviewing for adequacy Procedures to ensure sampling methods are adequate for their intended use have not been [adequately] established.  Specifically,***
3267 21 CFR 820.86 1 Maintained The acceptance status of product was not clearly identified throughout [manufacturing] [packaging] [labeling] [installation] [servicing] of the product.  Specifically, ***
3271 21 CFR 820.80(d) 1 Quarantine of finished devices Finished devices were not adequately controlled until acceptance tests were completed, results approved, and devices released.  Specifically, ***
3290 21 CFR 820.90(b)(2) 1 Retesting and reevaluation of reworked product Rework of nonconforming product did not include [complete] retesting and reevaluation to ensure that the reworked product met current approved specifications.  Specifically, ***
3322 21 CFR 820.170(a) 1 Instructions available from manufacturer Complete installation instructions and procedures were not supplied to the person installing the device.  Specifically, ***
3323 21 CFR 820.170(b) 1 Installer's performance The person installing the device did not [adequately] document the inspection and test results to demonstrate proper installation. 
3349 21 CFR 820.200(d) 1 No documentation Service reports were not documented. Specifically, ***
3355 21 CFR 820.198(f) 1 Records accessible to manufacturing site Investigated complaints and records of investigation were not accessible to the manufacturing establishment.  Specifically, ***
3372 21 CFR 820.198(d)(1) 1 Determination of whether device met specifications Investigation records of MDR reportable complaints do not include required information.  Specifically *** 
3376 21 CFR 820.198(e)(2) 1 Date complaint received Records of complaint investigations do not include the date the complaint was received.  Specifically, ***
3383 21 CFR 820.198(g) 1 Foreign complaint files accessible in U.S. The manufacturer's formally designated complaint unit is located outside of the United States and complaint records are not reasonably accessible in the United States.  Specifically, *** 
3399 21 CFR 820.80(d)(4) 1 No release authorization date Finished devices were released for distribution without the authorization being dated.  Specifically, ***
3404 21 CFR 820.80(e)(5) 1 Equipment Acceptance records did not identify the equipment used in the tests.  Specifically, ***
3418 21 CFR 820.70(a)(3) 1 Standards or codes Process controls do not include testing devices for compliance with applicable standards or codes, as required by device specifications.  Specifically, ***
3691 21 CFR 820.100(a)(4) 1 Verification vs validation There is no corrective and preventive action procedure to determine when verification can be conducted in lieu of validation.  Specifically, ***
3694 21 CFR 820.100(a)(6) 1 Dissemination of problem information Information related to quality problems or nonconforming product is not disseminated to those directly responsible for assuring the [quality of the product] [prevention of the quality problem].  Specifically, ***
3707 21 CFR 820.250(b) 1 Documenting review for changes Review of sampling plans when changes occur was not documented. Specifically, ***
3839 21 CFR 820.70(a)(4) 1 Approval of process equipment Process equipment has not been approved.  Specifically, ***
4167 21 CFR 820.70(g) 1 Specified requirements Equipment used in the manufacturing process does not meet specified requirements.  Specifically, ***
4169 21 CFR 820.100(a)(7) 1 Identifying relevant info for management review Procedures addressing identification of relevant information to be submitted for management review were not [established] [defined] [documented] [complete] [implemented].  Specifically, ***
4206 21 CFR 806.10(c)(13) 1 Explanation of info. not available In reports of devices subject to correction or removal actions there is no written explanation as to why any required information is not immediately available and when it will be.  Specifically,***
4210 21 CFR 806.20(b)(2) 1 Device model identification The records of devices subject to correction and removal actions did not contain the [model] [catalog] [code number] of the device and the manufacturing [lot] [serial number] [identifying number] of the device.  Specifically,***
4249 21 CFR 821.25(c) 1 Not established, maintained Written procedures for the collection, maintenance, and auditing of device tracking information were not [established] [implemented] [complete] [provided to the FDA].  Specifically,***
4429 21 CFR 803.18(d)(2) 1 Record retention period - distributor The device distributor has not maintained required copies of device complaint records [including information regarding the evaluation of the allegations] for a period of [2 years from the date of inclusion of the record in the file] [time equivalent to the expected life of the device].  Specifically, ***
4430 21 CFR 803.18(d)(1) 1 Distributor responsibilities for records Device complaint records are not [established] [maintained] by the device distributor, including any relevant [incident information] [information regarding the evaluation of the allegations].  Specifically, ***
6801 21 CFR 807.21(a) 1 Initial registration An initial establishment registration was not submitted within 30 days after starting an operation requiring registration.  Specifically,
6805 21 CFR 807.25(b) 1 Device activities not reported Device activities have not been reported to FDA.  Specifically, ***
6807 21 CFR 807.25(c) 1 List not maintained of officers, directors, and partners No listing is maintained of all officers, directors, and partners for each registered establishment.  Specifically, ***
6812 21 CFR 807.31(a) 1 Not maintained A historical file has not been maintained for each device.  Specifically, ***
9670 21 CFR 809.10(a)(4) 1 "For IVD Use" statement The [product label] [outside container] [wrapper] of an in vitro diagnostic product does not bear the statement "For In Vitro Diagnostic Use".  Specifically, *** 
14509 21 CFR 812.150(b)(1) 1 Sponsor evaluation report incomplete, inaccurate Reports of the results of evaluation of unanticipated adverse device effects were not all [complete] [accurate].  Specifically, ***
14518 21 CFR 812.35(a)(3)(iv) 1 No 5 day notification of IDE change FDA was not notified within five working days of [developmental changes that do not constitute a significant change] [manufacturing changes that do not constitute a significant change] [changes to the clinical protocol that do not change the validity of the data or information, scientific soundness of the investigational plan, or the rights, safety, or welfare of the subjects involved].  Specifically, ***

Back to top

Drugs

Center Name Cite Id Ref No Frequency Short Description Long Description
Drugs 1105 21 CFR 211.22(d) 112 Procedures not  in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not [in writing] [fully followed].  Specifically, ***
3585 21 CFR 211.110(a) 70 Control procedures to monitor and validate performance Control procedures are not established which [monitor the output] [validate the performance] of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.  Specifically, ***
3603 21 CFR 211.160(b) 69 Scientifically sound laboratory controls Laboratory controls do not include the establishment of scientifically sound and appropriate [specifications] [standards] [sampling plans] [test procedures] designed to assure that [components] [drug product containers] [closures] [in-process materials] [labeling] [drug products] conform to appropriate standards of identity, strength, quality and purity.  Specifically, ***
2027 21 CFR 211.192 65 Investigations of discrepancies, failures There is a failure to thoroughly review [any unexplained discrepancy] [the failure of a batch or any of its components to meet any of its specifications] whether or not the batch has been already distributed.  Specifically, ***
1358 21 CFR 211.100(b) 58 SOPs not followed / documented Written production and process control procedures are not [followed in the execution of production and process control functions] [documented at the time of performance].  Specifically, ***
1213 21 CFR 211.67(a) 56 Cleaning / Sanitizing / Maintenance Equipment and utensils are not [cleaned] [maintained] [sanitized] at appropriate intervals to  prevent [malfunctions] [contamination] that would alter the safety, identity, strength, quality or purity of the drug product.  Specifically, ***
1361 21 CFR 211.100(a) 52 Absence of Written Procedures  There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.  Specifically, ***
1112 21 CFR 211.25(a) 48 Training--operations, GMPs, written procedures Employees are not given training in [the particular operations they perform as part of their function] [current good manufacturing practices] [written procedures required by current good manufacturing practice regulations].  Specifically, ***
1215 21 CFR 211.67(b) 43 Written procedures not established/followed Written procedures are not [established] [followed] for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.  Specifically, ***
1883 21 CFR 211.165(a) 42 Testing and release for distribution Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the [final specifications] [identity and strength of each active ingredient] prior to release.  Specifically, ***
2009 21 CFR 211.188 42 Prepared for each batch, include complete information Batch production and control records [are not prepared for each batch of drug product produced] [do not include complete information relating to the production and control of each batch].  Specifically, ***
1274 21 CFR 211.68(a) 38 Calibration/Inspection/Checking not done Routine [calibration] [inspection] [checking] of  [automatic] [mechanical] [electronic] equipment is not performed according to a written program designed to assure proper performance.  Specifically, ***
1177 21 CFR 211.63 37 Equipment Design, Size and Location Equipment used in the manufacture, processing, packing or holding of  drug products is not [of appropriate design] [of adequate size] [suitably located] to facilitate operations for its [intended use] [cleaning and maintenance].  Specifically, ***
4391 21 CFR 211.180(e)(2) 36 Items to cover on annual reviews Written procedures are not [established] [followed] for evaluations done at least annually and including provisions for a review of [complaints] [recalls] [returned or salvaged drug products] [investigations conducted for each drug product].  Specifically, ***
1809 21 CFR 211.160(a) 35 Following/documenting laboratory controls Established [specifications] [standards] [sampling plans] [test procedures] [laboratory control mechanisms] are not [followed] [documented at the time of performance].  Specifically, ***
1943 21 CFR 211.180(e)(1) 34 Review of representative number of batches Written procedures are not [established] [followed] for  evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.  Specifically, ***
2028 21 CFR 211.192 34 Extent of discrepancy, failure  investigations Investigations of [an unexplained discrepancy] [a failure of a batch or any of its components to meet any of its specifications]  did not extend to [other batches of the same drug product] [other drug products that may have been associated with the specific failure or discrepancy].  Specifically, ***
1890 21 CFR 211.165(e) 32 Test methods  The [accuracy] [sensitivity] [specificity] [reproducibility] of test methods have not been [established] [documented].  Specifically, ***
4352 21 CFR 211.160(b)(4) 32 Calibration - at intervals, written program, remedial action The calibration of [instruments] [apparatus] [gauges] [recording devices] is not done at suitable intervals [in accordance with an established written program] [with provisions for remedial action in the event accuracy and/or precision limits are not met].  Specifically, ***
1914 21 CFR 211.166(a) 31 Lack of written stability program There is no written testing program designed to assess the stability characteristics of drug products.  Specifically, ***
2419 21 CFR 211.198(a) 30 Complaint Handling Procedure Procedures describing the handling of written and oral complaints related to drug products are [not written or followed] [deficiently written or followed].  Specifically, ***
2026 21 CFR 211.192 28 Quality control unit review of records Drug product production and control records, are not [reviewed] [approved] by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.  Specifically, ***
4576 21 CFR 211.192 28 No written record of investigation Written records are not [always] made of investigations into [unexplained discrepancies] [the failure of a batch or any of its components to meet specifications].  Specifically, ***
1133 21 CFR 211.25(a) 27 GMP Training Frequency GMP training is not conducted [on a continuing basis] [with sufficient frequency] to assure that employees remain familiar with CGMP requirements applicable to them.  Specifically, ***
4389 21 CFR 211.198(a) 26 Procedures to be written and followed Procedures describing the handling of all written and oral complaints regarding a drug product are not [established] [written] [followed].  Specifically, ***
4402 21 CFR 211.192 26 Written record of investigation incomplete Written records of investigations into [unexplained discrepancies] [the failure of a batch or any of its components to meet specifications] do not [always] include the conclusions and follow-up.  Specifically, ***
1227 21 CFR 211.67(c) 25 Cleaning/maintenance records not kept Records are not kept for the [maintenance] [cleaning] [sanitizing] [inspection] of equipment.  Specifically, ***
4314 21 CFR 211.84(d)(2) 24 Reports of Analysis (Components) Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without [performing at least one specific identity test on each component] [establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals].  Specifically, ***
1767 21 CFR 211.137(a) 23 Expiration date lacking Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.  Specifically, ***
4340 21 CFR 211.142 23 Written warehousing procedures established/followed Procedures describing the warehousing of drug products are not [established] [followed].  Specifically, ***
4413 21 CFR 211.194(a)(8) 23 Second person sign off Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for [accuracy] [completeness] [compliance with established standards].  Specifically, ***
1833 21 CFR 211.84(d)(1) 22 Identity Testing of Each Component The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.  Specifically, ***
1787 21 CFR 211.80(a) 21 Procedures To Be in Writing Written procedures are lacking which describe in sufficient detail the [receipt] [identification] [storage] [handling] [sampling] [testing] [approval] [rejection] of [components] [drug product containers] [closures].  Specifically, ***
1111 21 CFR 211.25(a) 20 Training , Education , Experience overall Employees  engaged in the [manufacture] [processing] [packing] [holding] of a drug product lack the [education] [training] [experience] required to perform their assigned functions.  Specifically, ***
4303 21 CFR 211.67 b) 19 Written procedures fail to include Written procedures for cleaning and maintenance fail to include [assignment of responsibility] [maintenance and cleaning schedules] [description in sufficient detail of methods, equipment and materials used] [description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance] [instructions for removal or obliteration of previous batch identification] [instructions for protection of clean equipment from contamination prior to use] [parameters relevant to the operation].  Specifically, ***
9001 21 CFR 211.22(a) 19 Lack of quality control unit There is no quality control unit.  Specifically, ***
1912 21 CFR 211.166(a) 18 Written program not followed The written stability testing program is not followed.  Specifically, ***
4369 21 CFR 211.188(b)(11) 18 Identification of persons involved, each significant step Batch production and control records do not include the identification of the persons [performing] [directly supervising] [checking] each significant step in the operation, for each batch of drug product produced.  Specifically, ***
4372 21 CFR 211.188(b)(8) 18 Labeling control records including specimens or copies Batch production and control records do not include complete labeling control records, including specimens or copies of all labeling used for each batch of drug product produced.  Specifically, ***
1810 21 CFR 211.160(a) 17 Lab controls established, including changes The establishment of [specifications] [standards] [sampling plans] [test procedures] [laboratory control mechanisms] including any changes thereto, are not [drafted by the appropriate organizational unit] [reviewed and approved by the quality control unit].  Specifically, ***
1975 21 CFR 211.182 17 Written records kept in individual logs Written records of major equipment [cleaning] [maintenance] [use]  are not included in individual equipment logs.  Specifically, ***
3572 21 CFR 211.100(b) 17 Procedure Deviations Recorded and Justified Deviations from written production and process control procedures are not [recorded] [justified].  Specifically, ***
3583 21 CFR 211.110(a) 17 Written in-process control procedures Written procedures are not [established] [followed] that describe the [in-process controls] [tests] [examinations] to be conducted on appropriate samples of in-process materials of each batch.  Specifically, ***
1451 21 CFR 211.113(b) 16 Procedures for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not [established] [written] [followed].  Specifically, ***
1540 21 CFR 211.125(a) 16 Strict control not exercised over labeling issued Strict control is not exercised over labeling issued for use in drug product labeling operations.  Specifically, ***
1395 21 CFR 211.103 15 Actual vs. theoretical yields not determined Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of [manufacturing] [processing] [packaging] [holding] of the drug product.  Specifically, ***
2205 21 CFR 211.186(b)(9) 15 Manufacturing Instructions and Specifications The master production and control records are deficient in that they do not include complete [manufacturing] [control] [instructions] [sampling] [testing] [procedures] [specifications] [special notations] [precautions].  Specifically, ***
3602 21 CFR 211.160(a) 15 Deviations from laboratory control requirements Deviations from written [specifications] [standards] [sampling plans] [test procedures] [laboratory mechanisms] are not [recorded] [justified].  Specifically, ***
1452 21 CFR 211.113(b) 14 Validation lacking for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include [adequate] validation of the sterilization process.  Specifically, ***
1495 21 CFR 211.122(a) 14 Written procedures describing in detail There is a lack of written  procedures describing in sufficient detail the [receipt] [identification] [storage] [handling] [sampling] [examination] [testing] of labeling and packaging materials.  Specifically, ***
1891 21 CFR 211.165(f) 14 Failing drug products not rejected Drug products failing to meet established [standards] [specifications] [quality control criteria] are not rejected.  Specifically, ***
1920 21 CFR 211.166a)(3) 14 Valid stability test methods The written stability program for drug products does not include [reliable] [meaningful] [specific] test methods.  Specifically, ***
2031 21 CFR 211.194(a) 14 Complete test data included in records Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.  Specifically, , ***
3571 21 CFR 211.100(a) 14 Changes to Procedures Not Reviewed, Approved Changes to written procedures are  not [drafted, reviewed and approved by the appropriate organizational unit] [reviewed and approved by the quality control unit].  Specifically, ***
3632 21 CFR 211.170(b) 14 Annual visual exams of drug products Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.  Specifically, ***
4306 21 CFR 211.80(a) 14 Written Procedures Not Followed Written procedures are not followed for the [receipt] [identification] [storage] [handling] [sampling] [testing] [approval] [rejection] of [components] [drug product containers] [closures].  Specifically, ***
4401 21 CFR 211.186(b)(9) 14 Complete instructions, procedures, specifications et. al. Master production and control records lack [complete manufacturing and control instructions] [sampling and testing procedures] [specifications] [special notations] [precautions to be followed].  Specifically, ***
1550 21 CFR 211.125(f) 13 Procedures Written and Followed Procedures describing in sufficient detail the controls employed for the issuance of labeling are not [written] [followed]. Specifically, ***
1885 21 CFR 211.165(b) 13 Microbiological testing Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.  Specifically, ***
3547 21 CFR 211.46(b) 13 Equipment for Environmental Control Equipment for adequate control over [air pressure] [micro-organisms] [dust] [humidity] [temperature] is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.  Specifically, ***
3565 21 CFR 211.58 13 Buildings not maintained in good state of repair Buildings used in the [manufacturing] [processing] [packing] [holding] of a drug product are not maintained in a good state of repair.  Specifically, ***
1450 21 CFR 211.113(a) 12 Procedures for non-sterile drug products Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not [established] [written] [followed].  Specifically, ***
4342 21 CFR 211.142(b) 12 Storage under appropriate conditions Drug products are not stored under appropriate conditions of [temperature] [humidity] [light] so that their identity, strength, quality, and purity are not affected.  Specifically, ***
1448 21 CFR 211.111 11 Establishment of time limitations Time limits are not established when appropriate  for the completion of each production phase to assure the quality of the drug product.  Specifically, ***
2008 21 CFR 211.186(a) 11 Written procedures followed Procedures for the preparation of master production and control records are not [described in a written procedure] [followed].  Specifically, *** 
2033 21 CFR 211.194(c) 11 Testing and standardization of standards et. al. Laboratory records do not include complete records of any testing and standardization of laboratory [reference standards] [reagents] [standard solutions].  Specifically, ***
3570 21 CFR 211.100(a) 11 Approval and review of procedures Written procedures are not [drafted, reviewed and approved by the appropriate organizational units] [reviewed and approved by the quality control unit].  Specifically, ***
4368 21 CFR 211.188(b)(12) 11 Investigations made into any unexplained discrepancy Batch production and control records do not include the results of any investigation made into any unexplained discrepancy, whether or not the batch of drug product had already been distributed.  Specifically, ***
1261 21 CFR 211.68(a) 10 Written calibration / inspection records not  kept Records of the [calibration checks] [inspections] of  automatic, mechanical or electronic equipment, including computers or related systems are not maintained.  Specifically, ***
1942 21 CFR 211.180(e) 10 Records reviewed annually  Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.  Specifically, ***
2619 21 CFR 211.198(b)(2) 10 Complaint Investigation/Follow-Up Findings Complaint records are deficient in that they do not include the findings of the [investigation] [follow-up].  Specifically, ***
3616 21 CFR 211.165(d) 10 Acceptance criteria for sampling & testing Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet [each appropriate specification] [appropriate statistical quality control criteria] as a condition for their approval and release.  Specifically, ***
4378 21 CFR 211.188(b)(2) 10 Identity of major equipment and lines used Batch production and control records do not include the identity of individual major [equipment] [lines] used for each batch of drug product produced.  Specifically, ***
1162 21 CFR 211.28(a) 9 Protective Apparel Not Worn Protective apparel is not worn as necessary to protect drug products from contamination.  Specifically, ***
1169 21 CFR 211.42(a) 9 Buildings of Suitable Size, Construction, Location Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable [size] [construction] [location] to facilitate cleaning, maintenance, and proper operations.  Specifically, ***
1626 21 CFR 211.130 9 Procedures are written, and followed Procedures designed to assure that correct [labels] [labeling] [packaging materials] are used for drug products are not [written] [followed].  Specifically, ***
1790 21 CFR 211.80(b) 9 Handling and Storage to Prevent Contamination There was a failure to handle and store [components] [drug product containers] [closures] at all times in a manner to prevent contamination.  Specifically, ***
1926 21 CFR 211.166(b) 9 Adequate number of batches on stability An adequate number of batches of each drug product are not tested [nor are records of such data maintained] to determine an appropriate expiration date.  Specifically, ***
1927 21 CFR 211.166(b) 9 Accelerated stability studies Accelerated stability studies, combined with basic stability information, used to support tentative expiration dates are not  supported with ongoing full shelf life studies.  Specifically, ***
2007 21 CFR 211.186(a) 9 Signature and checking of records -- 2 persons The master production and control records for each batch size of drug product are not  [prepared, dated, and signed by one person with a full handwritten signature] [independently checked, dated, and signed by a second person].  Specifically, ***
2034 21 CFR 211.194(d) 9 Laboratory equipment calibration records Laboratory records do not include complete records of the periodic calibration of laboratory [instruments] [apparatus] [gauges] [recording devices].  Specifically, ***
3559 21 CFR 211.56(a) 9 Sanitation--buildings not clean, free of infestation Buildings used in the manufacture, processing, packing or holding of drug products are not [maintained in a clean and sanitary condition] [free of infestation by rodents, birds insects, and other vermin]. Specifically, ***
3561 21 CFR 211.56(b) 9 Written sanitation procedures lacking There is a lack of written procedures [assigning responsibility] [providing cleaning schedules] [describing in sufficient detail the methods, equipment and materials to be used] for sanitation.  Specifically, ***   
3582 21 CFR 211.105(a) 9 Identification of containers, lines, equipment All [compounding and storage containers] [processing lines] [major equipment] used during the production of a batch of drug product is not properly identified at all times to indicate [contents] [the phase of processing of the batch].  Specifically, *** 
4382 21 CFR 211.198(b)(2) 9 Written record of complaint to include findings, follow-up Written records of investigation of a drug complaint do not include [the findings of the investigation] [the follow-up].  Specifically, ***
6732 21 CFR 314.80(c)(1)(i) 9 Late submission of 15-day report Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.  Specifically, ***
1033 21 CFR 211.22(a) 8 Authority lacking to review records, investigate errors The quality control unit lacks authority  to [review production records to assure that no errors have occurred] [fully investigate errors that have occurred].  Specifically, ***
1194 21 CFR 211.42(c) 8 Defined areas of adequate size for operations The [separate or defined areas][control systems] necessary to prevent contamination or mix-ups are deficient. Specifically, ***
1454 21 CFR 211.115(a) 8 Reprocessing procedures not written or followed Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are  not [written] [followed].  Specifically, ***
1725 21 CFR 211.134(c) 8 Examinations documented The results of the examination of the packaged and labeled products were not documented in the batch production or control records.  Specifically, ***
1886 21 CFR 211.165(c) 8 Sampling and testing plans not described Sampling and testing plans for drug products are not described in written procedures which include the [method of sampling] [number of units per batch to be tested].  Specifically, ***
1918 21 CFR 211.166(a)(2) 8 Stability sample storage conditions described The written stability program for drug products does not describe the storage conditions for samples retained for testing.  Specifically, ***
2003 21 CFR 211.184(c) 8 Individual inventory record Records fail to include an individual inventory record of each [component] [reconciliation of the use of each component] [drug product container] [drug product closure] with sufficient information to allow determination of any associated  batch or lot of drug product.  Specifically, ***
4336 21 CFR 211.150 8 Written distribution procedure Written distribution procedures are not [established] [followed].  Specifically, ***
1270 21 CFR 211.68(b) 7 input/output verification Input to and output from [the computer] [related systems of formulas] [records or data] are not checked for accuracy.  Specifically, *** 
1633 21 CFR 211.130(d) 7 Examination of packaging and labeling Examination of packaging and labeling materials for suitability and correctness before packaging operations is [not performed] [not documented in the batch production records].  Specifically, ***
1774 21 CFR 211.142(a) 7 Quarantine - actual practice Drug products are not quarantined before being released by the quality control unit.  Specifically, ***
1801 21 CFR 211.84(a) 7 Components withheld from use pending release Each lot of [components] [drug product containers] [closures] is not withheld  from use until the lot has been sampled, tested, examined, and released by the quality control unit.  Specifically, ***
2044 21 CFR 211.196 7 Distribution Record Requirements Distribution records do not contain the [name and strength of the drug product] [description of dosage form] [name and address of consignee] [date and quantity shipped] [lot or control number of drug product].  Specifically, ***
3613 21 CFR 211.160(b)(4) 7 Establishment of calibration procedures Procedures describing the calibration of instruments, apparatus, gauges and recording devices are [not written or followed] [deficiently written or followed].  Specifically, ***
4315 21 CFR 211.84(d)(2) 7 Testing Each Component for Conformity with Specs Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.  Specifically, ***
4357 21 CFR 211.166(a) 7 Results not used for expiration dates, storage cond. Results of stability testing are not used in determining [appropriate storage conditions] [expiration dates].  Specifically, ***
4371 21 CFR 211.188(b)(9) 7 Description of containers and closures Batch production and control records do not include a description of drug product [containers] [closures] used for each batch of drug product produced.  Specifically, ***
6730 21 CFR 314.80(b) 7 Failure to develop written procedures Written procedures have not been developed for the [surveillance] [receipt] [evaluation] [reporting to FDA] of post marketing adverse drug experiences. Specifically, ***
1434 21 CFR 211.42(c)(10)(iv) 6 Environmental Monitoring System Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.  Specifically, ***
1728 21 CFR 211.87 6 Retest of approved components/containers/closures Approved [components] [drug product containers] [closures] are not retested or reexamined as appropriate for identity, strength, quality and purity after [storage for long periods] [exposure to conditions that might have an adverse effect]  with subsequent approval or rejection by the quality control unit.  Specifically, *** 
1917 21 CFR 211.166(a)(1) 6 Sample size - test intervals The written stability program for drug products does not include [sample size] [test intervals] based on statistical criteria for each attribute examined to assure valid estimates of stability.  Specifically, ***
2569 21 CFR 211.198(b) 6 Maintenance of Complaint File Complaint procedures are deficient in that written complaint records are not maintained in a file designated for drug product complaints.  Specifically, ***
4338 21 CFR 211.150(b) 6 Recall facilitation A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary, has not been established.  Specifically, ***
4350 21 CFR 211.160(b)(3) 6 Drug products-sampling procedures/specifications Laboratory controls do not include a determination of conformance to [written descriptions of sampling procedures] [appropriate specifications] for drug products.  Specifically, ***
4355 21 CFR 211.165(c) 6 Sampling and testing plans not followed Written procedures for sampling and testing plans are not followed for each drug product.  Specifically, ***  
4373 21 CFR 211.188(b)(7) 6 Actual yield, % of theoretical yield The batch production and control records do not include a statement of the [actual yield] [percentage of theoretical yield] at appropriate stages of processing for each batch of drug product produced.  Specifically, ***
4400 21 CFR 211.186(b)(8) 6 Description of containers, labels, et. al. Master production and control records lack [a description of the drug product containers, closures and packaging materials] [a specimen or copy of each label and all other labeling] [the signatures and dates entered by the person or persons responsible for the approval of labeling].  Specifically, ***
4404 21 CFR 211.194(a)(1) 6 Sample identification and other information Laboratory records do not include [a description of the sample received for testing] [the source or location from where the sample was obtained] [the quantity of the sample] [the lot number or other distinctive code of the sample] [the date the sample was taken] [the date the sample was received for testing].  Specifically, *** 
8907 21 CFR 314.81(b)(1)(ii) 6 Contamination, chemical or physical change, deterioration An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning [bacteriological contamination] [significant chemical, physical, or other change or deterioration] in a distributed drug product.   Specifically, ***
8911 21 CFR 314.81(b)(1)(ii) 6 Failure to meet specifications An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application.   Specifically, ***
8912 21 CFR 314.81(b)(2) 6 Timely submission An annual report was not submitted [each year] [within 60 days of the anniversary date of U.S. approval of the application] to the FDA division responsible for reviewing the application.   Specifically, ***
1134 21 CFR 211.25(b) 5 Supervisor Training/Education/Experience Individuals responsible for supervising the [manufacture] [processing] [packing] [holding] of a drug product lack the  [education] [training] [experience] to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it purports or is represented to possess.  Specifically, ***
1388 21 CFR 211.101(d) 5 Component addition checked by 2nd person Each component is not added to a batch by one person and verified by a second person.  Specifically, ***
1632 21 CFR 211.130(c) 5 Lot or control number assigned The drug product is not identified with a lot or control number that permits the determination of the history of the manufacture and control of the batch.  Specifically, ***
1722 21 CFR 211.134(a) 5 Correct labels during finishing operations Packaged and labeled products are not examined during finishing operations to provide assurance that containers and packages in the lot have the correct label.  Specifically, ***
1724 21 CFR 211.134(b) 5 Representative samples after completion Samples of representative units were not [collected] [visually examined] for correct labeling at the completion of finishing operations.  Specifically, ***
1791 21 CFR 211.80(c) 5 Storage off Floor, Spaced Suitably Bagged or boxed components of drug product [containers] [closures] are not [stored off the floor] [suitably spaced to allow cleaning and inspection].  Specifically, ***
1933 21 CFR 211.167(a) 5 Sterility/pyrogens - test methods written, followed Test procedures relative to appropriate laboratory testing for [sterility] [pyrogens] are not [written] [followed].  Specifically, ******
1978 21 CFR 211.182 5 Personnel  dating/signing equipment log The persons [performing] [double-checking] the cleaning and maintenance are not [dating] [signing or initialing] the equipment cleaning and use log.  Specifically, ***
2399 21 CFR 211.194(a)(2) 5 Laboratory Test Method Verification Verification of the suitability of the testing methods is deficient in that they are not [performed under actual conditions of use] [documented on the laboratory records].  Specifically, ***
2567 21 CFR 211.198(a) 5 Adverse Drug Experience Complaint procedures are deficient in that they do not include provisions that allow for the review to determine if the complaints represent [serious] [unexpected adverse drug experiences] which are required to be reported to FDA. Specifically, ***
2621 21 CFR 211.198(b)(3) 5 Reason for Not Conducting Complaint Investigation Complaint records are deficient in that they do not document the reason and the individual  making the decision not to conduct a complaint investigation.  Specifically, ***
3557 21 CFR 211.52 5 Washing and toilet facilities are deficient Washing and toilet facilities lack [hot and cold water] [soap or detergent] [air driers or single-service towels] [cleanliness].  Specifically, ***
3569 21 CFR 211.89 5 Quarantine of Rejected Components et. al. Rejected [components] [drug product containers] [closures] are not controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.  Specifically, ***
3592 21 CFR 211.110(c) 5 In-process materials characteristics testing In-process materials are not tested for [identity] [strength] [quality] [purity] and approved or rejected by the quality control unit [during the production process] [after storage for long periods]. Specifically, ***
4307 21 CFR 211.80(d) 5 Status of Each Lot Identified Each lot of [components] [drug product containers] [closures] was not appropriately identified as to its status in terms of being quarantined, approved or rejected.  Specifically, ***
4325 21 CFR 211.110(a) 5 Control procedures fail to include the following Control procedures fail to include [tablet or capsule weight variation] [disintegration time] [adequacy of mixing to assure uniformity and homogeneity] [dissolution time and rate] [clarity, completeness or pH of solutions].  Specifically,***
4370 21 CFR 211.188(b)(10) 5 Records of any sampling performed Batch production and control records do not include a record of any sampling performed, for each batch of drug product produced.  Specifically, ***
4387 21 CFR 211.198(a) 5 Reporting of adverse drug experience to FDA Written procedures describing the handling of all written and oral complaints do not include provisions for review to determine whether the complaint represents a serious and unexpected adverse drug experience which is required to be reported to the Food and Drug Administration.  Specifically, ***
4388 21 CFR 211.198(a) 5 Complaints reviewed by Quality Control Unit Written procedures describing the handling of complaints do not include provisions for [review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications] [a determination as to the need for an investigation of any unexplained discrepancy] [explaining the reasons for the failure of the batch or any of its components to meet specifications].  Specifically, ***
4406 21 CFR 211.194(a)(2) 5 Suitability of testing methods verified The suitability of all testing methods is not verified under actual conditions of use.  Specifically, ***
6823 21 CFR 314.80(c) 5 Failure by applicant to report ADE Adverse drug experience information has not been reported to FDA.  Specifically, ***
6832 21 CFR 314.80(c)(2) 5 Late submission of annual safety reports Not all annual periodic adverse drug experience reports have been submitted within 60 days of the anniversary date of the approval of the application.  Specifically, ***
1049 21 CFR 211.22(a) 4 Approve or reject components, products  The quality control unit lacks the responsibility and authority to [approve] [reject] all [components] [drug product containers] [closures] [in process materials] [packaging material] [labeling] [drug products].  Specifically, ***
1079 21 CFR 211.22(a) 4 Contract drug products--lack of responsibility The quality control unit lacks responsibility for approving or rejecting drug products [manufactured] [processed] [packed] [held] under contract by another company.  Specifically, ***
1086 21 CFR 211.22(b) 4 Adequate lab facilities not available  Adequate lab facilities for testing and approval or rejection of [components] [drug product containers] [closures] [packaging materials] [in-process materials] [drug products] are not available to the quality control unit.  Specifically, ***
1098 21 CFR 211.22(c) 4 Approve or reject procedures or specs The quality control unit lacks responsibility to [approve] [reject] all procedures or specifications impacting on the [identity] [strength] [quality] [purity] of drug products.  Specifically, ***
1136 21 CFR 211.25(c) 4 Inadequate number of  personnel The number of qualified  personnel is inadequate to [perform] [supervise] the [manufacture] [processing] [packing] [holding] of each drug product. Specifically, ***
1220 21 CFR 211.67(b)(3) 4 Cleaning SOPs/instructions Procedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper cleaning and maintenance.  Specifically, ***
1263 21 CFR 211.68(b) 4 Computer control of master formula records Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.  Specifically, ***
1384 21 CFR 211.101(c) 4 Weighing/measuring/subdividing operations Component [weighing] [measuring] [subdividing] operations are not adequately supervised.  Specifically, ***
1411 21 CFR 211.105(b) 4 Distinctive ID or code not recorded in batch record The batch records do not record the distinctive [identification number] [code] [name of equipment]  to identify major equipment to show the specific equipment used in the manufacture of a batch of a drug product.  Specifically, ***
1844 21 CFR 211.84(d)(2) 4 Establish reliability of supplier's C of A Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.  Specifically, ***
1876 21 CFR 211.180(a), (b) 4 Record maintenance 1 year (except exempt OTC) All records of  [production] [control] [distribution] [components] [drug product containers] [closures] [labeling] associated with a batch of drug product are not maintained at least one (1) year after the expiration date.  Specifically, ***
1938 21 CFR 211.167(c) 4 Controlled release dosage form testing Each batch  of controlled-release dosage form drug product is not laboratory tested to determine conformance to the specifications for the rate of release for each active ingredient.  Specifically, ***
1976 21 CFR 211.182 4 Specific information required in individual logs Individual equipment logs do not show [time] [date] [product] [lot number of each batch processed].  Specifically, ***
1979 21 CFR 211.182 4 Chronological Order of Equipment Log Entries The entries in the equipment cleaning and use logs are not in chronological order.  Specifically, ***
2618 21 CFR 211.198(b)(1) 4 Complaint Record required information Complaint records are deficient in that they do not include the known [name and strength of the drug product] [lot number] [name of complainant] [nature of complaint] [reply to complainant].  Specifically, ***
3548 21 CFR 211.46(c) 4 Air filtration system lacking in production area The production area air supply lacks an appropriate air filtration system.  Specifically, ***
3562 21 CFR 211.56(c) 4 Written procedures lacking for use of pesticides etc. Written procedures are lacking for the use of  [rodenticides] [insecticides] [fungicides] [fumigating agents] [cleaning and sanitizing agents] designed to prevent the contamination of [equipment] [components] [drug product containers] [closures] [packaging, labeling materials] [drug products].  Specifically, ***
3591 21 CFR 211.110(b) 4 In-process materials specifications In-process specifications are not [consistent with drug product final specifications] [derived from previous acceptable process average and process variability estimates where possible] [determined by the application of suitable statistical procedures where appropriate].  Specifically, ***
3594 21 CFR 211.110(d) 4 Rejected in-process materials not quarantined Rejected in-process materials are not [identified] [controlled under a quarantine system] to prevent their use in manufacturing or processing operations for which they are unsuitable.  Specifically, ***
3629 21 CFR 211.170(b) 4 Reserve samples identified, representative, stored Reserve drug product samples  are not [appropriately identified] [representative of each lot or batch of drug product] [retained and stored under conditions consistent with product labeling].  Specifically, ***
4317 21 CFR 211.84(d)(3) 4 Certificates of Testing (Containers, Closures) Certificates of testing of [containers] [closures] are accepted in lieu of testing without [a visual identification] [establishing the reliability of the supplier's test results through appropriate validation of the test results at appropriate intervals].  Specifically, ***
4320 21 CFR 211.84(d)(6) 4 Microbiological Contamination Exam Each lot of a [component] [drug product container] [closure] that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use.  Specifically, ***
4323 21 CFR 211.115(a) 4 Reprocessing procedures lack steps to be taken Reprocessing procedures lack the steps to be taken to insure that reprocessed batches will conform with all established standards, specifications, and characteristics.  Specifically, ***
4324 21 CFR 211.110(b) 4 In-process materials specifications testing Examination and testing of samples is not done to assure that in-process materials conform to specifications.  Specifically, ***
4351 21 CFR 211.160(b)(3) 4 Drug products - samples representative, identified properly Samples taken of drug products for determination of conformance to written specifications are not [representative] [properly identified].  Specifically, ***
4366 21 CFR 211.188(a) 4 Accurate reproduction included Batch production and control records for each batch of drug product produced do not include an accurate reproduction of the appropriate master production or control record which was  checked for accuracy, dated and signed.  Specifically, ***
4380 21 CFR 211.198(b)(3) 4 Determination not to conduct investigation of complaint The written record did not include the [reason an investigation was found not to be necessary] [name of the responsible person making the determination not to conduct an investigation] when an investigation into [unexplained discrepancies] [the failure of a batch or any of its components to meet specifications] was not conducted.  Specifically, *** 
4410 21 CFR 211.194(a)(5) 4 Calculations performed are in the records Laboratory records do not include a record of all calculations performed in connection with the test.  Specifically, *** 
6831 21 CFR 314.80(c)(2) 4 Late submission of quarterly safety reports Not all quarterly periodic adverse drug experience reports have been submitted within 30 days of the close of the quarter.  Specifically, ***
10021 21 CFR 314.98(a) 4 (Flag to indicate ANDA applicant) (DO NOT PRINT ON FDA 483.  This cite is to be used as a flag to indicate that the recipient of an FDA 483 involving ADE reporting is the applicant for one or more approved ANDAs, as opposed to approved NDAs.  No specifics text is required for this cite.)
1163 21 CFR 211.28(b) 3 Habits of good sanitation & health  Production personnel were not practicing good sanitation and health habits.  Specifically, ***
1174 21 CFR 211.42(b) 3 Product flow through building is inadequate The flow  of [components] [drug product containers] [closures] [labeling] [in-process materials ] [drug products] though the building is not designed to prevent contamination.  Specifically, ***
1371 21 CFR 211.101(a) 3 Batches Formulated to less than 100% Written production and control procedures  include batches formulated with the intent to provide less than  100 percent of the labeled or established amount of active ingredient.  Specifically, ***
1393 21 CFR 211.103 3 Yield calculations not verified by 2nd person Yield calculations are not performed by one person and independently verified by a second person.  Specifically, ***
1435 21 CFR 211.42(c)(10)(v) 3 Cleaning System Aseptic processing areas are deficient regarding the system for cleaning  and disinfecting the [room] [equipment] to produce aseptic conditions.  Specifically, ***
1436 21 CFR 211.42(c)(10)(vi) 3 Equipment to control conditions Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.  Specifically, ***
1449 21 CFR 211.111 3 Deviations of production time limits Deviations from production time limits [are not justified] [are not documented] [compromise the quality of the drug product].  Specifically, ***
1496 21 CFR 211.122(a) 3 Sampling/testing of labeling/packaging materials Labeling and packaging materials are not  [representatively sampled] [examined] [tested] upon receipt and before use in packaging and labeling of a drug product.  Specifically, ***
1503 21 CFR 211.122(c) 3 Records not kept for each shipment Records are not maintained for each shipment received of each different labeling and packaging material.  Specifically, ***
1505 21 CFR 211.122(d) 3 Label storage access limited to authorized personnel Access to the storage area for labels and labeling materials is not limited to authorized personnel.  Specifically, ***
1546 21 CFR 211.125(d) 3 Destruction of excess labels with lot numbers Excess labeling bearing lot or control numbers is not destroyed.  Specifically, ***
1630 21 CFR 211.130(b) 3 Unlabeled filled containers controls Filled drug product containers which are set aside and held in an unlabeled condition are not [identified] [handled] to preclude mislabeling of individual containers, lots or portions of lots.  Specifically, ***
1798 21 CFR 211.82(b) 3 Quarantine Storage of Components Incoming [components] [drug product containers] [closures] are not stored under quarantine until they have been tested or examined, as appropriate, and released.  Specifically, ***
1802 21 CFR 211.84(b) 3 Representative Samples Representative samples are not taken of each shipment of each lot of [components] [drug product containers] [closures] for testing or examination.  Specifically, ***
1870 21 CFR 211.94(d) 3 Written Procedures to Remove Pyrogens There are no written [standards or specifications] [methods of testing] [methods of cleaning] [methods of sterilization] [methods of processing] to remove pyrogenic properties.  Specifically, ***
1922 21 CFR 211.166(a)(4) 3 Testing in same container - closure system The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.  Specifically, *** 
1928 21 CFR 211.166(c)(1) 3 Homeopathic drugs, assessment of stability There is no written assessment of stability of homeopathic drug products based at least on [testing or examination of the drug product for compatibility of the ingredients] [marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use].  Specifically, ***
1939 21 CFR 211.167(c) 3 Controlled release test methods written, followed Test procedures describing the testing of controlled release dosage form drug product are not [written] [followed].  Specifically, ***
2004 21 CFR 211.184(d) 3 Labeling: documentation of exam and review There is no documentation of the examination and review of labels and labeling for conformity with [established specifications] [the assigning of a lot or control number].  Specifically, ***
2203 21 CFR 211.186(b)(7) 3 Theoretical Yield and Percentages The master production and control records are deficient in that they do not include a statement of theoretical yield and [minimum] [maximum] [yield percentages].  Specifically, ***
2397 21 CFR 211.194(a)(1) 3 Description and Identification of Samples Laboratory records are deficient in that they do not include a [description and identification of the sample received] [quantity] [lot number] [date sample taken] [date sample received for testing].  Specifically, ***
3556 21 CFR 211.50 3 Sewage and refuse disposal in safe manner Disposal of  [sewage] [trash] [refuse] from the [building] [immediate premises] is not done  in a safe and sanitary manner.  Specifically, ***
3581 21 CFR 211.101(d) 3 Verification of component addition Each component is not added to the batch by one person and verified by a second person..  Specifically, ***
3623 21 CFR 211.170(a) 3 Active ingredient retained sample kept A sample which is representative of each lot in each shipment of each active ingredient is not [appropriately identified] [retained].   Specifically, ***
3639 21 CFR 211.204 3 Returned drug procedures in writing and followed Procedures describing the [holding] [testing] [reprocessing] of returned drug products are not [in writing] [followed].  Specifically, ***
3640 21 CFR 211.204 3 Returned drug products identified and held Returned drug products are not [identified as such] [held].  Specifically, ***
4304 21 CFR 211.68(b) 3 Written record not kept of program and validation data A written record of the program along with appropriate validation data has not been maintained in situations where backup data is eliminated by computerization or other automated processes.  Specifically, ***
4321 21 CFR 211.101(b) 3 Identification of new containers For components removed from the original containers, the new container fails to be identified with [component name or item code] [receiving or control number] [weight or measure] [batch for which component was dispensed including product name, strength and lot number].  Specifically, ***
4328 21 CFR 211.122(a) 3 Written procedures not followed Written procedures for the [receipt] [identification] [storage] [handling] [sampling] [examination] [testing] of packaging and labeling materials are not followed.  Specifically, ***
4330 21 CFR 211.130(e) 3 Packaging line inspection documentation Results of inspection of packaging and labeling facilities are not documented in the batch production records.  Specifically, ***
4353 21 CFR 211.160(b)(4) 3 Instruments, apparatus, et. al. not meeting specs The use of [instruments] [apparatus] [gauges] [recording devices] not meeting established specifications was observed.   Specifically, ***
4354 21 CFR 211.165(d) 3 Acceptance/Rejection Levels The statistical quality control criteria fail to include appropriate [acceptance levels] [rejection levels].  Specifically, ***
4367 21 CFR 211.188(b)(13) 3 Examinations for correct labeling Batch production and control records do not include results of examinations made of packaged and labeled products for correct labeling.  Specifically, ***
4374 21 CFR 211.188(b)(6) 3 Inspection of packaging and labeling area Batch production and control records do not include results of the inspection of the packaging and labeling area [before] [after] use for each batch of drug product produced.  Specifically, ***
4375 21 CFR 211.188(b)(5) 3 In-process and laboratory control results  Batch production and control records do not include [in-process] [laboratory control] results for each batch of drug product produced.  Specifically, ***
4376 21 CFR 211.188(b)(4) 3 Weights and measures of components used Batch production and control records do not include the weights and measures of components used in the course of processing each batch of drug product produced.  Specifically, ***
4377 21 CFR 211.188(b(3) 3 Identification of each  component or in-process material Batch production and control records do not include the specific identification of each batch of [component] [in-process material] used for each batch of drug product produced.  Specifically, ***
4379 21 CFR 211.188(b)(1) 3 Dates not included for each significant step Batch production and control records do not include dates of each significant step in the [manufacture] [processing] [packing] [holding] of the batch for each batch of drug product produced.  Specifically, ***
4399 21 CFR 211.186(b)(7) 3 Theoretical yield statement including percentages Master production and control records lack a statement of theoretical yield [including the maximum and minimum percentages of theoretical yield beyond which investigation is required].  Specifically, ***
4407 21 CFR 211.194(a)(2) 3 Reference and method not stated Laboratory records of methods of testing used do not [indicate the method] [provide the reference] when employing methods in [recognized standard references] [an approved new drug application and the referenced method is not modified].  Specifically, ***
4418 21 CFR 211.42(b) 3 Adequate space lacking  to prevent mix-ups and contamination The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between [different components] [drug product containers] [closures] [labeling] [in-process materials] [drug products] and to prevent contamination.  Specifically, *** 
6829 21 CFR 314.80(c)(2) 3 Failure to report non-alert ADEs Individual ADEs which were not reported to FDA in a post marketing 15-day alert have not been included in a periodic safety report.  Specifically, ***
1159 21 CFR 211.28(a) 2 Clothing appropriate for duties performed Clothing of personnel engaged in the [manufacturing] [processing] [packing] [holding] of drug products is not  appropriate for the duties they perform.  Specifically, ***
1164 21 CFR 211.28(c) 2 Unauthorized Personnel in Limited Access Areas Unauthorized personnel have access to enter areas of the buildings and facilities designated as limited access areas.  Specifically, ***
1168 21 CFR 211.34 2 Consultant Records Records are not maintained stating the consultant's [name] [address] [qualifications] [type of service provided].  Specifically, ***
1224 21 CFR 211.67(b)(6) 2 Cleaning SOP/inspection Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.  Specifically, ***
1413 21 CFR 211.42(c)(5) 2 Mfg / Processing Operations Area Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.  Specifically, ***
1433 21 CFR 211.42(c)(10)(iii) 2 Air Supply Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.  Specifically, ***
1506 21 CFR 211.122(e) 2 Destruction of obsolete labeling Obsolete or outdated labels, labeling and packaging materials are not destroyed.  Specifically, ***
1541 21 CFR 211.125(b) 2 Examination of issued labels Labeling materials issued for a batch were not carefully examined for identity and conformity to the labeling specified in the master or batch production records.  Specifically, ***
1636 21 CFR 211.130(e) 2 Packaging line inspection before use Inspection of the [packaging] [labeling] facilities immediately before use is not done to assure that all drug products have been removed from previous operations.  Specifically, ***
1777 21 CFR 211.150(b) 2 Distribution Recall System The distribution system is deficient in that each lot of drug product cannot be readily determined to facilitate its recall if necessary.  Specifically,  ***
1794 21 CFR 211.80(d) 2 Disposition recorded by lot identification The distinctive code for each lot of [components] [drug product containers] [closures] is not used in recording the disposition of each lot.  Specifically, ***
1842 21 CFR 211.84(d)(1) 2 Component identity verification Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.  Specifically,***
1879 21 CFR 211.180(c) 2 Records not made readily available to FDA Records associated with drug product [components] [containers] [closures] [labeling] [production] [control] [distribution] and within the retention period for such records, were not made readily available for authorized inspection.  Specifically, ***
1958 21 CFR 211.180(f) 2 Responsible firm officials notified in writing Procedures are not established which are designed to assure that the responsible officials of the firm, if they are not personally involved in or immediately aware of such actions,  are notified in writing of [investigations conducted] [recalls] [reports of inspectional observations issued by FDA] [any regulatory actions brought by FDA relating to good manufacturing practices].  Specifically, ***
2005 21 CFR 211.184(e) 2 Records of disposition of rejected material Records do not include the disposition of rejected [components] [drug product containers] [closures] [labeling].  Specifically, ***
2024 21 CFR 211.188(b)(12) 2 Documentation of Batch Investigations The batch production and control records are deficient in that they do not  include documentation of batch investigations performed.  Specifically, ***
2198 21 CFR 211.186(b)(3) 2 Component Name and Code The master production and control records are deficient in that they do not include a complete list of components designated by [name] [code] sufficiently specific to indicate any special characteristic.  Specifically, ***
2404 21 CFR 211.194(a)(6) 2 Comparison of Test Results to Specifications Laboratory records are deficient in that they do not include a statement of the results of tests and how they compare to the established [specifications] [standards].  Specifically, ***
2406 21 CFR 211.194(a)(8) 2 Identification of Person Performing Review of Lab Records Laboratory records are deficient in that they do not include the [initials] [signature] of the second person reviewing the record for accuracy.  Specifically, ***
3445 21 CFR 211.65(a) 2 Equipment construction - reactive surfaces Equipment surfaces that contact [components] [in-process materials] [drug products] are reactive, additive or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.  Specifically, ***
3545 21 CFR 211.44 2 Adequate lighting not provided Adequate lighting is not provided in all  areas.  Specifically, ***
3553 21 CFR 211.48(a) 2 Plumbing System Defects The plumbing system contains defects that could contribute to the  contamination of drug products.  Specifically, ***
3555 21 CFR 211.48(b) 2 Drains--Size, Back-siphonage Prevention Drains are not [of adequate size] [provided with an air break or other mechanical device to prevent back-siphonage where connected directly with a sewer].  Specifically, ***
3558 21 CFR 211.52 2 Washing and toilet facilities not provided and accessible Washing and toilet facilities are not [provided] [easily accessible to working areas].  Specifically, ***
3606 21 CFR 211.160(b)(1) 2 Retesting The specifications for [components] [drug product containers] [closure] are deficient in that they do not include appropriate retesting requirements.  Specifically, ***
3611 21 CFR 211.160(b)(3) 2 Acceptance of drug products Determinations of conformance to appropriate written specifications for acceptance are [not made] [deficient] for drug products.  Specifically, ***
3631 21 CFR 211.170(b) 2 Investigation of reserve sample deterioration Evidence of reserve drug product sample deterioration was not  [investigated] [recorded and maintained with other stability data].  Specifically, ***
4302 21 CFR 211.56(b) 2 Written sanitation procedures not followed Written procedures for sanitation are not followed.  Specifically, ***
4329 21 CFR 211.122(b) 2 Rejection of unapproved labeling/packaging materials Labeling or packaging materials which did not meet written specifications were not rejected to prevent their use in operations for which they are unsuitable.  Specifically, ***
4343 21 CFR 211.160(b)(1) 2 Incoming lots - conformance to written specs- Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of [components] [drug product containers] [closures] [in-process materials] [labeling] [drug products] used in the manufacture, processing, packing, or holding of drug products.  Specifically, ***
4345 21 CFR 211.160(b)(1) 2 Samples (various types) representative, identified properly Samples taken to determine conformance to appropriate written specifications for the acceptance of each lot within each shipment of [components] [drug product containers] [closures] [labeling] are not [representative] [adequately identified].  Specifically, ***
4383 21 CFR 211.198(b)(1) 2 Written complaint record must include Written complaint records do not include, where known, [the name and strength of the drug product] [lot number] [name of complainant] [nature of complaint] [reply to complainant].  Specifically, ***
4392 21 CFR 211.186(b)(1) 2 Name, strength, dosage form  The master production and control records do not include [the name and strength of the product] [a description of the dosage form].  Specifically, ***
4395 21 CFR 211.186(b)(4) 2 Weight or measure of each component The master production and control records lack an accurate statement of the [weight]  [measure] of each component [using the same weight system for each component]. Specifically, ***
4405 21 CFR 211.194(a)(2) 2 Statement of methods and data Laboratory records do not include a statement of [each method used in the testing of a sample] [the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested].  Specifically, *** 
4409 21 CFR 211.194(a)(4) 2 Data secured in course of each test Laboratory records do not include a complete record of all data secured in the course of each test, including all [graphs] [charts] [spectra] from laboratory instrumentation, properly identified to show the [specific component] [drug product container] [closure] [in-process material] [lot tested] [drug product tested].  Specifically, ***
4411 21 CFR 211.194(a)(6) 2 Test results, comparison with standards not included Laboratory records do not include a statement of the results of tests and how the results compare with established standards of identity, strength, quality, and purity for the [component] [drug product container] [closure] [in-process material] [drug product] tested.  Specifically, ***
4412 21 CFR 211.194(a)(7) 2 Signatures and dates--person who performs test Laboratory records do not include [the initials or signature of the person who performs each test] [the date(s) the tests were performed].  Specifically, ***
6735 21 CFR 314.80(c)(1)(ii) 2 Failure to investigate serious, unexpected events Adverse drug experiences that were the subject of post marketing 15-day reports were not [promptly] investigated.  Specifically, ***
6830 21 CFR 314.80(c)(2) 2 Interval Periodic reports of non-alert adverse drug experiences have not been submitted [quarterly for an application which was approved less than three years ago] [yearly for an application which was approved three or more years ago].  Specifically, ***
6833 21 CFR 314.80(c)(2)(ii) 2 Incomplete periodic safety report Not all periodic reports contained [a narrative summary and analysis of the information in the report] [an analysis of the post marketing 15-day Alert reports submitted during the reporting interval] [an FDA Form 3500A for each adverse drug experience not reported as a post marketing 15-day Alert report] [an index containing a line listing of your patient identification number and adverse reaction term(s)] [a history of actions taken since the last report because of adverse drug experiences].  Specifically, ***
1219 21 CFR 211.67(b)(2) 1 Cleaning SOPs/schedules Procedures for the cleaning and maintenance of equipment are deficient regarding maintenance and cleaning schedules, including, where appropriate, sanitizing schedules.  Specifically, ***
1251 21 CFR 211.42(c)(1) 1 Incoming material area Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the receipt, identification, storage, and withholding from use of [components] [drug product containers] [closures] [labeling] pending sampling, testing, or examination by the quality control unit before release for manufacturing or packaging.  Specifically, ***
1266 21 CFR 211.42(d) 1 Penicillin processing area not  kept separate The operations relating to the [manufacture] [processing] [packing] of penicillin are not performed in facilities separate from those used for other drug products for human use.  Specifically,  ***
1398 21 CFR 211.42(c)(3) 1 Released Material Area Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the storage of released [components] [drug product containers] [closures] [labeling].  Specifically, ***
1498 21 CFR 211.122(b) 1 Labeling and packaging improperly approved/released Labeling and packaging materials not meeting the appropriate written specifications were [approved] [released for use].  Specifically, *** 
1504 21 CFR 211.122(d) 1 Labels and labeling stored  separately  Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.  Specifically, ***
1509 21 CFR 211.122(h) 1 Printing devices Printing devices used to imprint labeling upon the drug product [unit label] [case] are  not monitored to assure that all imprinting conforms to the print specified in the batch production record. Specifically, ***
1549 21 CFR 211.125(e) 1 Return of  labeling Returned labeling is not maintained and stored in a manner to [prevent mix-ups] [provide proper identification].  Specifically, ***
1637 21 CFR 211.130(e) 1 Packaging line inspection after use Inspection of the [packaging] [labeling] facilities is not done after use to assure that materials not suitable for subsequent operations have been removed.  Specifically, ***
1768 21 CFR 211.137(b) 1 Storage conditions Drug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies.  Specifically, ***
1770 21 CFR 211.137(d) 1 Expiration date location on labeling Drug product expiration dates do not appear on the labeling in the manner prescribed by regulations..  Specifically, ***
1796 21 CFR 211.80(d) 1 Identification of Each Lot in Each Shipment Each lot in each shipment received was not identified with a distinctive code for each container or grouping of containers for [components] [drug product containers] [closures].  Specifically, *** 
1803 21 CFR 211.84(b) 1 Representative Samples Criteria The [number of containers to be sampled] [amount of material taken from each container] is not based upon appropriate criteria.  Specifically, ***
1843 21 CFR 211.84(d)(2) 1 Component written specification Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.  Specifically,  ***
1845 21 CFR 211.84(d)(3) 1 Container/Closure Written Test Procedure Drug product container and closure test procedures are deficient in that [containers] [closures] are not tested for conformance in accordance with  appropriate written procedures.  Specifically,  ***
1851 21 CFR 211.84(e) 1 Rejecting  When Specifications Not Met Failure to reject any lot of [components] [drug product containers] [closures] that did not meet the appropriate written specifications for identity, strength, quality, and purity.  Specifically, ***
1868 21 CFR 211.94(b) 1 Protection from external factors Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.  Specifically, ***
1869 21 CFR 211.94(c) 1 Containers & Closures Clean, Sterilized, Pyrogen-free Drug product [containers] [closures] were not [clean] [sterilized and processed to remove pyrogenic properties] to assure that they are suitable for their intended use.  Specifically, ***
1932 21 CFR 211.167(a) 1 Sterility/pyrogen-free testing  Each batch of drug product purporting to be [sterile] [pyrogen-free] is not laboratory tested to determine conformance to such requirements.  Specifically, ***
1936 21 CFR 211.167(b) 1 Ophthalmic ointments -test methods written, followed Test procedures for ophthalmic ointments are not [written] [followed].  Specifically, ***
1956 21 CFR 211.180(e)(1) 1 Representative Number of Batches for Annual Review The procedures for the annual quality standards record evaluation are deficient in that they do not address a review of a representative number of  [approved] [rejected] batches.  Specifically, ***
1957 21 CFR 211.180(e)(2) 1 Review of problem drugs The procedures for the annual quality standards record evaluation are deficient in that they do not  address a review of [complaint] [recall] [returned drug product] [salvaged drug product] [investigation] records for each drug product.  Specifically, ***
1977 21 CFR 211.182 1 Dedicated equipment: records part of batch record The records of [cleaning] [maintenance] [use] for dedicated equipment are not part of the batch record.  Specifically, ***
2001 21 CFR 211.184(b) 1 Component Test Records The [component] [drug product container] [closure] [labeling] records do not include the [results of tests or examinations performed] [the conclusions derived from tests or examinations performed].  Specifically, ***
2012 21 CFR 211.188(b) 1 Batch production and Batch Control Record Requirements The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in [manufacturing] [processing] [packing] [holding].  Specifically, ***
2019 21 CFR 211.188(b)(7) 1 Documentation of Actual Yield and Theoretical Yield The batch production and control records are deficient in that they do not  include a statement of the [actual yield] [percentage of theoretical yield].  Specifically, ***
2020 21 CFR 211.188(b)(8) 1 Labeling Control Records and Label Copies The batch production and control records are deficient in that they do not  include [complete labeling control records] [specimen] [copy] of labeling.  Specifically, ***
2022 21 CFR 211.188(b)(10) 1 Documentation of Sampling Performed The batch production and control records are deficient in that they do not include documentation of sampling performed.  Specifically, ***
2023 21 CFR 211.188(b)(11) 1 Identification of Persons Performing Significant Steps The batch production and control records are deficient in that they do not include identification of persons [performing] [supervising] [checking] each significant step in the operation.  Specifically, ***
2025 21 CFR 211.188(b)(13) 1 Results of drug product inspections and examinations The batch production and control records are deficient in that they do not include results of drug product [examinations] [inspections].  Specifically, ***
2035 21 CFR 211.194(e) 1 Stability testing records not  included Laboratory records do not include complete records of all stability testing performed.  Specifically, ***
2089 21 CFR 211.208 1 No records maintained No records are maintained for salvaged drug products.  Specifically, ***
2090 21 CFR 211.208 1 Records for salvaged drug products Records for salvaged drug products do not  include [name] [lot number] [disposition].  Specifically, ***
2196 21 CFR 211.186(b)(1) 1 Product Name and Strength The master production and control records are deficient in that they do not  include the [name] [strength] of the drug product and a description of the dosage form.  Specifically, ***
2197 21 CFR 211.186(b)(2) 1 Active Ingredient Name and Weight The master production and control records are deficient in that they do not include the [name] [weight] of each active ingredient per dosage unit or unit of weight statement of total weight or measure of any dosage unit.  Specifically, ***
2402 21 CFR 211.194(a)(5) 1 Testing Calculations Laboratory records are deficient in that they do not include all calculations performed during testing.  Specifically, ***
2405 21 CFR 211.194(a)(7) 1 Identification of Person Performing the Testing Laboratory records are deficient in that they do not include the [initials] [signature] of the person performing the tests and the dates the tests were performed.  Specifically, ***
2420 21 CFR 211.198(a) 1 Quality Control Review Complaint procedures are deficient in that they do not include provisions that allow for the review and determination of an investigation by the quality control unit.  Specifically, ***
2572 21 CFR 211.198(b) 1 Complaint File Location Complaint procedures are deficient in that written complaint files are not maintained at the manufacturing site nor were they readily available from their off-site location.  Specifically, ***
2587 21 CFR 211.198(b) 1 Retention time of complaints Complaint procedures are deficient in that written complaint records are not maintained for [at least one (1) year after the expiration date of the drug product] [at least one (1) year after the date that the complaint was received].  Specifically, ***
3549 21 CFR 211.46(c) 1 Air recirculation of dust from production areas Air is recirculated to production areas, without adequate measures to control recirculation of dust.  Specifically, ***
3550 21 CFR 211.46(c) 1 Exhaust systems inadequate to control air contamination Adequate exhaust systems or other systems to control contaminants are lacking in areas where air contamination occurs during production.  Specifically, ***
3567 21 CFR 211.84(d)(2) 1 Component identification test Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.  Specifically, ***
3597 21 CFR 211.122(g)(3) 1 Visual inspection The packaging and labeling operation involving cut labels and relying on visual inspection does not provide for [100-percent examination for correct labeling during or after completion of finishing operations for hand-applied labeling] [examination to be performed by one person and independently verified by a second person].  Specifically, ****
3598 21 CFR 211.132(b)(1) 1 OTC products requiring tamper-evident packaging OTC products packaged for retail sale which are not specifically excluded from the requirement for tamper-evident packaging are not sold in tamper-evident packages.  Specifically, ***
3607 21 CFR 211.160(b)(2) 1 Acceptance of in-process materials Determinations of conformance to appropriate written specifications for acceptance are [not made] [deficient] for in-process materials.  Specifically, ***
3614 21 CFR 211.160(b)(4) 1 Written calibration procedures Written calibration procedures for instruments, apparatus, gauges, and recording devices are deficient in that they do not include specific [directions] [schedules] [limits for accuracy and precision] [provisions for remedial action if limits are not met].  Specifically, ***
3625 21 CFR 211.170(a)(1) 1 Retention time for reserve samples of actives Reserve samples of active drug ingredients are deficient in that they are not retained at least one year after the expiration date of the last lot of the drug containing the active drug ingredient.  Specifically, ***
3630 21 CFR 211.170(b) 1 Drug product reserve containers Drug product reserve samples are not stored in [the same immediate container-closure system as the marketed product] [an immediate container-closure system that has essentially the same characteristics as the marketed product].  Specifically, ***
3641 21 CFR 211.204 1 Record information inclusions Records of returned drug products do not include the  [name] [labeled potency] [lot, control or batch number] [reason for return] [quantity] [date of disposition] [ultimate disposition].  Specifically, ***
4305 21 CFR 211.68(b) 1 Backup data not assured as exact and complete Backup data is not assured as [exact] [complete] [secure from alteration, erasure or loss] through keeping hard copy or alternate systems.  Specifically, ***
4313 21 CFR 211.84(c)(6) 1 Containers Marked to Show Samples Taken Containers from which samples have been taken are not marked to show that samples have been taken from them.  Specifically, ***
4316 21 CFR 211.84(d)(3) 1 Testing Containers & Closures Conformity with Specs Containers and closures are not tested for conformance with all appropriate written procedures.  Specifically, ***
4327 21 CFR 211.122(c) 1 Records fail to include Records kept for each different labeling and packaging material shipment fail to include [the receipt] [results of examination or testing] [a statement of whether the shipment was accepted or rejected].  Specifically, ***
4341 21 CFR 211.142(a) 1 Quarantine - written procedures Written procedures for the warehousing of drug products do not include quarantine of drug products before release by the quality control unit.  Specifically, ***
4346 21 CFR 211.160(b)(1) 1 Retesting when subject to deterioration Procedures designed to assure conformance to written specifications do not require appropriate retesting of [components] [drug product containers] [closures] subject to deterioration.  Specifically, ***
4347 21 CFR 211.160(b)(2) 1 In process materials - conformance to written specs Laboratory controls do not include a determination of conformance to written  specifications  for in-process materials.  Specifically, ***
4349 21 CFR 211.160(b)(2) 1 In-process samples representative, identified properly Samples taken of in-process materials for determination of conformance to specifications are not [representative] [properly identified].  Specifically, ***
4360 21 CFR 211.170(b) 1 Reserve drug product sample quantity - all tests The reserve sample of drug product does not consist of at least twice the quantity necessary to perform all the required tests of drug product.  Specifically, ***
4386 21 CFR 211.198(b) 1 Written complaint record  to be maintained at facility A written record of each complaint is not maintained in a file designated for drug product complaints [at the facility where the drug product was manufactured, processed or packed] [at a facility other than the facility in which the drug product was manufactured, processed or packed provided the written records are readily available for inspection at that other facility].  Specifically, *** 
4390 21 CFR 211.180c) 1 Photocopying of records not allowed Records or copies of records were not made  available for photocopying or other means of reproduction.  Specifically, *** 
4397 21 CFR 211.186(b)(5) 1 Calculated excess The master production and control records lack a statement concerning a calculated excess of component.  Specifically, ***
4403 21 CFR 211.194(b) 1 Test method modification records do not  include Records maintained of any modification of an established method employed in testing do not include [the reason for the modification] [the data to verify that the modification produced results that are at least as accurate and reliable for the material being tested as the established method].  Specifically, ***
4408 21 CFR 211.194(a)(3) 1 Weight or measure of sample Laboratory records do not include a statement of the weight or measure of sample used for each test, where appropriate.  Specifically, ***
4414 21 CFR 211.204 1 Record information maintained Records of returned drug products are not maintained.  Specifically, ***
4415 21 CFR 211.204 1 Returned drug products with doubt cast as to safety et. al. Returned drug products held, stored or shipped before or during their return under conditions which cast doubt on their safety, identity, strength, quality or purity are not [destroyed] [subjected to examination, testing or other investigation to prove the drug products do meet all the necessary parameters].  Specifically, ***
4416 21 CFR 211.204 1 Reprocessed returned drug products Returned drug products were reprocessed without assuring that the subsequent drug product met the appropriate standards of safety, identity, strength, quality and purity.  Specifically, ***
6728 21 CFR 314.80(b) 1 Failure to review ADE information Adverse drug experience information obtained or otherwise received from any source was not [promptly] reviewed, including information from [commercial marketing experience] [post marketing clinical investigations] [post marketing epidemiological/surveillance activities] [reports in the scientific literature] [unpublished scientific papers].  Specifically, ***
6731 21 CFR 314.80(c) 1 (NDA product) Failure to submit report to correct office Two copies of each report of an adverse drug experience have not been submitted to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Road, Beltsville, MD 20705-1266.  Specifically, ***
6736 21 CFR 314.80(c)(1)(ii) 1 Submission of report follow-up Follow-up reports were not submitted [within 15 calendar days of receipt of new information] [as requested by FDA] concerning post marketing 15-day reports.  Specifically, ***
6835 21 CFR 314.80(d)(1) 1 Failure to submit scientific article Not all post marketing 15-day Alert reports based upon scientific literature were accompanied by a copy of the published article.  Specifically, ***
6840 21 CFR 314.80(f)(1) 1 Wrong form - domestic ADE An FDA Form 3500A has not been completed for each report of a domestic adverse drug experience.  Specifically, ***
6844 21 CFR 314.98(b) 1 (ANDA product) Failure to submit report to correct office One copy of [each post marketing alert report] [each periodic report of adverse drug experiences] has not been submitted to the Division of Epidemiology and Surveillance (HFD-730), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.  Specifically, ***
8906 21 CFR 314.81(b)(1)(i) 1 Mix-up An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning an incident that caused a drug product or its labeling to be [mistaken for] [applied to] another article.   Specifically, ***
8910 21 CFR 314.81(b)(2)(iii) 1 Labeling information An annual report did not include [currently used professional labeling] [patient brochures or package inserts] [a representative sample of the package labels] [a summary of any changes in labeling that have been made since the last report, listed by date in the order in which they were implemented, or if no changes, a statement of that fact].   Specifically, ***
8919 21 CFR 314.81(b)(2)(vii) 1 Post marketing study status not included An annual report did not include the status of each post marketing study concerning [clinical safety] [clinical efficacy] [clinical pharmacology] [non-clinical toxicology] required by FDA or to which the applicant has committed in writing to conduct.  Specifically, ***
8922 21 CFR 314.81(b)(2)(viii) 1 Post marketing study status report for other studies An annual report did not include a status report for all post marketing studies being performed by, or on behalf of, the applicant and not covered by the requirements of 21 CFR 314.81(b)(2)(vii).  Specifically, ***
8938 FDCA 760(c)(1) 1 Timing of AE report submission (non-RX drugs) An adverse event report for a nonprescription drug was not submitted to the Secretary of HHS within 15 business days of receipt of the report. 
10022 21 CFR 310.305(a) 1 Failure to develop written procedures Written procedures have not been developed for the [surveillance] [receipt] [evaluation] [reporting to FDA] of postmarketing adverse drug experiences. Specifically, ***

Back to top

Bioresearch Monitoring

Center Name Cite Id Ref No Frequency Short Description Long Description
Bioresearch monitoring 7560 21 CFR 312.60 181 FD-1572, protocol compliance An investigation was not conducted in accordance with the [signed statement of investigator] [investigational plan]. Specifically***
7530 21 CFR 312.62(b) 107 Case history records- inadequate or inadequate Failure to prepare or maintain [adequate] [accurate] case histories with respect to [observations and data pertinent to the investigation] [informed consent].   Specifically, ***
7526 21 CFR 312.62(a) 51 Accountability records Investigational drug disposition records are not adequate with respect to [dates] [quantity] [use by subjects].  Specifically, ***
7227 21 CFR 50.27(a) 36 Consent form not approved/signed/dated Informed consent was not properly documented in that the written informed consent used in the study [was not approved by the IRB] [was not signed by the subject or the subject’s legally authorized representative at the time of consent ] [was not dated by the subject or the subject's legally authorized representative at the time of consent]. Specifically, ***
7318 21 CFR 56.115(a)(2) 36 Minutes of IRB meetings Minutes of IRB meetings have not been [prepared] [maintained] in sufficient detail to show [attendance at the meetings] [actions taken by the IRB] [the vote on actions, including the number of members voting for, against and abstaining] [the basis for requiring changes in or disapproving research] [a written summary of the discussion of controverted issues and their resolution].  Specifically, ***
7562 21 CFR 312.60 36 Informed consent Failure to obtain informed consent in accordance with 21 CFR Part 50 from each human subject prior to [drug administration] [conducting study-related tests] .  Specifically***
7281 21 CFR 56.108(a)(1) 35 Initial and continuing reviews The IRB [has no] [did not follow its] written procedure for conducting its [initial] [continuing] review of research. Specifically, ***
7498 21 CFR 312.66 21 Unanticipated problems Failure to report promptly to the IRB all unanticipated problems involving risk to human subjects or others.  Specifically, ***
7334 21 CFR 56.115(a)(5) 19 List of members A list of IRB members has not been [prepared] [maintained], identifying members by [name] [earned degrees] [representative capacity]  [indications of experience sufficient to describe each member's chief anticipated contribution to IRB deliberations] [any employment or other relationship between each member and the institution].  Specifically, ***
7520 21 CFR 312.64(b) 17 Safety reports Failure to report [promptly] to the sponsor adverse effects that may reasonably be regarded as caused by, or probably caused by, an investigational drug. Specifically, ***
7290 21 CFR 56.108(c) 16 Members present for review For other than expedited reviews, the IRB does not always review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas.  Specifically, ***
7293 21 CFR 56.109(f) 16 Continuing review The IRB does not conduct continuing review of research at intervals [appropriate to the degree of risk] [of not less than once per year].  Specifically, ***
7552 21 CFR 312.66 16 Changes in research Not all changes in research activity were approved by an Institutional Review Board prior to implementation.  Specifically, ***
7286 21 CFR 56.108(b)(1) 15 Prompt reporting of unanticipated problems The IRB [has no] [did not follow] written procedures for ensuring prompt reporting to [the IRB] [appropriate institutional officials] [the FDA] of any unanticipated problems involving risks to human subjects or others.  Specifically, ***
7317 21 CFR 56.115(a)(1) 14 Copies of all research proposals and related documents Copies have not been [prepared] [maintained] of all [research proposals reviewed] [scientific evaluations, if any, accompanying research proposals] [approved sample consent documents] [progress reports submitted by investigators] [reports of injuries to subjects].  Specifically, ***
7517 21 CFR 312.66 13 Initial and continuing review Failure to assure that an IRB [complying with applicable regulatory requirements] was responsible for the initial and continuing review and approval of a clinical study.  Specifically, ***
7278 21 CFR 56.107(e) 12 Conflict of interest The IRB allowed a member to participate in the IRB's [initial] [continuing review] of a project in which the member had a conflicting interest.  Specifically, ***
7342 21 CFR 56.108(b)(2) 12 Prompt reporting of noncompliance The IRB [has no] [did not follow] written procedures for ensuring prompt reporting to [the IRB] [appropriate institutional officials] [the FDA]  of any instance of serious or continuing noncompliance with theses regulations or the requirements or determinations of the IRB.  Specifically, ***
7316 21 CFR 56.115(a)(4) 10 Copies of IRB/CI correspondence Copies have not been maintained of all correspondence between the IRB and the investigators.  Specifically, ***
7531 21 CFR 312.62(c) 10 Record retention Investigational records were not retained for a period of two years following [approval of a drug's marketing application] [discontinuance of the investigation and notification of FDA].   Specifically, ***
7335 21 CFR 56.115(a)(6) 9 Written procedures per 56.108(a) and (b) Documentation has not been [prepared] [maintained] of written procedures for the IRB, as required by 21 CFR 56.108(a) and (b).  Specifically, ***
7343 21 CFR 56.108(b)(3) 9 Reporting  of suspension/termination The IRB [has no] [did not follow] written procedures for ensuring prompt reporting to [the IRB] [appropriate institutional officials] [the FDA] of any suspension or termination of IRB approval .  Specifically, ***
7371 21 CFR 56.108(a)(1) 9 Reporting findings and actions to investigator/institution The IRB [has no] [did not follow its] written procedure for reporting its [findings] [actions] to the [investigator] [institution].  Specifically, ***
7411 21 CFR 312.53(c)(1) 9 Investigator statement (FDA 1572) Failure to obtain [an] [a complete] investigator statement, form FDA-1572, before permitting an investigator to participate in an investigation.  Specifically, ***
7459 21 CFR 312.57(a) 9 Records of receipt, shipment, disposition Lack of [adequate] records covering [receipt] [shipment to investigators] [disposition] of an investigational drug.  Specifically, ***
4007 21 CFR 58.130(a) 8 Conduct: in accordance with protocol Not all nonclinical laboratory studies were conducted in accordance with the protocol.  Specifically, ***
7480 21 CFR 312.50 8 Ensuring compliance with plan and protocol Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.  Specifically, ***
7482 21 CFR 312.50 8 General responsibilities of sponsors Failure to [select qualified investigators] [provide investigators with the information needed to conduct the study properly] [ensure proper monitoring of the study] [ensure the study is conducted in accordance with the  protocol and/or investigational plan] [ensure that FDA and all investigators are promptly informed of significant new adverse effects or risks].  Specifically, ***
7654 21 CFR 56.110(b) 8 Research not eligible for expedited review The IRB used an expedited review procedure for research which did not appear in an FDA list of categories eligible for expedited review, and which had not previously been approved by the IRB [within one year].   Specifically, ***  
7321 21 CFR 56.110(c) 7 Method to keep members advised The IRB uses an expedited review procedure, but [has not adopted] [is not following] a method for keeping members advised of research proposals which have been approved under the procedure.  Specifically, *** 
7368 21 CFR 56.108(a)2) 7 More frequent reviews, verification of no changes The IRB [has no] [did not follow its] written procedure for determining which projects [require review more often than annually] [need verification from sources other than the investigator that no material changes have occurred since previous IRB review] . Specifically, ***
7391 21 CFR 50.25(a)(5) 7 Confidentiality, FDA inspection of records There was no statement in the informed consent document that [described the extent, if any, to which confidentiality of records identifying the subject would be maintained] [noted the possibility that the Food and Drug Administration might inspect the records].  Specifically, ***
7209 21 CFR 50.25(a)(1) 6 Procedures, identification of those which were experimental The informed consent document did not contain [a description of the procedures to be followed] [identification of any procedures which were experimental].  Specifically, ***
7319 21 CFR 56.115(a)(3) 6 Records of continuing review Records have not been [prepared] [maintained] of all continuing review activities.  Specifically, ***
7387 21 CFR 50.25(a)(1) 6 Statement of research, purpose, duration of participation The informed consent document did not contain [a statement that the study involved research] [an explanation of the purposes of the research, and the expected duration of the subject's participation].  Specifically, ***
7388 21 CFR 50.25(a)(2) 6 Reasonably foreseeable risks or discomforts  The informed consent document lacked a description of reasonably foreseeable risks or discomforts to the subject.  Specifically, ***
7479 21 CFR 312.56(a) 6 Monitoring investigations Failure to monitor the progress of an investigation conducted under your IND.  Specifically, ***
7664 21 CFR 50.20 6 Circumstances of obtaining consent The general requirements for informed consent were not met in that [you] [the investigator] did not seek consent under circumstances that [provided the prospective subject or the subject's representative sufficient opportunity to consider whether or not to participate] [minimized the possibility of coercion or undue influence].  Specifically, ***
7320 21 CFR 56.109(e) 5 IRB approvals/disapprovals - general The IRB has not promptly notified in writing [the investigator] [the institution] when the IRB has [approved] [disapproved] [required modifications to secure IRB approval of] proposed research activity.   Specifically, ***
7337 21 CFR 56.115(b) 5 Retention of records Records required by 21 CFR 56 have not been maintained for three years following completion of the research.  Specifically, ***
7527 21 CFR 312.62(a) 5 Unused drug disposition (investigator) Unused supplies of an investigational drug were not [returned to the sponsor] [disposed of in accordance with sponsor instructions].  Specifically, ***
7666 21 CFR 50.20 5 Understandable language The general requirements for informed consent were not met in that the information given was not in language understandable to the subject or the subject's representative.  Specifically, ***
3923 21 CFR 58.33(f) 4 Study director: transfer of data to archives The study director failed to assure that all raw data, documentation, protocols, specimens, and final reports were transferred to the archives during or at the close of the study.  Specifically, ***
7333 21 CFR 56.104(c) 4 Emergency use and IRB approval A clinical investigator did not report to the IRB [, within five days of use,] the emergency use of a test article for which the IRB had not reviewed the research proposal.  Specifically, ***
7370 21 CFR 56.111(c) 4 Children as subjects The IRB approved the conduct of research involving children as subjects, but did not determine that the research was in compliance with 21 CFR 50 Subpart D.  Specifically, ***
7392 21 CFR 50.25(a)(7) 4 Whom to contact The informed consent document lacked an explanation of whom to contact [for answers to pertinent questions about the research and research subjects' rights] [in the event of a research-related injury to the subject].  Specifically, ***
7406 21 CFR 56.109(a) 4 Scope of reviews The IRB does not review all research activities covered by the regulations.  Specifically, ***
7638 21 CFR 312.20(a) 4 Failure to submit an IND The sponsor failed to submit an IND to the FDA prior to conducting a clinical investigation with an investigational new drug. Specifically,***
3920 21 CFR 58.33(c) 3 Study director: unforeseen circumstances The study director failed to assure that unforeseen circumstances that might affect the quality and integrity of the nonclinical laboratory study were noted when they occurred and corrective action was taken and documented.  Specifically, ***
3931 21 CFR 58.35(b)(5) 3 QAU: authorize deviations from protocols or SOPs The quality assurance unit failed to determine whether any deviations from approved protocols or standard operating procedures had been made with proper authorization and documentation.  Specifically, ***
3932 21 CFR 58.35(b)(6) 3 QAU: review final study report The quality assurance unit failed to review the final study report to assure that such report accurately described the methods and standard operating procedures, and that the reported results accurately reflected the raw data of the study.  Specifically, ***
3977 21 CFR 58.90(g) 3 Animal care: analysis of feed and water Not all animal feed and water were analyzed periodically to ensure that expected contaminants were not present at levels above those specified in the protocol.  Specifically, ***
4025 21 CFR 58.185(a)(9) 3 Final report: circumstances affecting data qual., integrity The final study report did not include a description of all circumstances that may have affected the quality or integrity of the data.  Specifically, ***
4040 21 CFR 58.190(d) 3 Archives: unauthorized personnel Unauthorized personnel entered the archives.  Specifically, ***
7270 21 CFR 56.103(a) 3 IRB review requirement A clinical investigation requiring prior submission to the FDA was initiated without [IRB review] [IRB approval] [being subject to continuing IRB review].  Specifically, ***
7305 21 CFR 56.110(b)(2) 3 Minor changes The IRB used an expedited review procedure to review supposedly minor changes to previously-approved research, but the changes were not minor in nature.  Specifically, ***
7339 21 CFR 56.108(a)(4) 3 Changes in approved research The IRB [has no] [did not follow its] written procedure for ensuring that changes in approved research, during the periods for which IRB approval had already been given, would not be initiated without IRB review and approval (except where necessary to eliminate apparent immediate hazards to the human subjects).  Specifically, ***
7340 21 CFR 56.108(a)(3) 3 Prompt reporting of changes The IRB [has no] [did not follow its] written procedure for ensuring prompt reporting to the IRB of changes in research activity.  Specifically, ***
7453 21 CFR 312.56(b) 3 Investigator non-compliance An investigator who did not comply with [the signed agreement] [the general investigational plan] [applicable regulatory requirements] was not [promptly brought into compliance] [terminated].  Specifically, ***
7543 21 CFR 312.61 3 Unauthorized recipients (investigator) A study drug was [administered to subjects] [provided to persons] not under the investigator's personal supervision or under the supervision of a subinvestigator responsible to the investigator.   Specifically, ***
3912 21 CFR 58.31(d) 2 Management: testing of test and control articles Testing facility management failed to assure that all test and control articles or mixtures had been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable.  Specifically, ***
3918 21 CFR 58.33(a) 2 Study director: follow study protocol The study director failed to assure that the protocol, including any change, was approved and was followed.  Specifically, ***
3951 21 CFR 58.51 2 Facility: archives Space is not provided for archives, limited to access by authorized personnel only, for the storage and retrieval of all raw data and specimens from completed studies.  Specifically, ***
3956 21 CFR 58.63(c) 2 Equipment: maintenance records Adequate written records are not maintained of all equipment inspection, maintenance, testing, calibrating and/or standardizing operations.  Specifically, ***
3958 21 CFR 58.81(a) 2 SOPs: authorization and documentation of deviations Not all deviations from standard operating procedures in a study were authorized by the study director and  documented in the raw data.  Specifically, ***
3960 21 CFR 58.81(b) 2 SOPs: required Standard operating procedures have not been established for [animal room preparation] [animal care] [receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles] [test system observations] [laboratory tests] [handling of animals found moribund or dead during study] [necropsy of animals or postmortem examination of animals] [collection and identification of specimens] [histopathology] [data handling, storage, and retrieval] [maintenance and calibration of equipment] [transfer, proper placement, and identification of animals].  Specifically, ***
4006 21 CFR 58.120(b) 2 Protocol: approval of changes Not all changes in, or revisions of, an approved protocol and the reasons therefore were documented, signed by the study director, dated, and maintained with the protocol.  Specifically, ***
4021 21 CFR 58.185(a)(5) 2 Final report: stability of test and control articles The final study report did not include the stability of the test and control articles under the conditions of administration.  Specifically, ***
4028 21 CFR 58.185(a)(12) 2 Final report: reports of individual scientists The final study report did not include the signed and dated reports of each of the individual scientists or other professionals involved in the study.  Specifically, ***
7231 21 CFR 50.20 2 Consent not obtained, exceptions do not apply Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.  Specifically, ***
7276 21 CFR 56.107(c) 2 One scientific and one non-scientific member The IRB does not include [at least one member whose primary concerns are in the scientific area] [at least one member whose primary concerns are in nonscientific areas].  Specifically, ***
7378 21 CFR 50.27(a) 2 Copy of consent form not provided A copy of the written consent form which had been approved by the IRB and signed and dated by the subject or the subject's legally authorized representative, was not provided to the subject or the subject's legally authorized representative at the time of consent.  Specifically, ***
7428 21 CFR 312.53(c)(2) 2 Investigator CV or other statement of qualifications Failure to obtain a curriculum vitae or other statement of the qualifications of the investigator, before permitting an investigator to participate in an investigation.  Specifically, ***
7488 21 CFR 312.59 2 Records of unused drug disposition Failure to maintain [adequate] written records of the disposition of an investigational drug in accordance with 21 CFR Part 312.57.  Specifically, ***
7546 21 CFR 312.64(d) 2 Financial info update Updated financial information was not provided to the study sponsor when relevant changes occurred during [the course of the investigation] [the year following completion of the study].  Specifically, ***
7629 21 CFR 312.56(c) 2 Annual report Failure to submit to FDA [within 60 days of the anniversary date that the IND went into effect] an annual report of the investigation.  Specifically, ***
7652 21 CFR 56.113 2 Reporting The IRB's [suspension] [termination of approval] for research was not reported [promptly] to [the investigator] [appropriate institutional officials] [the Food and Drug Administration].  Specifically, ***
7656 21 CFR 56.108(c) 2 Approval from a majority of members present For other than expedited reviews, research approved by the IRB does not always receive the approval of a majority of those IRB members present.  Specifically, ***
3902 21 CFR 58.29(a) 1 Personnel: education, training, experience Not all individuals engaged in the conduct of or responsible for the supervision of a nonclinical laboratory study have education, training, and experience, or combination thereof, to enable that individual to perform assigned functions.  Specifically, ***
3903 21 CFR 58.29(b) 1 Personnel: summary of training, job description The testing facility failed to maintain a current summary of training and experience and job description for each individual engaged in or supervising the conduct of a nonclinical laboratory study.  Specifically, ***
3906 21 CFR 58.29(e) 1 Personnel: appropriate clothing Not all personnel engaged in a nonclinical laboratory study  wear clothing appropriate for the duties they perform.  Specifically, ***
3909 21 CFR 58.31(a) 1 Management: designating the study director Testing facility management failed to designate a study director before each study was initiated.  Specifically, ***
3911 21 CFR 58.31(c) 1 Management: assure there is a QAU Testing facility management failed to assure that there was a quality assurance unit in conformance with FDA GLP regulations.  Specifically, ***
3914 21 CFR 58.31(f) 1 Management: personnel understand their functions Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.  Specifically, ***
3919 21 CFR 58.33(b) 1 Study director: all data recorded and verified The study director failed to assure that all experimental data, including observations of unanticipated responses of the test system, were accurately recorded and verified.  Specifically, ***
3933 21 CFR 58.35(b)(7) 1 QAU: signed statement in final report The quality assurance unit failed to prepare and sign a statement to be included with the final study report which specified the dates inspections were made and findings reported to management and to the study director.  Specifically, ***
3935 21 CFR 58.35(d) 1 QAU: access to SOPs, certify inspections  The quality assurance unit failed to provide access to the testing facility's written procedures for inspection of nonclinical laboratory studies.  Specifically, ***
3936 21 CFR 58.41 1 Facility: suitable size and construction The testing facility is not of suitable size and construction to facilitate the proper conduct of nonclinical laboratory studies.  Specifically, ***
3942 21 CFR 58.43(d) 1 Facility: vermin, odors, disease and contamination Disposal facilities are not [provided] [operated] to minimize [vermin infestation] [odors] [disease hazards] [environmental contamination].  Specifically, ***
3952 21 CFR 58.61 1 Equipment: appropriate design and adequate capacity Not all [equipment used in the generation, measurement, or assessment of data] [equipment used for facility environmental control] is of appropriate design and adequate capacity to function according to the protocol and is suitably located for operation, inspection, cleaning, and maintenance.  Specifically, ***
3953 21 CFR 58.63(a) 1 Equipment: inspection, cleaning and maintenance Not all equipment is adequately inspected, cleaned, and maintained.  Specifically, ***
3957 21 CFR 58.81(a) 1 SOPs: laboratory methods The testing facility does not have written standard operating procedures setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of a study.  Specifically, ***
3959 21 CFR 58.81(a) 1 SOPs: authorized changes Not all significant changes in established standard operating procedures were properly authorized in writing by management.  Specifically, ***
3961 21 CFR 58.81(c) 1 SOPs: availability Not all laboratory areas have immediately available laboratory manuals and standard operating procedures relative to the laboratory procedures being performed.  Specifically, ***
3976 21 CFR 58.90(f) 1 Animal care: cage and equipment cleaning Not all animal cages, racks and accessory equipment were cleaned and sanitized at appropriate intervals.  Specifically, ***
3981 21 CFR 58.90(i) 1 Animal care: pest control documentation Not all uses of pest control materials were documented.  Specifically, ***
3985 21 CFR 58.105(b) 1 Test article: stability The stability of each test or control article was not determined by the testing facility or by the sponsor before study initiation, or concomitantly according to written standard operating procedures which provide for periodic analysis of each batch.  Specifically, ***
3986 21 CFR 58.105(c) 1 Test article: storage container labeling Not all storage containers for a test or control article were labeled by name, chemical abstract number or code number, batch number, expiration date, if any, and, where appropriate, storage conditions necessary to maintain the identity, strength, purity, and composition of the test or control article.  Specifically, ***
3988 21 CFR 58.105(d) 1 Test article: reserve sample retention Not all reserve samples from each batch of test and control articles for studies of more than 4 weeks' duration were retained for the required period of time.  Specifically, ***
3990 21 CFR 58.113(a)(1) 1 Mixtures: uniformity and concentration Not all test or control articles mixed with a carrier were tested by appropriate analytical methods to determine [the uniformity of the mixture] [periodically, the concentration of the test or control article in the mixture].  Specifically, ***
3991 21 CFR 58.113(a)(2) 1 Mixtures: stability Not all test or control articles mixed with a carrier were tested by appropriate analytical methods to determine the stability of the test or control article in the mixture as required by the conditions of the study.  Specifically, ***
3993 21 CFR 58.120(a) 1 Protocol: approved Not all studies had an approved written protocol that clearly indicated the objectives and all methods for the conduct of the study.  Specifically, ***
3994 21 CFR 58.120(a)(1) 1 Protocol: descriptive title and purpose Not all protocols contained a descriptive title and statement of the purpose of the study.  Specifically, ***
4002 21 CFR 58.120(a)(9) 1 Protocol: tests, analyses, and measurements Not all protocols contained the type and frequency of tests, analyses, and measurements to be made.  Specifically, ***
4013 21 CFR 58.130(e) 1 Conduct: changes not obscuring original entries Not all changes in entries were made so as not to obscure the original entry, indicated the reason for such change, and were dated and signed or identified at the time of the change.  Specifically, ***
4014 21 CFR 58.130(e) 1 Conduct: identification of individual inputting data In automated data collection systems, the individual responsible for direct data input was not identified at the time of data input.  Specifically, ***
4020 21 CFR 58.185(a)(4) 1 Final report: data on test and control articles The final study report did not include the test and control articles identified by name, chemical abstracts number or code number, strength, purity, and composition or other appropriate characteristics.  Specifically, ***
4022 21 CFR 58.185(a)(6) 1 Final report: description of methods The final study report did not include a description of the methods used.  Specifically, ***
4026 21 CFR 58.185(a)(10) 1 Final report: names of those involved The final study report did not include [the name of the study director] [the names of other scientists or professionals] [the names of all supervisory personnel] involved in the study.  Specifically, ***
4032 21 CFR 58.185(c) 1 Final report: corrections or additions Not all corrections or additions to a final report were in the form of an amendment by the study director.  Specifically, ***
4038 21 CFR 58.190(b) 1 Archives: reference other storage locations The testing facility archive failed to specifically reference other locations where raw data or specimens are stored.  Specifically, ***
4039 21 CFR 58.190(c) 1 Archives: individual responsible An individual was not identified as responsible for the archives.  Specifically, ***
4041 21 CFR 58.190(e) 1 Archives: indexing, expedient retrieval Not all material retained or referred to in the archives was indexed to permit expedient retrieval. Specifically, ***
4044 21 CFR 58.195(d) 1 Archives: maintenance of records by QAU Not all master schedules, copies of protocols, and records of quality assurance inspections were maintained by the quality assurance unit as an easily accessible system of records for the required period of time.  Specifically, ***
4047 21 CFR 58.195(g) 1 Archives: records not retained as originals, true copies Not all required records were retained as original records or as true copies of the original records.  Specifically, ***
7229 21 CFR 50.27(b)(1) 1 Adequate opportunity to read before signing The investigator did not give [the subject] [the subject's legally authorized representative] adequate opportunity to read the informed consent document before it was signed. Specifically, ***
7277 21 CFR 56.107(d) 1 One non-affiliate member The IRB does not include at least one member who is not otherwise affiliated with the institution, and who is not part of the immediate family of a person who is affiliated with the institution.  Specifically, ***
7279 21 CFR 56.107(f) 1 Invited individual allowed to vote with IRB The IRB invited an individual with competence in a special area to assist in the review of complex issues which required expertise beyond or in addition to that available on the IRB; however, the IRB allowed the individual to vote with the IRB.  Specifically, ***
7297 21 CFR 56.109(b) 1 Information given to subjects The IRB does not require that information given to subjects as part of informed consent contain all necessary elements of informed consent.  Specifically, ***:
7322 21 CFR 56.111 (a)(2) 1 Risks to subjects reasonable The IRB approved the conduct of research, but did not determine that the risks to subjects were reasonable in relation to the anticipated benefits (if any) to subjects, and to the importance of the knowledge that might be expected to result.  Specifically, ***
7325 21 CFR 56.111(a)(5) 1 Informed consent documented The IRB approved the conduct of research, but did not determine that informed consent would be appropriately documented.  Specifically, ***
7326 21 CFR 56.111(a)(6) 1 Monitoring of data collected The IRB approved the conduct of research, but did not determine, where appropriate, that the research plan made adequate provisions for monitoring the data collected to ensure the safety of subjects.  Specifically, ***
7367 21 CFR 50.55(e)(2) 1 Two parents' permission: studies under Parts 50.53 - 50.54  For a clinical investigation involving children, conducted under [21 CFR 50.53] [21 CFR 50.54], the investigator did not always obtain the permission of both parents where feasible.  Specifically, ***
7369 21 CFR 56.109(h) 1 Children as subjects The IRB did not determine [at the time of initial review] [at the time of continuing review for an on-going study which was started on/before April 30, 2001] that a study was in compliance with 21 CFR Part 50 Subpart D, "Additional Safeguards for Children in Clinical Investigations."  Specifically, ***
7386 21 CFR 50.25(b)(4) 1 Consequences of withdrawing The informed consent document did not provide information regarding the consequences of a subject's decision to withdraw from the research, and procedures for orderly termination of participation by the subject.  Specifically, ***
7390 21 CFR 50.25(a)(4) 1 Alternate procedures, courses of treatment There was [no] [an incomplete] disclosure in the informed consent document of appropriate alternate procedures or courses of treatment, if any, that might be advantageous to the subject.  Specifically, ***
7396 21 CFR 50.24(a)(3) 1 Prospect of direct benefit not determined In approving an investigation without requiring informed consent, the IRB did not [find] [document] that participation in the research held out the prospect of direct benefit to the subjects because [they faced a life-threatening situation requiring intervention] [evidence from preclinical studies supported the potential for intervention to provide a direct benefit to subjects] [associated risks were reasonable under the circumstances].  Specifically,***
7410 21 CFR 312.53(a) 1 Investigator selection Investigators who were not qualified by training and experience as appropriate experts were selected to investigate a drug.  Specifically, ***
7456 21 CFR 312.57(d) 1 Bioequivalence samples Samples of the [test article] [reference standard] used in a [bioavailability] [bioequivalence] study were not [retained] [released to FDA upon request as required by 21 CFR Part 320.138].  Specifically, ***
7458 21 CFR 312.57(b) 1 Records of Financial Interests Failure to maintain [complete] [accurate] records of disclosable financial interests paid to clinical investigators by the sponsor.  Specifically, ***
7499 21 CFR 312.64(a) 1 Progress reports Not all investigational progress reports were furnished to the drug study sponsor.  Specifically, ***
7507 21 CFR 312.52(a) 1 Transfer of obligations Transfer of obligations to a contract research organization [was not described in writing] [did not describe each of the obligations assumed by the contract research organization, where not all obligations were assumed]. Specifically, ***
7518 21 CFR 312.64(d) 1 Financial info Information necessary for submission of required financial [certification] [disclosure] statements to FDA was not provided to the sponsor.  Specifically, ***
7533 21 CFR 312.69 1 Controlled substances (investigator) Inadequate precautions to prevent theft or diversion with respect to [storage of] [access to] an investigational drug which is a controlled substance. Specifically, ***
7534 21 CFR 312.68 1 FDA access to clinical investigator records Failure to permit an authorized officer or employee of FDA to [have access to] [copy] [verify] records or reports.  Specifically, ***
7554 21 CFR 312.53(c)(4) 1 Financial information - sufficient and accurate Failure to obtain from an investigator [sufficient] [accurate] financial information to allow complete and accurate certification or disclosure statements.  Specifically, ***
7628 21 CFR 312.57(b) 1 Other financial interests of the investigator Failure to maintain [complete] [accurate] records of all financial interests of clinical investigators subject to financial interest reporting requirements.  Specifically, ***
7635 21 CFR 312.7(b) 1 Commercial distribution of an investigational drug The investigational new drug was [commercially distributed] [test marketed]. Specifically, ***
7651 21 CFR 56.113 1 Statement of reasons The IRB's [suspension] [termination of approval] for research did not include a statement of the reasons for the IRB's action.  Specifically, ***
7657 21 CFR 50.25(b)(5) 1 Significant new findings The informed consent document did not include a statement that significant new findings developed during the course of the research, which might relate to the subject's willingness to continue participation, would be provided to the subject.  Specifically, ***
7659 21 CFR 50.25(a)(6) 1 Compensation, medical treatment in event of injury For research involving more than minimal risk, the informed consent document lacked an explanation as to whether any [compensation] [medical treatments] were available if injury occurred, and, if so, [of what they consisted] [where further information might be obtained].  Specifically, ***
7665 21 CFR 50.20 1 Exculpatory language, waiving of rights The general requirements for informed consent were not met in that the consent form contained exculpatory language [through which the subject or the subject's representative was made to waive or appear to waive some of the subject's legal rights] [that released or appeared to release the investigator, sponsor, the institution, or its agents from liability for negligence]. Specifically, ***

Back to top

Veterinary Medicine

Center Name Cite Id Ref No Frequency Short Description Long Description
Veterinary medicine 4185 FDCA 402(a)(4) 86 Record keeping Treatment records were not [maintained] [complete].  Specifically,*** 
4093 21 CFR 530.11(d) 51 Tissue residue Causing a residue of an approved human or animal drug above an established safe level, safe concentration, or tolerance, through use of the drug contrary to its labeling.  Specifically, ***
7001 FDCA 402(a)(4) 32 Drug inventory You lack an adequate inventory system for determining the quantities of drugs used to medicate your [cows] [calves] [livestock].  Specifically, ***
4182 FDCA 501(a)(5) 27 Extra label use w/o veterinary client-patient relationship Use of [a human] [an animal] drug in a manner contrary to label directions without benefit of a valid veterinary client-patient relationship.  Specifically, ***
4097 21 CFR 530.20(a)(2)(iv) 24 Tissue residue Causing an illegal residue in a food-producing animal of an approved human or animal drug through [prescribing the use of] [using] the drug contrary to its labeling, and failing to take appropriate measures to assure that [assigned timeframes for withdrawal were met] [no illegal residue would occur].  Specifically, ***
1442 FDCA 402(a)(4) 23 Records review prior to slaughter Failure to systematically review treatment records prior to offering an animal for slaughter for human food, to assure that drugs have been used only as directed and that appropriate withdrawal times have been observed.  Specifically, ***
13508 FDCA 402(a)(4) 18 Medication status of animals  Failure to inquire about the medication status of the animal(s) that you [transported] [purchased] and delivered for [sale] [consignment] at  [an auction yard] [a slaughter plant].  Specifically, ***
13521 21 CFR 530.41(a) 18 Drugs prohibited for extralabel use in food producing animal A prohibited [drug] [substance] was administered in an extralabel manner to [a] food-producing animal(s).  Specifically, ***
1360 FDCA 501(a)(5) 13 Expired drugs Expired drug(s) were observed in the drug storage area.  Specifically, ***
13509 FDCA 402(a)(4) 11 Identity of animals Failure to [identify] [maintain records regarding the identity of] [record the existing identification of] the animal(s) that you [purchased] [transported] and delivered for [sale] [consignment] at [an auction yard] [a slaughter plant].  Specifically, ***
4186 FDCA 402(a)(4) 10 System for administration of drugs Failure to have a system to control administration of drug treatments to your animals.  Specifically, ***
4298 21 CFR 530.11(a) 9 Rx not followed Failure to follow your veterinarian's prescription for [dosage] [frequency and duration of treatment] [route of administration] [species or class of animal] [pre-slaughter withdrawal time] [special cautionary directions].  Specifically, ***
1362 21 CFR 530.11(a) 8 Species or class Administration of an approved human or animal drug to a [species of animal] [class of animal] for which the drug was not labeled, without benefit of a valid veterinarian-client-patient relationship.  Specifically, ***
1389 21 CFR 530.11(a) 8 Withdrawal period Administration of an approved animal drug contrary to the labeling, without benefit of a valid veterinarian-client-patient relationship, in that pre-slaughter withdrawal time was not observed.  Specifically, ***
1469 21 CFR 225.20(b)(3) 8 Pest access minimized The building is not constructed to minimize access by [rodents] [birds] [insects] [pests].  Specifically, ***
4184 FDCA 501(a)(5) 8 Conditions of use Administration of a drug for conditions not [specified in its labeling] [prescribed].  Specifically, ***
1446 FDCA 402(a)(4) 7 Hospital pen Failure to [identify] [segregate] [quarantine] treated animals.  Specifically, ***
1811 21 CFR 225.58(b)(1) 7 Three assays per year Periodic assays are not performed during the calendar year on at least three representative samples of medicated feeds requiring a medicated feed mill license, for each drug or drug combination used.  Specifically, ***
4132 21 CFR 589.2000(d)(1) 7 Protein blenders, feed manufacturers, distributors Products that contain or may contain prohibited material fail to bear the caution statement, "Do not feed to cattle or other ruminants."  Specifically, ***
1850 21 CFR 225.58(d) 6 Assay results out of specification Failure to [investigate] [implement corrective action] [maintain a record on the premises of corrective action] when assay results show medicated feeds [not in accord with label specifications] [not within permissible assay limits].  Specifically,***
4099 21 CFR 530.20(a)(2)(ii) 6 Extended withdrawal period A substantially extended withdrawal period, supported by appropriate scientific information, was not established for the use of an approved drug in a food-producing animal, in an extralabel manner.  Specifically, ***
4560 21 CFR 225.165 6 Establishment and use of adequate procedures Adequate procedures are not [established] [used] for all equipment used in the production and distribution of medicated feeds to avoid unsafe contamination of medicated [and nonmedicated] feeds.  Specifically, ***
1366 21 CFR 530.11(a) 5 Dosage level Administration of an approved animal drug in excess of the indicated dosage, without benefit of a valid veterinarian-client-patient relationship.  Specifically, ***
1373 21 CFR 530.11(a) 5 Route of administration Administration of an approved animal drug via a route, [oral] [intramuscular] [intravenous] [subcutaneous] [topical] [intramammary] [intrauterine], which was not indicated in the labeling, without benefit of a valid veterinarian-client-patient relationship.  Specifically, ***
1466 21 CFR 225.20(b)(2) 5 Maintained in clean and orderly condition Buildings are not maintained in a reasonably clean and orderly manner.  Specifically, ***
1493 21 CFR 225.30(b)(4) 5 Calibration of scales and metering devices Failure to calibrate scales and metering devices [upon installation] [at least once a year after installation] [as frequently as necessary] to insure their accuracy.  Specifically, ***
1765 21 CFR 225.42(b)(6)(i) - (v) 5 Information required Daily inventory records for each drug used do not include [the quantity of drug on hand at the beginning and end of the work day] [the amount of each drug used, sold, or otherwise disposed of] [the batches or production runs of medicated feed in which each drug was used] [information concerning any semiprocessed intermediate mix to be used in a medicated feed] [the action taken to reconcile any discrepancies in the inventory record].  Specifically, ***  
1792 21 CFR 225.42(b)(7) 4 Discrepancies Failure to [investigate] [take corrective action for] a significant discrepancy between actual drug usage and theoretical drug usage.  Specifically, ***
1923 21 CFR 225.65(b) 4 Reasonable and effective procedures followed All equipment that comes in contact with [active drug components] [feeds in process] [finished medicated feed] is not subject to all reasonable and effective procedures to prevent unsafe contamination of manufactured feed.  Specifically, ***
2074 21 CFR 225.102(a) 4 Lack of MRF Failure to have a  Master Record File for manufacturing a specific product, which provides the complete procedure for manufacturing a specific product.  Specifically, ***
2097 21 CFR 225.102(b)(4) 4 Daily review of production records The batch production records are not checked by a responsible individual at the end of the working day to determine whether all required production steps have been performed.  Specifically, ***
1575 21 CFR 225.42(b)(4) 3 Integrity and identity Failure to properly [identify] [store] [handle] [control] drugs in the mixing areas to maintain their integrity and identity.  Specifically, ***
1760 21 CFR 225.42(b)(6) 3 Lot number or shipment I.D. number The daily inventory records for drugs do not include [the manufacturer's lot number] [the feed manufacturer's shipment identification number].  Specifically, ***
4137 21 CFR 589.2000(d)(1) 3 Maintaining records Receipt of materials that contain or may contain protein derived from mammalian tissues, and failure to maintain records sufficient to track the materials throughout their receipt, processing, and distribution.  Specifically, ***
4541 21 CFR 225.42(b) 3 Adequate procedures established Adequate procedures are not established for the [receipt] [storage] [inventory control] of all drugs to aid in assuring their identity, strength, quality and purity when incorporated into products.  Specifically, ***
4552 21 CFR 225.142 3 Adequate procedures for Type A and Type B articles Adequate procedures are not [established] [maintained] for the [identification] [storage] [inventory control (receipt and use)] of all Type A medicated articles and Type B medicated feeds intended for use in the manufacture of medicated feeds.  Specifically, ***
13541  FDCA 501(a)(5) 3 Use of veterinary prescription drugs without a prescription Administration of veterinary prescription drugs was performed without the lawful written or oral order of a licensed veterinarian. Specifically, ***
1254 21 CFR 225.10(b)(1) 2 Training Employees involved in the manufacture of medicated feeds lack an understanding of the manufacturing or control operations which they perform.  Specifically, ***
1457 FDCA 402(a)(4) 2 Feeding colostrum Feeding colostrum or milk from treated cows to calves intended for slaughter.  Specifically, ***
1482 21 CFR 225.30(b)(1) 2 Capability to produce a medicated feed Equipment does not possess the capability to produce a medicated feed of intended [potency] [safety] [purity].  Specifically, ***
1638 21 CFR 225.42(b)(5) 2 Elements of receipt record Drug receipt records do not accurately indicate the [identity] [quantity] [name of the supplier] [supplier's lot number or other identifying number] [date of receipt] [condition of the drug when received] [return of any damaged drugs] for each lot of drug received.  Specifically, ***
1782 21 CFR 225.42(b)(7) 2 Daily comparison, actual vs theoretical A daily comparison is not made between the actual amount of drug used and the theoretical amount of drug to be used in terms of the [semiprocessed] [intermediate] [finished] medicated feeds manufactured.  Specifically, ***
1882 21 CFR 225.58(e) 2 Subsequent production Following distribution of a medicated feed which failed to meet its labeled drug potency, subsequent production of that feed  was resumed prior to the establishment of proper control procedures.  Specifically, ***
1930 21 CFR 225.65(b)(3) 2 Sequential production Sequential production of medicated feeds is not done on a predetermined basis designed to prevent unsafe contamination of feeds with residual drugs.  Specifically, ***
1955 21 CFR 225.80(a) 2 Appropriate labeling for medicated feed Medicated feed is not identified by appropriate labeling which provides the user with directions for use which if adhered to, will assure the article is safe and effective for its intended purpose.  Specifically, ***
2076 21 CFR 225.102(b)(1) 2 Elements of the MRF The Master Record File does not contain [the name of the medicated feed] [the name and weight percentage or measure of each drug or drug combination and each nondrug ingredient to be used in manufacturing a stated weight of medicated feed] [a copy or description of the label that will accompany the medicated feed] [manufacturing instructions or reference thereto that have been determined to yield a properly mixed medicated feed of the specified formula for each medicated feed produced]  [appropriate control directions including the collection of samples for specified laboratory assays] [the basis for estimating quantity produced, where actual yield cannot be accurately determined when finished feed is stored in bulk].  Specifically, ***
2093 21 CFR 225.102(b)(2)(i)-(iv) 2 Elements of production record(s) Production record(s) fail to include [the product identification] [the date of production] [a written endorsement in the form of a signature or initials by a responsible individual] [the quantity and name of drug components used] [the theoretical quantity of medicated feed to be produced] [the actual quantity of the medicated feed produced] [an estimate of the quantity to be produced and stored in bulk, based on the basis for the estimate in the MRF].  Specifically, ***
2098 21 CFR 225.102(b)(4) 2 Discrepancies investigated, reported When significant discrepancies were noted on the batch production records, there was a failure to [institute an investigation immediately] [describe the corrective action taken on the production record].  Specifically, ***
4108 21 CFR 530.12(a) 2 Name and address - drug dispensed by veterinarian Failure to provide labeling showing the name and address of the prescribing veterinarian for a human or animal drug prescribed for use in an animal contrary to the drug's labeling.  Specifically, ***
4113 21 CFR 530.12(e) 2 Withdrawal, withholding, or discard time Failure to provide labeling containing [withdrawal] [withholding] [discard] time as specified by the veterinarian for a human or animal drug prescribed for use in an animal contrary to the drug's labeling.  Specifically, ***
4134 21 CFR 589.2000(c)(1)(ii) 2 Maintaining records Manufacture of products that contain or may contain protein derived from mammalian tissues, and failure to maintain records sufficient to track the materials throughout their receipt, processing, and distribution.  Specifically, ***
4158 21 CFR 225.80(b)(4) 2 Label stock review Label stock is not [reviewed periodically] [discarded when discontinued labels are found].  Specifically, ***
4183 FDCA 501(a)(5) 2 Frequency of administration Administration of a drug [over a longer time period] [more frequently] than [specified in its labeling] [prescribed].  Specifically, ***
4545 21 CFR 225.120 2 Vermin and pest infestation Buildings and grounds are not constructed and maintained in a manner to minimize vermin and pest infestation.  Specifically, ***
4553 21 CFR 225.142 2 Packaged Type A and Type B designated areas The [packaged Type A medicated articles] [packaged Type B medicated feed] are not [stored in designated areas] [stored in their original closed containers].  Specifically, ***
4555 21 CFR 225.142 2 Use in accord with directions All [Type A medicated articles] [Type B medicated feeds] are not used in accordance with their labeled mixing directions.  Specifically, ***
4557 21 CFR 225.158 2 Investigation and corrective action Results of laboratory assays of drug components indicated that medicated feed was not in accord with the permissible limits, and no [investigation] [corrective action] was implemented immediately.  Specifically, ***
13532 21 CFR 511.1(b)(7)(ii) 2 Records: Test article accountability Complete records of the receipt and disposition of each shipment or delivery of the test article were not maintained by the investigator.  Specifically, ***
13534 21 CFR 511.1(b)(7)(ii) 2 Records: Maintenance Complete records of the investigation were not maintained.  Specifically, ***
1262 21 CFR 225.10(b)(2) 1 Evaluation and supervision of employees Failure to provide an on-going program of evaluation and supervision of employees in the manufacture of medicated feeds.  Specifically, ***
1447 FDCA 402(a)(4) 1 Feeding areas Failure to adequately clean feed and water containers to prevent cross-contamination of medicated and non-medicated feeds and liquids.  Specifically, ***
1491 21 CFR 225.30(b)(2) 1 Maintenance reasonably clean & orderly Equipment is not  maintained in a reasonably clean and orderly manner.  Specifically, ***
1492 21 CFR 225.30(b)(3) 1 Suitable for intended purpose Equipment is not of suitable [size] [design] [construction] [precision] [accuracy] for its intended purpose.  Specifically, ***
1494 21 CFR 225.30(b)(5) 1 Lubricants and coolants Failure to [construct] [maintain] equipment to prevent [lubricants] [coolants] from becoming unsafe additives in feed components or medicated feed.  Specifically, ***
1510 21 CFR 225.35(b) 1 Pesticide manufacture and storage Work areas and equipment used in the [manufacture] [storage] of medicated feeds or components thereof are not physically separated from [work areas] [equipment used] for the [manufacture] [storage] of [fertilizers] [herbicides] [insecticides] [fungicides] [rodenticides] [pesticides].  Specifically, *** 
1744 21 CFR 225.42(b)(6) 1 Daily inventory record kept Failure to maintain a daily inventory record for each drug used in the manufacture of medicated feeds.  Specifically, ***
1835 21 CFR 225.58(c) 1 Assay results kept one year Failure to maintain on the premises, originals or copies of all results of assays [including those from State feed control officials or any other governmental agency] for a period of not less than one year after distribution of the medicated feed.  Specifically, ***
1880 21 CFR 225.58(e) 1 Distribution discontinued Distribution of a medicated feed which failed to meet its labeled drug potency was not discontinued.  Specifically, ***
1951 21 CFR 225.80(b)(1) 1 Receipt, handling, and storage The [labels] [labeling] [placards] are not [received] [handled] [stored] in a manner to prevent mix-ups and assure correct labeling is employed for the medicated feed.  Specifically, ***
1953 21 CFR 225.80(b)(2) 1 Maintaining proofread label Proofread labels are not [initialed and dated by a responsible individual] [kept for one year after all the labels from that batch have been used].  Specifically, ***
2140 21 CFR 225.102(b)(5) 1 Identification which permits tracing history Failure to have identification which permits the tracing of the complete and accurate manufacturing history of the product by the manufacturer, including [an individual batch or production run number, code or date] [suitable identification applied to the label, package, invoice or shipping document].  Specifically, *** 
2189 21 CFR 225.110(b)(1) 1 Distribution record elements Distribution record(s) for medicated feeds fail to include the [date of shipment] [name and address of purchaser] [quantity shipped] [name of the medicated feed] [lot, control number, date of manufacture, or other suitable identification].  Specifically, ***
2232 21 CFR 225.115(b)(1) 1 Maintaining records of complaints The original or copy of a record of each oral or written complaint received relating to the safety and effectiveness of the product produced is not maintained on the premises.  Specifically, ***
2233 21 CFR 225.115(b)(1) 1 Records of oral or written complaints The record of each oral or written complaint relating to the safety and effectiveness of a  medicated feed  fails to include the [date of the complaint] [complainant's name] [complainant's address] [name and lot or control number or date of manufacture] [specific details of the complaint] [correspondence from the complainant and/or memoranda of conversations] [description of all investigations made by the manufacturer] [method of disposition of the complaint]. Specifically, ***
2379 21 CFR 226.40(e) 1 Cleaning to prevent contamination of Type A articles Failure to use adequate procedures for cleaning of those parts of equipment which come into contact with drug components of Type A medicated articles, to avoid contamination of Type A medicated articles.  Specifically, ***
2416 21 CFR 226.80(b)(2) 1 Label examination Packaging and labeling operations do not provide for careful checking of labeling for identity and conformity to the labeling specified in the batch production records.  Specifically, ***
4094 21 CFR 530.11(b) 1 Use in animal feed An approved drug was used in or on an animal feed in a manner not in accordance with the approved labeling. Specifically, ***
4100 21 CFR 530.20(a)(2)(iii) 1 Identity of treated animals Failure to assure that the identity of a food-producing animal was maintained, where you had prescribed or dispensed an approved human or animal drug contrary to the drug's labeling.  Specifically, ***
4111 21 CFR 530.12(c) 1 Directions for use Failure to provide labeling containing directions for use as specified by the veterinarian for a human or animal drug prescribed for use in an animal contrary to the drug's labeling.  Specifically, ***
4112 21 CFR 530.12(d) 1 Cautionary statements Failure to provide labeling containing cautionary statements as specified by the veterinarian for a human or animal drug prescribed for use in an animal contrary to the drug's labeling.  Specifically, ***
4145 21 CFR 589.2000(e)(1) 1 Use of clean-out procedures Failure to use clean-out procedures or other means adequate to prevent carryover of protein derived from mammalian tissues to animal protein or feeds that may be used for ruminants.  Specifically, ***
4146 21 CFR 589.2000(e)(1) 1 Written clean-out procedures Failure to maintain written clean-out procedures to prevent carryover of protein derived from mammalian tissues to animal protein or feeds that may be used for ruminants.  Specifically, ***
4160 21 CFR 226.58(d) 1 Expiration date lacking on Type A article Suitable expiration dates do not appear on the labels of Type A medicated articles to assure that  the appropriate standards of identity, strength, and purity are met at time of use.  Specifically, ***
4297 21 CFR 226.42(a) 1 Components receiving, testing, handling, et. al. Drug components used in the manufacture and processing of Type A medicated articles are not [received] [examined or tested] [stored] [handled] [controlled] in a manner to maintain the [integrity] [identification] of such articles.  Specifically, ***
4453 21 CFR 225.10(b)(1) 1 Employees lack understanding All employees involved in the manufacture of medicated feeds do not have an understanding of the [manufacturing or control operations they perform] [location and proper use of equipment].  Specifically, ***
4542 21 CFR 225.102((a) 1 Lack of Production Record(s) Failure to have production record(s) for specific products which include the complete history of each batch or production run.  Specifically, ***
4547 21 CFR 225.130 1 Cleanliness, inspection, cleanout  Equipment for producing medicated feeds of intended potency and purity is not [maintained in a reasonably clean and orderly manner] [designed, constructed, installed and maintained so as to facilitate inspection and use of cleanout procedures].  Specifically, ***
4564 21 CFR 225.180 1 Bagged or bulk deliveries All deliveries of medicated feeds, whether bagged or in bulk, are not adequately labeled to assure that the feed can be properly used.  Specifically, ***
4566 21 CFR 225.202 1 Elements of records Formula, production and distribution records are not maintained identifying the [formulation] [date of mixing] [date of shipment (if not for own use)].  Specifically, ***
4567 21 CFR 225.202 1 Facilitation of recall The [formula] [production] [distribution] records are not adequate to facilitate the recall of specific batches of medicated feed that have been distributed.  Specifically, *** 
13531 21 CFR 511.1(b)(7)(iii) 1 Reports: Adequate and Timely The investigator did not furnish adequate and timely reports of the investigation to the sponsor.  Specifically, ***

Back to top

Biologics

Center Name Cite Id Ref No Frequency Short Description Long Description
Biologics 76 21 CFR 606.100(b) 125 Maintained and followed Written standard operating procedures including all steps to be followed in the [collection] [processing] [compatibility testing] [storage] [distribution] of blood and blood components for [homologous transfusion] [autologous transfusion] [further manufacturing purposes] are not always [maintained] [followed] [maintained on the premises].  Specifically, ***
98 21 CFR 606.100(c) 37 Thorough investigations Failure to [perform a thorough investigation] [make a record of the conclusions and follow-up] of [an unexplained discrepancy] [a failure of a lot or unit to meet any of its specifications].  Specifically,***
9225 21 CFR 606.171 31 Biological product deviation report Failure to submit a biological product deviation report [within 45 days from the date you acquired information suggesting that a reportable event occurred].  Specifically, ***
31 21 CFR 606.20(b) 29 Qualifications of responsible personnel The personnel responsible for the [collection] [processing] [compatibility testing] [storage] [distribution] of blood or blood components are not adequate in [number] [educational background] [training and experience, including professional training as necessary]  to assure competent performance of their assigned functions, and to ensure that the final product has the safety, purity, potency, identity and effectiveness it purports or is represented to possess.  Specifically, ***
160 21 CFR 606.160(a)(1) 24 Person performing, test results, interpretation Records fail to [identify the person performing the work] [include dates of the various entries] [show test results] [include interpretation of the results] [show the expiration date assigned to specific products] [be as detailed as necessary] so as to provide a complete history of the work performed.  Specifically, ***
4425 21 CFR 606.60(a) 24 Equipment observed, standardized, calibrated Equipment used in the [collection] [processing] [compatibility testing] [storage and distribution] of blood and blood components is not [observed] [standardized] [calibrated] on a regularly scheduled basis as prescribed in the SOP Manual.  Specifically, ***
154 21 CFR 606.160(a)(1) 21 Concurrent documentation Records are not concurrently maintained with the performance of each significant step in the [collection] [processing] [compatibility testing] [storage] [distribution] of each unit of blood and blood components so that all steps can be clearly traced.  Specifically, ***
155 21 CFR 606.160(b) 19 Required records Failure to maintain [donor] [processing] [storage and distribution] [compatibility testing] [quality control] [general] records.  Specifically, ***
67 21 CFR 606.65(e) 16 Following manufacturer's instructions Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.  Specifically, ***
159 21 CFR 606.160(a)(1) 14 Legibility and indelibility Records are [illegible] [not indelible].  Specifically, ***
78 21 CFR 606.100(c) 11 Record review prior to release All records pertinent to a lot or unit were not reviewed before the release or distribution of a lot or unit of final product.  Specifically, ***
9044 21 CFR 600.10(b) 11 Personnel capabilities Failure to assure that personnel have [capabilities commensurate with] [the necessary training in] [necessary experience in] [a thorough understanding of] the operations which they perform.  Specifically, ***
208 21 CFR 640.3(a)(1) 10 Donor suitability procedures not followed  Failure to [follow] [maintain] [maintain on the premises] standard procedures and methods for determining the suitability of a donor as a source of blood.  Specifically, ***
224 21 CFR 640.4(f) 10 Arm preparation The phlebotomy site is not prepared by a method that gives maximum assurance of a sterile container of Whole Blood.  Specifically, ***
161 21 CFR 606.160(a)(2) 9 Determination of lot numbers and supplies Appropriate records are not available to determine the lot numbers of [supplies] [reagents] used for specific [lots] [units] of the final product.  Specifically, ***
61 21 CFR 606.60(a) 7 Provide proper equipment to meet requirements Failure of equipment to perform in the manner for which it was designed so as to assure compliance with the official requirements prescribed in 21 CFR 606.  Specifically, ***
77 21 CFR 606.100(b) 6 Written SOPs available for use by personnel Failure to make available written procedures for use by personnel in the areas where the procedures are performed.  Specifically, ***
94 21 CFR 606.100(b)(15) 6 Schedules and procedures for equipment & calibration The standard operating procedure fails to include a written description of schedules and procedures for equipment maintenance and calibration.  Specifically, ***
212 21 CFR 640.3(b)(3) 6 Qualifications of donor - hemoglobin Each  donor was not in good health as indicated in part by the blood hemoglobin level which was demonstrated to be less than 12.5 gm. of hemoglobin per 100 ml of blood (38% by microhematocrit).  Specifically, ***
9089 21 CFR 600.14(c) 6 When to report Biological product deviations [were] [are] not reported within the 45 calendar day timeframe.  Specifically, *** 
12202 21 CFR 606.170(a) 6 Adverse Reaction - Investigations A thorough investigation of each reported adverse reaction was not made.  Specifically,
12203 21 CFR 606.170(a) 6 Adverse Reaction- Reports of Investigations Written reports of investigations of adverse reactions, including conclusions and follow up, are not prepared and maintained.  Specifically, 
50 21 CFR 606.40(c) 5 Provide adequate handwashing Failure to provide [adequate] [clean] [convenient] handwashing facilities for personnel.  Specifically, ***
57 21 CFR 606.60(a) 5 Maintain and clean equipment Failure to [maintain] [locate] equipment used in the [collection] [processing] [compatibility testing] [storage] [distribution] of blood and blood products [in a clean and orderly manner] [so as to facilitate cleaning and maintenance].  Specifically, ***
143 21 CFR 606.140(b) 5 Provisions to monitor lab test procedures & instruments Failure to establish  adequate provisions for monitoring the [reliability] [accuracy] [precision] [performance] of laboratory test procedures and instruments.  Specifically, ***
150 21 CFR 606.151(e) 5 Procedures to maintain records of emergency transfusions Records [including signature by the physician requesting the procedure] are not maintained of all emergency transfusions [including complete documentation justifying the emergency action].  Specifically, ***
9220 21 CFR 606.100(b)(20) 5 Donor notification The standard operating procedure fails to include a written description of the [donor notification process] [process for follow-up if the initial attempt at donor notification fails].  Specifically, ***
9596 21 CFR 640.3(a) 5 Donor suitability by means of medical history Failure to [always] determine donor suitability on the day of collection by means of [medical history] [test for hemoglobin level] [physical examination].  Specifically, ***
41 21 CFR 606.40(a)(1) 4 Provide space for examination Failure to provide adequate space for [private] [accurate] examinations of individuals to determine their suitability as blood donors.  Specifically, ***
89 21 CFR 606.100(b)(10) 4 Controlling storage temperatures The standard operating procedure fails to include a written description of the storage temperatures and methods of controlling storage temperatures for all blood products and reagents  Specifically, ***
167 21 CFR 606.170(b) 4 Adverse reaction - fatality A confirmed, fatal complication of [blood collection] [transfusion]  was not [reported as soon as possible] [submitted in writing within 7 days after the fatality] to the Director, Office of Compliance, Center for Biologics Evaluation and Research by the [collecting facility in the event of a donor reaction] [facility that performed the compatibility tests in the event of a transfusion reaction].  Specifically, ***
9238 21 CFR 630.6(b)(3) 4 Results of testing Failure to notify the donor of the results of [tests for evidence of infection due to communicable disease agents that were a basis for deferral] [supplemental tests].   Specifically, ***
75 21 CFR 606.100(a) 3 SOP compliance Failure of the Standard Operating Procedure to comply with additional standards in 21 CFR 640.  Specifically, ***
117 21 CFR 606.121(f) 3 Labeling of blood products unsuitable for transfusion Failure to prominently label blood and blood components (except for recovered plasma) determined to be unsuitable for transfusion with ["NOT FOR TRANSFUSION"] [the reason the unit is considered unsuitable].  Specifically, ***
156 21 CFR 606.160(c) 3 Assignment of donor number Failure of records describing the history and ultimate disposition of blood products to include a donor number [assigned to each accepted donor] [which relates to the unit of blood collected from that donor] [which relates to the donor's medical record] [which relates to any component or blood product from the donor's unit of blood].  Specifically, ***
207 21 CFR 640.3(a) 3 Donor suitability not performed on day of collection Failure to determine the suitability of a donor as a source of blood by a qualified physician or by a trained person under his supervision on the day of collection.  Specifically, ***
238 21 CFR 640.11(a) 3 General requirements - storage Failure to [store] [maintain] the Red Blood Cells between 1 and 6 degrees Celsius immediately after processing.  Specifically, ***
32 21 CFR 606.20(c) 2 Exclusion of certain persons Failure to exclude persons whose presence can adversely affect the safety and purity of the products from areas where the [collection] [processing] [compatibility testing] [storage] [distribution] of blood or blood components is conducted.  Specifically, ***
35 21 CFR 606.40 2 Clean & orderly Failure to maintain facilities in a clean and orderly manner.  Specifically, ***
36 21 CFR 606.40 2 Suitable size, construction, etc. Failure to provide facilities of  suitable [size] [construction] [location] so as to facilitate adequate cleaning, maintenance and proper operations.  Specifically, ***
46 21 CFR 606.40(a)(6) 2 Provide space for quarantine of unsuitable for use items Failure to provide adequate space for the [quarantine] [storage] [handling] [disposition] of [products] and [reagents] not suitable for use.  Specifically, ***
63 21 CFR 606.65 2 Safe, sanitary, orderly storage Failure to store all supplies and reagents used in the [collection]  [processing] [compatibility testing] [storage] [distribution] of blood and blood components in a safe, sanitary and orderly manner.  Specifically, ***
64 21 CFR 606.65(b) 2 Visual examination Failure to inspect each blood collecting container [and its satellite container(s)] for damage or evidence of contamination including breakage of seals and abnormal discoloration [prior to its use] [immediately after filling].  Specifically, ***
80 21 CFR 606.100(b)(1) 2 Donor criteria The standard operating procedure fails to include written descriptions of criteria used to determine donor suitability, including acceptable medical history criteria.  Specifically, ***
82 21 CFR 606.100(b)(3) 2 Preparation of phlebotomy site The standard operating procedure fails to include written descriptions of solutions and methods used to prepare the site of phlebotomy to give maximum assurance of a sterile container of blood.  Specifically, ***
88 21 CFR 606.100(b)(9) 2 Written methods for investigating adverse reactions The standard operating procedure fails to include a written description of the procedures for investigating adverse donor and recipient reactions.  Specifically, ***
138 21 CFR 606.121(i)(4) 2 Labeling requirements - donor does not meet requirements A container of blood is intended for autologous use and is obtained from a donor who [fails to meet any of the donor suitability requirements] [is reactive in the hepatitis tests] and in place of the blood group label is not labeled  prominently and permanently: "FOR AUTOLOGOUS USE ONLY."  Specifically, ***
142 21 CFR 606.140(a) 2 Establishment of spec., standards, and test procedures Failure to establish scientifically sound and appropriate specifications, standards and test procedures to assure that blood and blood components are safe, pure, potent and effective.  Specifically, ***
158 21 CFR 606.160(e) 2 Unsuitable donors A record is not available from which unsuitable (deferred) donors may be identified so that products from such individuals will not be distributed.  Specifically, ***
165 21 CFR 606.170(a) 2 Adverse reaction - Maintenance of Reports Failure to maintain reports of complaints of adverse reactions regarding each unit of blood or blood product arising as a result of [blood collection] [transfusion].  Specifically, ***
205 21 CFR 640.3(f) 2 Donations in less than eight weeks A person served as a source of blood more than once in 8 weeks and was not examined at the time of donation and certified by a physician to be in good health as indicated in part in 21 CFR 640.3(b).  Specifically, ***
210 21 CFR 640.3(b)(1) 2 Qualifications of donor - temperature Each donor was not in good health as indicated in part by an abnormal temperature.  Specifically, ***
211 21 CFR 640.3(b)(2) 2 Qualifications of donor - blood pressure Each donor was not in good health as indicated in part by systolic and diastolic blood pressures which were not within normal limits and the examining physician has not determined that this individual with blood pressures outside these limits is otherwise qualified as a donor.  Specifically, ***
251 21 CFR 640.25(b) 2 Quality control Failure to test each month (of manufacture) four units prepared from different donors at the end of the storage period for [platelet count] [pH of not less than 6.0 measured at the storage temperature of the unit] [actual plasma volume].  Specifically, ***
260 21 CFR 640.31(b) 2 Criteria for plasmapheresis donor suitability Failure of a plasmapheresis donor to [meet the same criteria for donor suitability as specified for Source Plasma donors (21 CFR 640.63)] [be presented the informed consent].  Specifically, ***
3452 21 CFR 601.12(b) 2 Major changes to an approved application Failure to [submit a supplement] [receive supplement approval from FDA] prior to distributing product made using the change.  Specifically, ***
9078 21 CFR 600.12(a) 2 Maintenance  - tracing Records are not maintained in a manner which allows steps in the [manufacture] [distribution] of product to be traced.  Specifically, ***
9219 21 CFR 606.100(b)(20) 2 Donor deferral The standard operating procedure fails to include a written description of the donor deferral process.  Specifically, ***
9234 21 CFR 630.6(c) 2 Notification w/in 8 weeks Failure to make reasonable attempts to notify the donor within 8 weeks after determining that the donor is deferred or determined not to be suitable for donation.  Specifically, ***
9236 21 CFR 630.6(b)(1) 2 Deferred or not suitable Failure to notify the donor [that the donor is deferred or determined not to be suitable] [of the reason for deferral].  Specifically, ***
9240 21 CFR 630.6(d)(1) 2 Physician notification Failure to provide to an autologous donor's referring physician [information that the autologous donor is deferred based on the results of tests for evidence of infection due to communicable disease agents, and the reason for that decision] [the types of donation of blood and blood components that the autologous donor should not donate in the future] [the results of tests for evidence of infection due to communicable disease agent(s) that were a basis for deferral] [results of any supplemental tests].  Specifically, ***
9243 21 CFR 630.6(a) 2 Notification Failure to make reasonable attempts to notify a donor who has been [deferred based on the results of tests for evidence of communicable disease agent(s)] [determined not be to suitable as a donor based on suitability criteria].  Specifically, ***
9256 21 CFR 610.41 2 Donor Deferral Failure to defer a donor who tested reactive [by a screening test for evidence of infection due to a communicable disease agent] [for a serological test for syphilis] from further donations of human blood and blood components.  Specifically, ***
42 21 CFR 606.40(a)(2) 1 Provide space for blood withdrawal Failure to provide adequate space for the withdrawal of blood from donors with minimal [risk of contamination] [exposure to activities and equipment unrelated to blood collection].  Specifically, ***
49 21 CFR 606.40(a)(9) 1 Provide space for all packaging, labeling, & finishing ops. Failure to provide adequate space for the orderly conduction of all [packaging] [labeling] [other finishing] operations.  Specifically, ***
54 21 CFR 606.40(d)(2) 1 Provide adequate disposal of blood & blood components Failure to provide for safe and sanitary disposal for blood and blood components not suitable for use or distribution.  Specifically, ***
65 21 CFR 606.65(c) 1 Testing of representative samples of reagent lots Representative samples of each lot of [Anti-human globulin] [Blood grouping reagents] [Lectins] [Antibody screening and reverse grouping cells] [Hepatitis test reagents] [Syphilis serology reagents] [Enzymes] are not tested on a regularly scheduled basis as described in the SOP Manual  to determine their capacity to perform as required by the regulations.  Specifically, ***
66 21 CFR 606.65(d) 1 Rotation of supplies and reagents Failure to ensure that supplies and reagents that do not bear an expiration date are stored in such a manner that the oldest is used first.  Specifically, ***
81 21 CFR 606.100(b)(2) 1 Donor qualifying tests & measurements The standard operating procedure fails to include written descriptions of methods for performing donor qualifying tests and measurements, including minimum and maximum values for a test or procedure when a factor in determining acceptability.  Specifically, ***
83 21 CFR 606.100(b)(4) 1 Relate products to the donor The standard operating procedure fails to include a written description of the method for accurately relating the product(s) to the donor.  Specifically, ***
92 21 CFR 606.100(b)(13) 1 Procedures to relate blood from donor to final disposition The standard operating procedure fails to include a written description of the procedures used for relating a unit of blood or blood component from the donor to its final disposition.  Specifically, ***
93 21 CFR 606.100(b)(14) 1 QC procedures for supplies and reagents The standard operating procedure fails to include a written description of the quality control procedures for supplies and reagents employed in [blood collection] [processing] [pretransfusion testing].  Specifically, ***
97 21 CFR 606.100(b)(18) 1 Procedure for preparing recovered (salvaged) plasma The standard operating procedure fails to include a written description of the procedure for preparing recovered (salvaged) plasma,  including details of [separation] [pooling] [labeling] [storage] [distribution.]  Specifically, ***
110 21 CFR 606.120(b)(2) 1 Destruction of obsolete labels Failure to destroy stocks of obsolete labels.  Specifically, ***
116 21 CFR 606.121(e) 1 Container label requirements - particular products Failure to meet container label requirements for [whole blood cells] [red blood cells] [products with dating period of 72 hours or less] [plasma intended for transfusion] [recovered plasma] in accordance with 21 CFR 606.121(e).  Specifically, ***
119 21 CFR 606.121(h) 1 Labeling requirements for emergency shipment Failure to include [the statement, “FOR EMERGENCY USE ONLY BY __________”] [results of any tests prescribed under the regulations and completed] [tests prescribed under the regulations and not completed] on blood or blood components shipped in an emergency prior to completion of required tests.  Specifically, ***
121 21 CFR 606.121(c)(2) 1 Name, address, registration number The container label fails to include the [name] [address] [registration number] [the license number of each manufacturer, for a licensed product].  Specifically, ***
144 21 CFR 606.140(c) 1 Adequate identification and handling of test samples Failure to adequately provide for identification and handling of all test samples so that they are accurately related [to the specific unit of product being tested] [to its donor] [to the specific recipient].  Specifically, ***
157 21 CFR 606.160(d) 1 Retention period Failure to retain records [for 5 years after the  records of processing have been completed] [for 6 months after the latest expiration date for the individual product] [indefinitely where there is no expiration date].  Specifically, ***
198 21 CFR 640.2(c)(3) 1 Blood not stored between 1-6 deg / shipped 1-10 deg Reissued blood has not been [stored continuously at 1 to 6 C] [shipped between 1 and 10 C].  Specifically, ***
214 21 CFR 640.3(b)(5) 1 Qualifications of donor - infectious skin disease Each donor was not in good health as indicated by any infectious skin disease [at the site of phlebotomy] [generalized to such an extent as to create a risk of contamination of the blood].  Specifically, ***
215 21 CFR 640.3(b)(6) 1 Qualifications of donor - disease transmissible by blood Failure to determine whether each donor is free from any disease transmissible by blood as determined by history and examinations.  Specifically, ***
223 21 CFR 640.4(e) 1 Donor identification Blood is not identified so as to relate it to the individual donor.  Specifically, ***
229 21 CFR 640.4(g)(1) 1 Standard Failure to provide segments [with each unit of blood when issued or reissued] [from the donor who is the source of the unit of blood].  Specifically, ***
233 21 CFR 640.5(b) 1 Testing - ABO Failure to test blood for determination of ABO blood group [using two blood group tests] [using appropriate reagents] [using appropriate techniques].  Specifically, ***
234 21 CFR 640.5(c) 1 Testing - Rh factor Failure to [test blood for determination of the Rh factor] [indicate on the label the extent of typing and the result of all tests performed].  Specifically, ***
236 21 CFR 640.5(e) 1 Testing - inspection Failure to [visually inspect blood during storage and immediately prior to issue for] [prevent issuance of blood found to have] abnormal color, physical appearance, or indication or suspicion of microbial contamination.  Specifically, ***
241 21 CFR 640.11(b) 1 General requirements - inspection Failure to [inspect Red Blood Cells immediately after separation of the plasma, periodically during storage, and at the time of issue] [prevent issuance if Red Blood Cells are abnormal in color, physical appearance, or indicative of microbial contamination].  Specifically, ***
253 21 CFR 640.25(b)(4) 1 Corrective action Failure to [take immediate corrective action] [maintain a record of corrective action] when the quality control testing for platelets does not meet the prescribed requirements.  Specifically, ***
255 21 CFR 640.31 1 Donor suitability Failure to ensure that [whole blood] [plasmapheresis] donors meet suitability criteria.  Specifically, ***
316 21 CFR 640.63(c)(1) 1 Normal temperature Each donor was not in good health on the day of donation, as indicated in part by a normal temperature.  Specifically, ***
326 21 CFR 640.63(c)(11) 1 Viral hepatitis (history) Each donor was not in good health on the day of donation, as indicated in part by a history of viral hepatitis after the 11th birthday.  Specifically, ***
367 21 CFR 640.72(c) 1 Rejection of repeat donor or unsuitable plasma Failure of the donor's record to contain a full explanation if a repeat donor is rejected or a donor's plasma is found unsuitable.  Specifically, ***
376 21 CFR 640.120 1 Alternative procedures Failure to request from CBER and obtain approval for exceptions or alternatives to requirements regarding [blood] [blood components] [blood products].  Specifically, ***
3245 21 CFR 640.61 1 Explanation of hazards Failure to explain to the prospective Source Plasma donor [by a qualified physician] the [hazards of the plasmapheresis procedure] [risks of a hemolytic transfusion reaction] [hazards involved if the donor is hyperimmunized].  Specifically, ***
3246 21 CFR 640.61 1 Obtaining consent in an appropriate manner Failure to present the hazards and risks of plasmapheresis in such a manner that intelligent and informed consent can be given by the prospective Source Plasma donor.  Specifically, ***
3441 21 CFR 610.46(b) 1 Further testing and notification of results As part of lookback procedures when a donor had tested repeatedly reactive for antibody to human immunodeficiency virus or otherwise had been determined to be unsuitable when tested in accordance with the regulations, you failed to [perform] [notify consignees of the results of] a licensed, more specific test for HIV on the donor's blood within 30 days after the repeatedly reactive test.  Specifically, ***
3443 21 CFR 610.47 1 Notification of transfusion recipients Failure to [notify the attending physician of a recipient of a lookback unit] [make a minimum of three attempts within 8 weeks to notify the recipient of a lookback unit in the event the physician does not inform the recipient] [notify recipient's legal representative or relative] [document notifications of lookback units].  Specifically, ***
3453 21 CFR 601.12(c) 1 Moderate changes to an approved application Failure to submit a supplement [at least 30 days] prior to distributing product made using the change.  Specifically, ***
3543 21 CFR 610.46(a)(1) 1 Quarantine and notification When a donor tested repeatedly reactive for antibody to human immunodeficiency virus or otherwise was determined to be unsuitable when tested in accordance with the regulations, you did not take appropriate action within 72 hours to [institute a quarantine] [notify your consignee(s) for the purpose of instituting a quarantine] of [whole blood] [blood components] [source plasma] [source leukocytes] collected from the donor.  Specifically, ***
3618 21 CFR 606.100(b)(19) 1 Procedure for HIV lookback There is no written procedure to look at prior donations of Whole Blood, blood components, Source Plasma, and Source Leukocytes, when a donor of blood subsequently tests repeatedly reactive for antibody to human immunodeficiency virus, or otherwise is determined to be unsuitable when tested in accordance with the applicable regulations.  Specifically, ***
9004 21 CFR 606.100(b)(19) 1 Quarantine of blood etc. The written procedures for HIV "lookback" fail to include [in-house quarantine of] [procedures to notify consignees regarding the need to quarantine] [procedures to determine the release from quarantine of] Whole Blood, blood components, Source Plasma, and Source Leukocytes, intended for further manufacture into injectable products, from a donor of blood who has subsequently tested repeatedly reactive for antibody to human immunodeficiency virus, or otherwise has been determined to be unsuitable when tested in accordance with the applicable regulations.  Specifically, ***
9005 21 CFR 606.100(b)(19) 1 Notification of consignees re: antibody test results The written procedures for HIV "lookback" fail to include notification of consignees for Whole Blood, blood components, Source Plasma, and Source Leukocytes of the results of antibody testing of a donor of blood who has tested repeatedly reactive for antibody to human immunodeficiency virus, or otherwise has been determined to be unsuitable when tested in accordance with the applicable regulations.  Specifically, ***
9006 21 CFR 606.100(b)(19) 1 Notification of attending physicians The written procedures for HIV "lookback" fail to include procedures in accordance with 21 CFR 610.47 to notify attending physicians so that transfusion recipients are informed that they may have received [Whole Blood] [blood components] at increased risk for transmitting HIV.  Specifically, ***
9053 21 CFR 600.11(c) 1 Laboratory and bleeding rooms The [product processing areas] [bleeding rooms] [rooms for animal injection] [do not permit thorough cleaning and disinfection] [are not constructed to insure freedom from deleterious substances] [are not disinfected] [are not kept free from flies and vermin].  Specifically, ***
9077 21 CFR 600.12(a) 1 Maintenance - completeness The [manufacturing] [distribution] records [are not legible and indelible] [do not detail the various steps of manufacture of the product].  Specifically, ***
9080 21 CFR 600.12(b)(2) 1 Retention - Records of Recall Recall records for distributed product [were] [are] not [generated] [retained] [complete].  Specifically, ***
9086 21 CFR 600.14(a)(1) 1 Who must report - manufacturer Failure to submit [a] biological deviation [report] [reports].  Specifically, ***
9087 21 CFR 600.14(a)(1) 1 Who must report - receiving information Failure to [establish] [maintain] [follow] procedures for obtaining information on all [deviations] [complaints] [adverse events] for a distributed biological product subject to biological product deviation reporting.  Specifically, ***
9095 21 CFR 600.80(c)(1)(i) 1 Reporting Requirements - 15-day alert All [serious] [unexpected] adverse experiences were not reported within 15 calendar day of initial receipt of the information.  Specifically, ***
9223 21 CFR 606.160(b)(6) 1 Required records - transfusion reaction and complaints Failure to maintain records of transfusion reaction reports and complaints, including investigation and follow up.  Specifically, ***
9227 21 CFR 606.171(a) 1 BPDR - procedures Failure to establish a procedure to obtain information about [deviations] [complaints] [adverse events] from your contractor.  Specifically, ***
9237 21 CFR 630.6(b)(2) 1 Type of donations Failure to notify the donor of the types of donations of blood or blood components that the donor should not donate in the future.  Specifically, ***
9271 21 CFR 610.41 1 Donor Deferral - reentry The method or process used to requalify deferred donors was not found acceptable for such purposes by FDA.  Specifically, ***
9282 21 CFR 640.15(a) 1 Accompanying unit Failure to provide one or more segments with each unit of [Whole Blood] [Red Blood Cells] when [issued] [reissued].  Specifically, ***
9305 21 CFR 640.66 1 Procedures Failure to maintain immunization procedures on site.  Specifically, ***
9332 21 CFR 610.10 1 Potency Potency testing [is not performed] [was not designed so as to indicate potency of the product in an adequate manner].  Specifically, ***

Back to top

Parts 1240 and 1250

Center Name Cite Id Ref No Frequency Short Description Long Description
Parts 1240 and 1250 6560 21 CFR 1250.32(a) 66 Contamination Not all food-handling operations are accomplished so as to minimize the possibility of contaminating [food] [drink] [utensils].  Specifically, ***
7036 21 CFR 1250.67 44 Prevention of contamination Failure to [design] [construct] [maintain] [operate] servicing area [piping systems] [hydrants] [taps] [faucets] [hoses] [buckets] [equipment] in such a manner as to prevent contamination of [drinking] [culinary] water.  Specifically, ***
6569 21 CFR 1250.33(b) 41 Equipment kept clean Failure to keep all equipment clean.  Specifically, ***
6558 21 CFR 1250.30(d) 29 Plumbing design, installation, maintenance Plumbing is not [designed] [installed] [maintained] so as to prevent contamination of [the water supply] [food] [food utensils].  Specifically, ***
6570 21 CFR 1250.33(c) 25 Storage and handling after bactericidal treatment Failure to [store] [handle] utensils, after bactericidal treatment, in such a manner as to prevent contamination before reuse.  Specifically, ***
7032 21 CFR 1250.63 24 Prevention of the spread of communicable diseases Servicing area are not [provided with all necessary sanitary facilities] [operated] [maintained] as to prevent the spread of communicable diseases.  Specifically, *** 
6564 21 CFR 1250.33(a) 22 Maintained in good repair Not all [utensils] [working surfaces] used in connection with [preparation] [storage] [serving] of [food] [beverages] are maintained in good repair.  Specifically, ***
6580 21 CFR 1250.38(b) 21 Signs Signs directing food-handling employees to wash their hands after each use of toilet facilities are not [posted] [readily observable by such employees].  Specifically, ***
6581 21 CFR 1250.38(b) 21 Soap, sanitary towels, water Hand washing facilities for use by food-handling employees lack [soap] [sanitary towels] [hot and cold running water].  Specifically, ***
6552 21 CFR 1250.28 19 Handling to avoid contamination Ice coming into contact with [food] [drink] is not [handled] [stored] in such a manner as to avoid contamination.  Specifically, ***
6565 21 CFR 1250.33(a) 14 Adequate facilities for cleaning, bactericidal treatment Adequate facilities are not provided for the [cleaning] [bactericidal treatment] of [multiuse eating and drinking utensils] [equipment used in the preparation of food and beverages].  Specifically, ***
7053 21 CFR 1250.75(b) 14 Sanitary sewers or alternative methods Failure to dispose of toilet wastes through [sanitary sewers] [methods assuring sanitary disposal].  Specifically, ***
6572 21 CFR 1250.34 12 Thermometers Failure to equip each refrigerator with a thermometer located in the warmest region thereof.  Specifically, ***
6579 21 CFR 1250.38(a) 11 Suitable design and construction Failure to provide [toilet] [lavatory] facilities of suitable design and construction for use by food-handling employees.  Specifically, ***
6555 21 CFR 1250.30(a) 9 Clean and free from flies, rodents, and other vermin Not all [kitchens] [galleys] [pantries] [places] where food is prepared, served, or stored are [clean] [free from flies, rodents, and other vermin].  Specifically, ***
6591 21 CFR 1250.42(a) 9 Backflow protection A water system not protected against backflow.  Specifically, ***
6593 21 CFR 1250.42(b) 7 Connections easily cleanable, located and protected Filling connections not [easily cleanable] [located and protected] so as to minimize the hazard of contamination of the water supply.  Specifically, ***
6586 21 CFR 1250.39 5 Frequency of disposition Failure to dispose of [garbage] [refuse] as frequently as necessary and practicable.  Specifically, ***
7051 21 CFR 1250.75(a) 5 Contamination of passenger stations Failure to dispose of human wastes in such a manner as to avoid contamination of passenger [areas] [stations].  Specifically, ***
7090 21 CFR 1250.82(e) 5 Backflow prevention - general Lack of backflow prevention in the installation of [pipes] [fittings] conveying potable water to [fixtures] [apparatus] [equipment].  Specifically, ***
6549 21 CFR 1250.27 4 Storage of perishables Failure to keep perishable [food] [drink] at or below 50 degrees Fahrenheit except when being prepared or kept hot for serving.  Specifically, ***
7055 21 CFR 1250.75(b) 4 Equipment for cleaning and flushing Equipment for [cleaning soil cans and removable containers] [flushing nonremovable containers and waste carts] is [not designed so as to prevent backflow into the water line] [used for a purpose connected with the handling of food, water, or ice].  Specifically, ***
6554 21 CFR 1250.30(a) 3 Ventilation and lighting Not all [kitchens] [galleys] [pantries] [places] where food is prepared, served, or stored are adequately [lighted] [ventilated].  Specifically, ***
6567 21 CFR 1250.33(b) 3 Cleaning of multiuse eating and drinking utensils Failure to [thoroughly clean in warm water] [subject to an effective bactericidal treatment] multiuse eating and drinking utensils after each use.  Specifically, ***
6585 21 CFR 1250.39 3 Containers - close-fitting covers Garbage containers lack close-fitting covers.  Specifically, ***
7089 21 CFR 1250.82(d) 3 Identification marks on tanks and piping Not all [tanks] [piping] bear clear marks of identification.  Specifically, ***
6551 21 CFR 1250.28 2 Approved sources Ice coming into contact with [food] [drink] is not manufactured on board, but rather is obtained from a source not approved by competent health authorities.  Specifically, ***
6582 21 CFR 1250.38(c) 2 Maintained in clean condition Failure to maintain toilet rooms in a clean condition.  Specifically, ***
6612 21 CFR 1250.50 2 Designed to permit ready cleaning Lack of design of [toilet] [lavatory] facilities so as to permit ready cleaning.  Specifically, ***
7038 21 CFR 1250.67 2 Signs for non-potable water Outlets for non-potable water are not posted with [permanent] signs warning that the water is unfit for drinking.  Specifically, ***
6563 21 CFR 1250.33(a) 1 Easily cleaned, self-draining Not all [utensils] [working surfaces] used in connection with [preparation] [storage] [serving] of [food] [beverages] are constructed so as to be [easily cleaned] [self-draining].  Specifically, ***
6568 21 CFR 1250.33(b) 1 Cleaning of all other utensils Failure to [thoroughly clean in warm water] [subject to an effective bactericidal treatment] utensils (other than multiuse utensils) following the day's operation.  Specifically, ***
6584 21 CFR 1250.39 1 Containers - watertight, readily cleanable, non-absorbent Garbage containers are not [watertight] [readily cleanable] [non-absorbent].  Specifically, ***
6590 21 CFR 1250.42(a) 1 Complete and closed A water system which is not [complete] [closed] from the filling ends to the discharge taps (except for protected vent openings).  Specifically, ***
6609 21 CFR 1250.49 1 Clean and free of flies and mosquitoes Not all conveyances were kept [clean] [free of flies and mosquitoes] while in transit.  Specifically, ***
7030 21 CFR 1250.62 1 Submittal of construction plans Failure to submit plans for the [construction] [major reconstruction] of sanitation facilities at servicing areas to FDA for review.  Specifically, ***
7041 21 CFR 1250.70(a) 1 Adequate and readily accessible Adequate [toilet] [washroom] [locker] [essential sanitary] facilities for use of employees are not readily accessible adjacent to [places] [areas] where [land] [air] conveyances are [serviced] [maintained] [cleaned].  Specifically, ***
7054 21 CFR 1250.75(b) 1 Soil cans and removable containers Failure to [thoroughly] clean [soil cans] [removable containers] prior to return to use.  Specifically, ***
7058 21 CFR 1250.79(a) 1 Container construction Containers used to [receive] [store] garbage are not [water-tight] [readily cleanable] [nonabsorbent] [equipped with close-fitting covers].  Specifically, ***
7081 21 CFR 1250.82(a) 1 Separate systems The potable water system is [not separate and distinct from other water systems] [used for other purposes].  Specifically, ***

Back to top

Human Tissue for Transplantation

Center Name Cite Id Ref No Frequency Short Description Long Description
Human tissue for transplantation 12221 21 CFR 1271.47(a) 27 Procedures for all steps Procedures for all steps performed in the [testing] [screening] [determining] of donor eligibility of HCT/Ps were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12277 21 CFR 1271.75(a)(1) 19 Risk factors, clinical evidence Donors were not screened by a review of relevant medical records for [risk factors]  [clinical evidence] of communicable disease agents and diseases.  Specifically, ***
12416 21 CFR 1271.260(e) 15 Storage temperatures recorded, maintained Storage temperatures of HCT/Ps were not [recorded] [maintained].  Specifically, ***
12230 21 CFR 1271.50(a) 13 Responsible person to determine, document The eligibility of an HCT/P donor was not [determined] [documented] by a responsible person, based on results of donor screening and donor testing.  Specifically, ***
12213 21 CFR 1271.47(a) 11 Donor eligibility procedures Procedures for all steps performed in the [testing] [screening] [determining] of donor eligibility of HCT/Ps were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12336 21 CFR 1271.180(a) 11 Procedures to meet core CTGP Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12229 21 CFR 1271.50(a) 10 Determination based on screening and testing HCT/P donors were not determined to be eligible based on the results of donor screening and testing.  Specifically, ***
12286 21 CFR 1271.80(b) 10 Specimen collections not  timely Donor specimens used for testing of communicable disease agents were not collected at the appropriate time.  Specifically, ***
12287 21 CFR 1271.80(c) 10 Kits not FDA approved, specifically labeled Communicable disease agent tests [were not FDA-licensed, approved or cleared donor screening tests] [were not specifically labeled for cadaveric specimens when such a test was available and cadaveric specimens were used].  Specifically, ***
12494 21 CFR 1271.85(c) 8 Reproductive cells or tissues Donors of reproductive cells or tissues not recovered by a method that ensures freedom from contamination were not tested for communicable diseases of the genitourinary tract.  Specifically, ***
12223 21 CFR 1271.47(b) 7 Review and approval of procedures Donor eligibility procedures were not [reviewed] [approved] by a responsible person before implementation.  Specifically, ***
12433 21 CFR 1271.265(f) 7 Return to inventory--procedures Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12457 21 CFR 1271.320(a) 7 Procedures re complaints Procedures for the [review] [evaluation] [documentation] [investigation] of complaints relating to core CGTP requirements were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12431 21 CFR 1271.265(e) 6 Procedures and release criteria Procedures including  release criteria for activities relating to  the [receipt] [shipment] [distribution] of HCT/Ps were not [established] [maintained] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12492 21 CFR 1271.85(a) 6 Infection with communicable disease agents Donors were not tested for evidence of infection with communicable disease agents.  Specifically, ***
12278 21 CFR 1271.75(a)(2)  5 Risks associated with xenotransplantation Donors were not screened by a review of relevant medical records for disease risks associated with xenotransplantation.  Specifically, ***
12283 21 CFR 1271.75(e) 5 Abbreviated procedure  The abbreviated donor screening procedure [was used for donors who had no complete donor screening procedure in the previous six months] [did not determine and document changes in the donor's medical history that would make the donor ineligible].  Specifically, ***
12288 21 CFR 1271.80(c) 5 Manufacturer instructions not followed Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.  Specifically, ***
12301 21 CFR 1271.150(c)(1)(iii) 5 Ensurane of compliance You did not ensure that establishment(s) that  by contract, agreement or arrangement, perform manufacturing steps for you were in compliance with [applicable CGTP requirements prior to the initiation of the contract, agreement of arrangement] [applicable CGTP requirements after information became available that suggested the establishment was no longer in compliance].  Specifically, ***
12309 21 CFR 1271.160(a) 5 Program is appropriate for the HCT/Ps A quality program appropriate for the  HCT/Ps manufactured and manufacturing steps performed has not been [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12310 21 CFR 1271.160(a) 5 All core requirements covered in program A quality program which addresses all of the core CGTP requirements, appropriate for the HCT/Ps manufactured and the manufacturing steps performed, has not been [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12222 21 CFR 1271.47(a) 4 Design of procedures to ensure compliance Procedures were not designed to ensure compliance with the donor eligibility requirements.  Specifically, ***
12225 21 CFR 1271.47(d) 4 Departures: recording and justifying Departures from donor eligibility procedures relevant to preventing risks of communicable disease transmission were not [recorded] [justified].  Specifically, ***
12231 21 CFR 1271.50(b)(1) 4 Donor screening standards Donor screening of HCT/P donors considered eligible indicated that the donor was not free of [risk factors for infection due to communicable disease agents] [clinical evidence of infection due to communicable disease agents] [risk factors associated with xenotransplantation].  Specifically, ***
12247 21 CFR 1271.55(d)(2) 4 Accurate, indelible, legible Donor eligibility records are not [accurate] [indelible] [legible].  Specifically, ***
12351 21 CFR 1271.190(d)(1) 4 Procedures for cleaning, sanitation Procedures for facility cleaning and sanitation were not [established] [maintained] [defined] [documented] [implemented] [followed] [revised].  Specifically, ***
12369 21 CFR 1271.200(b) 4 Procedures inadequate Procedures for the [cleaning] [sanitizing] [maintenance] of equipment were not [established] [maintained] [defined] [documented] [implemented] [followed] [revised].  Specifically, ***
12436 21 CFR 1271.270(a) 4 Accurate, indelible, legible Records were not [accurate] [indelible] [legible].  Specifically, ***
12237 21 CFR 1271.55(a)(3) 3 Summary--records used to make determination After completion of the donor-eligibility determination, HCT/Ps were not accompanied with the summary of the records used to make the donor-eligibility determination.  Specifically, ***
12282 21 CFR 1271.75(d) 3 Donors with risks not determined ineligible Donors were not determined to be ineligible that had [risk factors or clinical evidence of communicable disease agents] [communicable disease risks associated with xenotransplantation].  Specifically, ***
12290 21 CFR 1271.80(d)(1) 3 Reactive tests--not determined ineligible Donors whose specimens test reactive on screening tests for communicable disease agents were not determined to be ineligible.  Specifically, ***
12319 21 CFR 1271.160(b)(3) 3 Actions taken and documented The quality program has not ensured that appropriate corrective actions relating to core CGTP requirements are [taken] [documented].  Specifically, ***
12325 21 CFR 1271.160(b)(6) 3 Deviations--evaluation, cause, corrective action Investigation of deviations related to core  CGTP requirements did not include [a review and evaluation of the deviation] [efforts to determine the cause of the deviation] [corrective action(s) to address the deviation and prevent recurrence].  Specifically, *** 
12334 21 CFR 1271.170(c) 3 Trained or re-trained as necessary Personnel have not been [trained] [re-trained as necessary] to adequately perform their assigned responsibilities.  Specifically, ***
12339 21 CFR 1271.180(c) 3 Availability of procedures Procedures for core CTGP requirements were not available to personnel  in the area where operations are performed, or in a nearby area when such availability is impractical.  Specifically, ***
12343 21 CFR 1271.190(a) 3 State of repair Facilities were not maintained in a good state of repair.  Specifically, ***
12412 21 CFR 1271.260(b) 3 Storage temperatures appropriate HCT/Ps were not stored at appropriate temperatures.  Specifically, ***
12419 21 CFR 1271.265(a) 3 Evaluation--microorganisms, damage Incoming HCT/Ps were [not evaluated for the presence and significance of microorganisms] [not inspected for damage and contamination].  Specifically, ***
12437 21 CFR 1271.270(a) 3 Records incomplete Records [did not identify the person performing the work] [did not show the dates of entries] [were not detailed as necessary to provide a complete history of work performed] [did not relate to the HCT/P involved].  Specifically, ***
12496 21 CFR 1271.85(b)(2) 3 SOP for release; reactive for CMV A standard operating procedure for the release of HCT/Ps from donors that test reactive for cytomegalovirus (CMV) was not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically. ***
15025 21 CFR 1271.85(b)(2) 3 Cytomegalovirus (CMV) Donors of viable, leukocyte-rich cells or tissue were not tested for evidence of infection due to cytomegalovirus (CMV).  Specifically, ***
12227 21 CFR 1271.47(e) 2 Adopting procedures from another organization Current donor eligibility procedures adopted from another organization were not verified to be [consistent with the donor eligibility requirements specified in the regulations] [appropriate for your operations].  Specifically, ***
12236 21 CFR 1271.55(a)(2) 2 Eligibility statement--basis of determination After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.  Specifically, ***
12240 21 CFR 1271.55(b)(3) 2 Name and address on summary The summary of records for HCT/Ps did not contain the [name] [address] of the establishment that made the donor-eligibility determination.  Specifically, ***
12246 21 CFR 1271.55(d)(1)(iii) 2 Documentation--determination, by whom, date Documentation of [the donor-eligibility determination] [the responsible person who made the donor-eligibility determination] [the date of the donor-eligibility determination] was not maintained.  Specifically, ***
12289 21 CFR 1271.80(c) 2 Test lab not certified or equivalent Testing for communicable disease agents was not performed by a laboratory certified to perform such testing on human specimens under the Clinical Laboratory Improvement Act of 1988 or has met equivalent standards determined by the Centers for Medicare and Medicaid Services.  Specifically, ***
12311 21 CFR 1271.160(b)(1) 2 Ensuring appropriate core requirements followed The quality program has not ensured that appropriate procedures related to core CGTP requirements were  [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [approved] [revised].  Specifically, ***
12314 21 CFR 217.160(b)(2)(iii) 2 Risk assessment, quarantine, recall, FDA The quality program has not ensured that procedures include provisions for [assessing the risk of] [quarantine of] [recall of] [reporting to FDA on] HCT/Ps that have been made available for distribution and for which there is information related to the possible contamination or communicable disease transmission.  Specifically, ***
12326 21 CFR 1271.160(c) 2 Quality audits performed periodically Periodic quality audits of activities related to core CGTP requirements have not been performed.  Specifically, ***
12328 21 CFR 1271.160(d) 2 Validation for intended use The performance of [custom computer software] [commercial computer software that has been customized or programmed], including changes to computer software, has not been validated for the intended use, when such software is relied upon to comply with core GTP requirements.  Specifically, ***
12346 21 CFR 1271.190(b)(2) 2 Sewage, trash removal Removal of [sewage] [trash or other refuse] was not done in a timely, safe and sanitary manner.  Specifically, ***
12354 21 CFR 1271.190(d)(2) 2 Documentation of activities Documentation of facility cleaning and sanitation activities was not maintained.  Specifically, ***
12365 21 CFR 1271.195(d) 2 Documentation not maintained Documentation of environmental control and monitoring activities was not maintained.  Specifically, ***
12367 21 CFR 1271.200(a) 2 Design appropriate, suitably located Equipment used in the manufacture of HCT/Ps was [not of appropriate design for its use] [not suitably located to facilitate operations, cleaning and maintenance].  Specifically, ***
12387 21 CFR 1271.220(a) 2 Causing contamination, increasing risks HCT/Ps were not processed in a way [that does not cause contamination or cross contamination during processing] [that does not increase the risk of introduction, transmission, or spread of communicable disease].  Specifically, ***
12411 21 CFR 1271.260(a) 2 Contamination, mix ups, improper release Storage areas and stock rooms were not controlled [to prevent mix-ups, contamination and cross contamination of HCT/Ps, supplies and reagents] [to prevent HCT/Ps from improperly being made available for distribution].  Specifically, ***
12415 21 CFR 1271.260(e) 2 Temperature limits Acceptable temperature limits were not established for the storage of HCT/Ps at each step of the manufacturing process to inhibit the growth of infectious agents.  Specifically, ***
12417 21 CFR 1271.260(e) 2 Periodic review of temperatures Recorded storage temperatures were not periodically reviewed to ensure that temperatures have been within acceptable limits.  Specifically, ***
12429 21 CFR 1271.265(d) 2 Shipping conditions appropriate Appropriate shipping conditions were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised] for each type of HCT/P.  Specifically, ***
12435 21 CFR 1271.270(a) 2 Records maintained concurrently Records were not maintained concurrently with the performance of each step.  Specifically, ***
12459 21 CFR 1271.320(b) 2 Sufficient information to draw conclusions The complaint file [did not contain sufficient information about each complaint for proper review and evaluation] [did not include the distinct identification code of the HCT/P involved] [did not contain sufficient information for determining whether the complaint is an isolated event or represents a trend].  Specifically, ***
12460 21 CFR 1271.320(c) 2 Review and evaluation, report to FDA  Complaints were not reviewed and evaluated to determine [if the complaint is related to an HCT/P deviation or adverse reaction] [whether a report to FDA is required].  Specifically, ***
12493 21 CFR 1271.90(b) 2 Eligibility not required--warning labels HCT/Ps for which the donor eligibility determination was not performed were not prominently labeled with the appropriate warning statements.  Specifically, ***
15020 21 CFR 1271.200(e) 2 Documentation of maintenance and cleaning Documentation of equipment maintenance, cleaning, sanitization, and calibration was not maintained.  Specifically, ***
3719 21 CFR 1270.21(a) 1 Testing of specimens Failure to test donor specimens for communicable viruses [using FDA-licensed donor screening tests] [in accordance with manufacturers' instructions].  Specifically, ***
3733 21 CFR 1270.31(a) 1 Significant steps in testing process - SOP's Failure to [prepare] [follow] written procedures which conform to all significant steps specified in the package inserts for infectious disease testing products.  Specifically, ***
3739 21 CFR 1270.31(c) 1 Quarantined tissues Failure to [prepare] [follow] written procedures for designating and identifying quarantined tissue.  Specifically, ***
3756 21 CFR 1270.35(a) 1 Results and interpretation of infectious disease tests Records fail to include documentation of results and interpretation of all required infectious disease tests.  Specifically, ***
3759 21 CFR 1270.35(d) 1 Destruction or other disposition Records fail to include documentation of destruction or other disposition of human tissue.  Specifically, ***
12226 21 CFR 1271.47(d) 1 Determining risks when departures involved A determination that departures from donor eligibility procedures did not increase the risk of communicable disease transmission was not made by a responsible person prior to making an HCT/P available for distribution.  Specifically, ***
12232 21 CFR 1271.50(b)(2) 1 Donor testing not negative for CD agents Donor testing of HCT/P donors considered eligible was not negative  or nonreactive for relevant communicable disease agents.  Specifically, ***
12234 21 CFR 1271.55(a)(1) 1 Identification code affixed to container After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a distinct identification code affixed to the HCT/P container.  Specifically, ***
12238 21 CFR 1271.55(b)(1) 1 Statement re: certified testing lab The summary of records for HCT/Ps did not contain a statement that the communicable disease testing was performed by a laboratory certified to perform such testing on human specimens under the Clinical Laboratory Improvement Act of 1988 or has met equivalent requirements determined by the Centers for Medicare and Medicaid Services.  Specifically, ***
12242 21 CFR 1271.55(c) 1 Name and personal info on accompanying records The accompanying records for HCT/Ps included [the donor's name] [personal information that might identify the donor].  Specifically, ***
12244 21 CFR 1271.55(d)(1)(i) 1 Documentation of CD testing and labs Documentation of [the results and interpretation of all relevant testing for communicable disease agents]  [the name and address of the communicable disease testing laboratory or laboratories] was not maintained.  Specifically, ***
12248 21 CFR 1271.55(d)(2) 1 Information, English or translated-authenticity Information on [the identity] [the relevant medical records] of donors of HCT/Ps were [not in English] [not retained and translated to English] [not accompanied by a statement of authenticity by the translator that specifically identifies the translated document].  Specifically, ***
12279 21 CFR 1271.75(b) 1 Risk factors, leukocyte-rich cells or tissues Donors of leukocyte-rich cells or tissues were not screened by a review of relevant medical records for [risk factors] [clinical evidence] of cell-associated communicable disease agents and diseases. Specifically, ***
12281 21 CFR 1271.75(c) 1 Reproductive cells/tissues-Chlamydia, Neisseria Donors of reproductive cells or tissues not recovered by a method that ensures freedom from contamination were not screened by a review of relevant medical records for [risk factors] [clinical evidence] of [Chlamydia trachomatis] [Neisseria gonorrhea].  Specifically, ***
12312 21 CFR 1271.160(b)(2) 1 Procedures for complaints and other information The quality program has not ensured that procedures exist for [receiving] [investigating] [evaluating] [documenting] information relating to core CGTP requirements, including complaints.
12320 21 CFR 1271.160(b)(3) 1 Actions verified, short and long term solutions Corrective actions relating to core CGTP requirements [have not been verified to ensure effectiveness and compliance with CGTP] [did not include both short term corrective actions to address the immediate deficiency and long term corrective actions to prevent recurrence].  Specifically, ***
12321 21 CFR 1271.160(b)(3) 1 Problem description, disposition, date et. al. Documentation of corrective actions did not include [a description of the HCT/Ps] [the disposition] [the nature of the problem] [the description of the corrective action] [the date of the corrective action].  Specifically, ***
12322 21 CFR 1271.160(b)(4) 1 Training of personnel The quality program has not ensured the proper training and education of personnel involved in core GTP activities.  Specifically, ***
12323 21 CFR 1271.160(b)(5) 1 Monitoring systems The quality program has not established and maintained appropriate monitoring systems.  Specifically, ***
12324 21 CFR 1271.160(b)(6) 1 Deviations--Investigation, documenting, trending The quality program does not include [the investigation] [the documentation] [the trending] [the reporting] of HCT/P deviations relating to core CTGP requirements.  Specifically, ***
12329 21 CFR 1271.160(d) 1 Documentation/approval prior to implementation Computer software [validation] [verification] activities and results have not been [documented] [approved] prior to implementation.  Specifically, ***
12331 21 CFR 1271.170(a) 1 Sufficient number Personnel are not sufficient to ensure compliance with the requirements.  Specifically, ***
12338 21 CFR 1271.180(b) 1 Review and approval-responsible person Procedures for core CGTP requirements were not [reviewed] [approved] by a responsible person before implementation.  Specifically, ***
12344 21 CFR 1271.190(a) 1 Lighting, ventilation, plumbing Facilities did not provide adequate [lighting] [ventilation] [plumbing] [drainage] [access to sinks and toilets] to prevent the introduction, transmission or spread of communicable disease.  Specifically, ***
12356 21 CFR 1271.195(a) 1 Adequate control, proper conditions Environmental conditions existed in which [contamination or cross contamination of HCT/Ps or equipment] [the accidental exposure of HCT/Ps to communicable disease agents] could occur, and [environmental conditions were not adequately controlled] [proper conditions for operations were not provided].  Specifically, ***
12357 21 CFR 1271.195(a)(1) 1 Temperature and humidity controls Environmental controls do not provide for adequate control of [temperature] [humidity].  Specifically, ***
12363 21 CFR 1271.195(c) 1 Monitoring--cross contamination, exposure to CD  Environmental conditions are not monitored when such conditions could cause [contamination or cross contamination of HCT/Ps or equipment] [the accidental exposure of HCT/Ps to communicable disease agents].  Specifically, ***
12364 21 CFR 1271.195(c) 1 Monitoring-microorganisms where appropriate Environmental conditions were not monitored for microorganisms.  Specifically, ***
12370 21 CFR 1271,200(c) 1 Calibration procedures and schedules (general) The [procedures] [schedules] for the calibration of equipment used for [inspection] [measuring] [testing] were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12371 21 CFR 1271.200(a) 1 Cleaned, sanitized per established schedules Equipment used for manufacturing HCT/Ps was not [cleaned] [sanitized] [maintained]  according to established schedules.  Specifically, ***
12373 21 CFR 1271.200(d) 1 Inspected routinely Equipment was not routinely inspected for [cleanliness] [sanitation] [calibration] [adherence to maintenance schedules].  Specifically, ***
12375 21 CFR 1271.210(a) 1 Use prior to verification  Supplies and reagents were used before they were verified to meet specifications designed to prevent the introduction, transmission, or spread of communicable disease.  Specifically, ***
12380 21 CFR 1271.210(d)(2) 1 Verification documentation maintained Documentation of the verification of [supplies] [reagents] was not maintained.  Specifically, ***
12381 21 CFR 1271.210(d)(2) 1 Verification elements Documentation of the verification of [supplies] [reagents] did not include [test results] [a certificate of analysis from the vendor].  Specifically, ***
12382 21 CFR 1271.210(d)(3) 1 Lot documentation maintained Documentation of the lot of [supplies] [reagents] used in the manufacture of each HCT/P was not maintained.  Specifically, ***
12398 21 CFR 1271.230(a) 1 Validation & approval--established procedures Processes with results which could not be fully verified by inspection and tests, were not validated and approved according to established procedures.  Specifically, ***
12399 21 CFR 1271.230(a) 1 Process validation procedures Procedures to validate and approve processes that cannot be fully verified by inspection and tests were not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12403 21 CFR 1271.230(c) 1 Change activities documented Activities related to a change to a validated process were not documented.  Specifically, ***
12414 21 CFR 1271.260(d) 1 Corrective actions Corrective actions were not [performed] [documented] when proper storage conditions were not met.  Specifically, ***
12421 21 CFR 1271.265(a) 1 Acceptance criteria designed to prevent CD  Incoming HCT/Ps were not [accepted] [rejected] [placed in quarantine] based on pre-established criteria designed to prevent communicable disease transmission.  Specifically, ***
12423 21 CFR 1271.265(b) 1 Shipment in quarantine of HCT/Ps HCT/Ps shipped as pre-distribution shipments [within your establishment] [between establishments] which do not meet the criteria for being available for distribution were not shipped in quarantine.  Specifically, ***
12426 21 CFR 1271.265(c)(2) 1 Improperly released for distribution HCT/Ps that were [in quarantine] [contaminated] [recovered from a donor determined to be ineligible] [recovered from a donor for whom a donor eligibility determination has not been completed] [determined to not meet release criteria designed to prevent communicable disease transmission] were made available for distribution.  Specifically, ***
12432 21 CFR 1271.265(e) 1 Documentation elements for activities Documentation for activities related to the [receipt] [shipment] [distribution] of HCT/Ps did not include [identification of the HCT/P and the establishment that supplied the HCT/P] [activities performed and the results of each activity] [date(s) of activity] [quantity of HCT/P subject to the activity] [disposition of the HCT/P (identity of consignee)].  Specifically, ***
12438 21 CFR 1271.270(b) 1 Management system re: core CGTPs A records management system relating to core CGTP requirements was not [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12439 21 CFR 1271.270(b) 1 Organized to facilitate review The records management system did not maintain records to facilitate review of particular HCT/Ps history [prior to becoming available for distribution] [subsequent to release as part of a follow-up evaluation or investigation].  Specifically, ***
12443 21 CFR 1271.270(d) 1 Retention time (10 year rules) Records were not retained for the appropriate length of time,  [10 years after their creation] [at least 10 years after the date of administration of a particular HCT/P] [at least 10 years after the date of a particular HCT/Ps distribution, disposition, or expiration, whichever is latest, when the date of administration is not known] [10 years after the appropriate disposition of archived specimens of dura mater].  Specifically, ***
12446 21 CFR 1271.290(a) 1 HCT/Ps not tracked HCT/Ps are not tracked [to facilitate the investigation of transmission of communicable disease] [to take corrective actions].  Specifically, ***
12451 21 CFR 1271.290(c) 1 Relating new code to old code When new identification codes are assigned to  HCT/Ps used at this establishment in place of distinct identification codes assigned to the same HCT/Ps by another establishment, procedures for relating the new codes to the old codes have not been [established] [maintained] [defined] [documented] [implemented] [followed] [reviewed] [revised].  Specifically, ***
12473 21 CFR 1271.350(b)(2) 1 Deviations not reported to FDA HCT/P deviations relating to core CGTP requirements that occurred [in your establishment] [at an establishment under contract, agreement, or arrangement with your establishment] were not reported to FDA.  Specifically, ***
12474 21 CFR 1271.350(b)(2) 1 Content of deviation reports HCT/P deviation reports did not include [descriptions of the deviation(s)] [information relevant to the event(s) and manufacture of the HCT/Ps involved] [follow-up actions that have or will be taken].  Specifically, ***
12484 21 CFR 1271.420(b) 1 Imports-hold intact until decision made HCT/Ps offered for import were not held intact under conditions necessary to prevent transmission of communicable disease until an admissibility decision was made.  Specifically, ***
12490 21 CFR 1271.85(b)(1) 1 Cell-associated CD  Donors of leukocyte-rich cells or tissues were not tested for cell-associated communicable diseases.  Specifically, ***
15019 21 CFR 1271.160(d) 1 Computer software verification The performance of computer software has not been verified.  Specifically, ***
15026 21 CFR 1271.85(c) 1 Reproductive cells or tissues-cell-associated CD Donors of viable, leukocyte-rich reproductive cells or tissues were not tested for cell-associated communicable diseases or cytomegalovirus (CMV).  Specifically, ***

Back to top

Radiological Health

Center Name Cite Id Ref No Frequency Short Description Long Description
Radiological health 5007 21 CFR 1002.13 2 Failure to submit You did not submit an annual report [by the September 1 deadline] for products requiring one.  Specifically, ***
5784 21 CFR 1010.2(b) 1 Certification other than by tag or label Certification of a product is not in conformance with [the manner prescribed in an applicable standard] [the alternate means approved by FDA].  Specifically, ***
5802 21 CFR 1002.13 1 Lack of required elements An annual report which you submitted did not [summarize the contents of the records required by 21 CFR 1002.30(a)] [provide the volume of products produced, sold, or installed] [cover the 12-month period ending on June 30 preceding the due date of the report]. Specifically, ***

Back to top